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 Aging is a complex biological process which stems from a growing imbalance 
between the regenerative capacity of an organism and endogenous as well as exogenous 
damaging factors.  This imbalance leads to the slow deterioration of individual cells, 
organs, and eventually the entire organism.  The free radical theory of aging combines the 
evolutionary and mechanistic aspects of aging, postulating that the innate process is 
caused by deleterious, irreversible, and inevitable changes in biological systems caused 
by oxidative damage that accumulates over the lifespan.  Evidence of this phenomenon 
is supported by the pathogenesis of age-related diseases, such as age-related macular 
degeneration and Alzheimer’s disease, which show that there is an age-related decrease 
of cellular antioxidant defenses. This results in the dyshomeostasis of redox-active metals, 
such as iron, copper, and zinc, and in turn exacerbates the oxidative stress induced by 
reactive oxygen species and free radicals such as superoxide, hydrogen peroxide, and 
the hydroxyl radical.   
 
Our laboratory has developed two series of multifunctional antioxidants (MFAOs), 
the JHX and HK series, which can simultaneously chelate biologically active transition 
metals and scavenge free radicals.  These orally-active compounds have demonstrated 
therapeutic effects against age-related eye diseases, such as cataract and macular 
degeneration.  Despite their efficacy, little is known about the ocular biodistribution of 
these orally-administered molecules.   
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I have conducted a biodistribution study of 24 such molecules.  These included the 
MFAOs, their monofunctional free radical scavenging (FRS) and biologically active 
transition metal chelating (CHL) analogs, as well as their nonfunctional (NF) analogs in 
Sprague Dawley rats.  In Chapter Two, I demonstrate that all compounds can be detected 
unmetabolized in the cornea, iris with the ciliary body, lens, neural retina, retinal pigmented 
epithelium with the choroid, brain, sciatic nerve, kidney, and liver.  In Chapter Three, I 
describe the predictive models of ocular, neural, and visceral tissue distribution, which I 
developed based on the biodistribution data from Chapter Two, using hierarchical cluster 
analysis (HCA) and quantitative structure activity relationship analysis (QSAR).  The 
results indicated that both HCA and QSAR analysis yielded many predictive models which 
agree with other reported trends of drug delivery to ocular, neural, and visceral tissues.  In 
Chapter Four, I present my investigation into the potential pharmacological chaperone 
activity of two oxysterols, lanosterol and 25-hydroxycholesterol, to three model αB-
crystallin chaperone proteins in silico and compare their binding against the MFAOs.  Our 
results confirm that the oxysterols fail to meet the predictive binding threshold, indicating 
weak binding affinity to the model αB-crystallin proteins.  However, their predicted Kd 
values matched experimentally reported values.  The MFAOs exceeded the threshold for 
predictive binding and support previous in vivo studies which suggest our molecules may 
have some chaperone activity.  Finally, in Chapter Five, I will present several synthetic 
approaches for the preparation of various novel triphenylphosphonium-linked (TPP) JHX-
series compounds.  I will also discuss their in vitro evaluation in HEI-OC1 inner ear cells.  
Since mitochondrial dysfunction is linked to neurodegeneration, we hypothesized that 
directly linking a mitochondria-targeting moiety to our compounds would increase their 
potency by quenching free radicals at their main generation source.  Our results indicate 
that the TPP compounds do not adversely affect mitochondria as shown using a viability 
assay and Rhodamine-123 fluorescence stain. 
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1.1 Oxidative Stress in Aging 
 
Aging is a complex biological process which results in senescence and eventually 
death.  Many theories have been proposed to explain the phenomenon of aging such as 
the Wear-and-Tear theory by Weismann [1] and the Mutation Accumulation theory by 
Medawar [2].  These two hallmark theories postulate that natural selection eliminates older 
members of a population so that they no longer compete with younger generations for 
resources, and that aging results from the accumulation of cellular damage and damage 
to genes coding for repair function,  respectively [3].  While the theories of aging continue 
to be refined, researchers have identified that many aging theories may not be mutually 
exclusive.  However, one aging theory has remained at the forefront of aging research: 
The Free Radical Theory of Aging proposed by Harnam [4].   
 
The free radical theory of aging combines evolutionary and mechanistic aspects 
of the aging process, suggesting that the innate process is caused by deleterious, 
irreversible changes to biological systems that increase in frequency over the lifespan [4].  
Moreover, it also postulates that aging is the cumulative result of oxidative damage to cells 
and tissues that arise primarily as due to aerobic metabolism.  Several lines of evidence 
support this hypothesis, such as that variations in species lifespan are correlated with 
metabolic rate and protective antioxidant activity [5], enhanced expression of antioxidant 
enzymes in experimental animals can produce a significant increase in longevity [6-8], 
cellular levels of free radical damage increase with age [9, 10], and reduced caloric intake 
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leads to a decline in the production of reactive oxygen species and an increased lifespan 
[11, 12].  Additionally, anti-aging research has demonstrated that persistent oxidative 
stress by reactive oxygen species (ROS) and reactive nitrogen species (RNS) contributes 
to the development of many disease pathologies such as cancer [13], diabetes [14], 
cardiovascular diseases [15],  neurodegenerative diseases [16], and eye diseases [17, 
18], all of which contribute to decreases in quality of life [19].   
 
A general diagram of the redox pathways in biological systems is summarized in 
Figure 1.1.  Starting with molecular oxygen (O2), its single electron reduction generates 
superoxide (O2•-) which may then undergo one of three reaction paths.  First, it may react 
with nitric oxide (•NO) to form peroxynitrite (ONOO-), a biomarker for oxidative stress that 
in high concentrations leads to apoptotic or necrotic cell death [20].  It is also in equilibrium 
with the hydroperoxyl radical (HOO•), which is an initiator of lipid peroxidation [21].  Finally, 
it may auto-dismutate or be catalytically dismutated by superoxide dismutase into 
hydrogen peroxide (H2O2).  Hydrogen peroxide may also undergo one of three reaction 
paths.  First, it may react with a biologically active redox metal such as Fe2+/Fe3+ through 
the Fenton reaction to yield either the hydroxyl radical (HO•) or the hydroperoxyl radical 
(HOO•).  Second, it can be generated and used by neutrophils to produce hypochlorous 
acid (HOCl) during the antimicrobial respiratory burst [22].  Finally, it can be dissociated 
by catalase to form water and oxygen.  The reactive species ONOO-, HOO•, and HO• have 
been reported to damage DNA, oxidize proteins, and cause the peroxidation of lipids, all 




Figure 1.1.  General schematic diagram of the redox cascade.  Molecular oxygen (O2) 
undergoes a variety of biochemical reactions to form different reactive oxygen species 
which can damage DNA, oxidize proteins, and cause lipid peroxidation, ultimately leading 




1.2 Multifunctional Antioxidants: A New Generation of Antioxidant Compounds 
 
The frontline defense against ROS and RNS in the biological system are the 
endogenous antioxidants which range from small molecules to large proteins.  Common 
small molecule antioxidants are shown in Figure 1.2 which include glutathione [23], lipoic 
acid [24], α-tocopherol (Vitamin E) [25], ubiquinone (Coenzyme Q10) [26], and ascorbic 
acid (Vitamin C) [27].  Additionally, proteins such as superoxide dismutase [28], 
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glutathione peroxidase [28], catalase [28], thioredoxin [29], transferrin [30], and 
metallothionine [31] also participate in redox pathways.   
 
 
Figure 1.2.  Common small molecule antioxidants.  Glutathione, lipoic acid, and 
Coenzyme Q10 are both biosynthesized endogenous antioxidants.  Both vitamin C and 




The endogenous antioxidant defense systems have been found to decrease in 
efficacy with age [32], which is due to the age-related decreased expression of 
endogenous antioxidant proteins [33-35] as well as decreased biosynthesis of 
endogenous antioxidants [36].  Hence, exogenous anti-oxidants are a critical necessity to 
synergistically assist the endogenous defense system to manage and prevent cumulative 
age-related oxidative damage [37].  These include a wide array of compounds such as the 
carotenoids β-carotene and astaxanthin, the polyphenols resveratrol and quercetin, 
vitamin E, and vitamin C.   
 
Antioxidants protect against oxidative damage mainly by scavenging and 
quenching free radicals and sequestering redox-active metals by chelation.  These 
mechanisms ensure the disruption of the redox cascade caused by free radicals and can 
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lead to the repair of molecules damaged by free radicals if administered early enough.  
Commercially available antioxidants generally work under the mechanism of free radical 
scavenging, and many research formulations have included chelators or protein mimetics 
that can decrease specific ROS interactions with bio-active transition metals [38, 39].   
 
In order to be effective, these antioxidants must be administered at high enough 
concentrations to deliver to the appropriate site of action.  However, the delivery of these 
antioxidants should not exceed maximum therapeutic concentrations or minimum toxic 
concentrations which varies depending on the antioxidant [40].  Surpassing the antioxidant 
therapeutic threshold shifts the beneficial anti-oxidative properties to detrimental pro-
oxidative ones, which consequently exacerbates oxidative stress and propagates the 
pathological processes that were intended to be mitigated.  This phenomenon has been 
documented to occur with Vitamin C [41, 42], quercetin [43], beta-carotene [44], and 
Vitamin E [45]. 
 
Despite the reported protective effects on antioxidant supplementation in basic 
research, the clinical use of antioxidants has unfortunately had limited success [46].  The 
lack of clinical benefit is likely due to critical components of drug delivery: absorption, 
distribution, metabolism, and excretion (ADME).  Antioxidants used in clinical trials were 
not chosen based on potency, but rather on ease of accessibility and administration (i.e., 
oral agents) [47].  A meta-analysis of seven randomized trials of vitamin E treatment and 
of eight trials of beta-carotene treatment indicated there were no cardiovascular or 
mortality benefits of supplementation [48].  Moreover, supplementation with beta-carotene 
led to a small, but significant increase in cardiovascular deaths, suggesting its long-term 
supplementation may be harmful [49, 50].  Similarly, although ROS-mediated cardiac 
injury is implicated in the development of heart failure, antioxidant supplement trials in 
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heart failure patients have been disappointing and a meta-analysis concluded that vitamin 
E may contribute to the development or aggravation of heart failure [51].  Furthermore, 
daily ingestion of vitamin C and E abrogated exercise-related enhancement of insulin 
sensitivity [52], and the HDL-raising effects of nicotinic acid was blunted with high-dose 
vitamin E [53].   
 
Mounting evidence suggests that diets rich in fruits and vegetables are associated 
with a lower incidence of various disease pathologies [54, 55], such as cardiovascular 
disease [56] and neurodegenerative disease [57].  Studies have also examined whether 
dietary antioxidants could mitigate the damaging effects of ROS [58, 59], and a recent 
meta-analysis reported that adherence to diets rich in fruits and vegetables reduce the risk 
of all-cause mortality [60].   Moreover, there is evidence that consumption of whole foods 
is better than isolated food components such as dietary supplements and nutraceuticals.  
For instance, increased consumption of carotenoid-rich fruits and vegetables offered 
better protective effects than carotenoid dietary supplements by increasing LDL-oxidation 
resistance, lowering DNA damage, and inducing higher DNA repair activity [61, 62].   
 
Studies indicate that antioxidant supplements as oral agents do not result in 
significant protective effects, but antioxidant-rich diets with fruits and vegetables can 
reduce overall mortality and improve health [55, 63].  This suggests that the delivery 
platform (i.e., food versus pill) affects the ADME properties of antioxidants [64].  
Importantly, antioxidant efficacy is not just a delivery platform problem.  If the antioxidant 
reacts before it can reach its target tissue, it can no longer quench free radicals causing 
oxidative damage.  Therefore, antioxidant efficacy is also a distribution problem.  Topical 
skin formulations highlight the importance of both delivery route and appropriate 
distribution/tissue targeting.  When delivered to the appropriate site of action, significant 
7 
 
therapeutic effects have been observed, both by patients and their dermatologists, with 
topical skin formulations containing 5% Vitamin C against photo-aging [65, 66].  None of 
the systemically administered antioxidants tested in clinical trials have been site-specific 
(i.e., targeted), which supports that both the poor delivery to, and un-targeted distribution 
of, antioxidants may account for the lack of clinical efficacy.  If these barriers to delivery 
can be overcome, antioxidants have the potential to become potent therapeutic modalities 
against age-related diseases such as cardiovascular disease, cancer, cataract, and 
Alzheimer’s [67].  Therapeutic potential can be maximized if a molecule is site-specific, 
stable in-transit, potent, and contains multiple antioxidant mechanisms to combat the 
overproduction of ROS or RNS. 
 
Our laboratory has developed a novel class of compounds called the 
multifunctional antioxidants (MFAOs).  These MFAOs use the innovative therapeutic 
strategy of integrating two independent functional motifs, a free radical scavenging moiety 
(FRS) and a transition metal chelating moiety (CHL), into one molecule to maximize their 
therapeutic efficacy against oxidative stress.  Because the MFAOs both scavenge free 
radicals and independently sequester and re-distribute free bio-active transition metals, 
they are superior to compounds which only scavenge free radicals or only bind to bio-
active transition metals.  The scaffolds of these compounds (Figure 1.3, top row) possess 
a similar central amine-based skeleton with varying “top ring” modifications which include 
either a piperazine, pyrrolidine, or piperidine system.  Each of the top ring moieties are 
conjugated to the 1,3-pyrimidine “bottom ring” at its 2-position.   
 
The first JHX-series of MFAOs were developed based on an in vivo study which 
demonstrated that oral administration of the nonfunctional parent (NF), JHX-1, delayed 
the progression of diabetic cataracts without reducing the levels of hyperglycemia or lens 
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polyols [68].  The second series of MFAOs, known as the HK-series, replaced the 
piperazine “top-ring” with either a pyrrolidine or piperidine to increase compound 
lipophilicity, thereby increasing the likelihood of compound delivery into the brain.  
Moreover, these modifications also decreased compound susceptibility to the acid- or 
base-catalyzed decomposition of their respective imide derivatives (Figure 1.3, second 
row).  Compared to the piperazine-2,6-dione of the JHX-series, both the pyrrolidine-2,5-
dione (succinimide) and piperidine-2,6-dione (glutarimide) of the HK-series are less likely 
to be hydrolyzed in acidic or basic conditions due to their increased lipophilic profiles [69].   
 
Unlike other small molecule antioxidants which contain phenolic moieties that 
scavenge ROS, the MFAOs contain the 2-amino-5-hydroxypyrimidine moiety.  The 
incorporation of nitrogen atoms into the aromatic ring of the phenolic compounds was 
found to significantly increase antioxidant potency [70].  Compared to phenols, 5-
hydroxypyrimidine possesses a greater O-H bond dissociation energy and oxidation 
potential while maintaining similar or higher reactivity towards ROS [70-72].  This means 
they are less susceptible to auto-oxidation while maintaining their specific mechanism of 
ROS-scavenging action.  This specific system increases the inherent stability of the 
antioxidant and the probability that the antioxidant will be delivered to the desired site of 
action.  Additionally, many compounds containing the 5-hydroxypyrimidine moiety have 
been reported as anti-inflammatory and cytoprotective, with targets including 
lipoxygenases and cyclooxygenases [73].  This suggests that these compounds may also 
have a targeted mechanism of action.  These two ring systems were combined, and the 
scaffolds were modified to create four functional derivatives (Figure 1.3, last row) which 
include a nonfunctional parent (NF), a monofunctional free radical scavenger (FRS), a 
monofunctional bio-active transition metal chelator (CHL), and a multifunctional 
antioxidant (MFAO).  Mechanistically, the NF derivative contains no known antioxidative 
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properties.  The para-hydroxyl group on the pyrimidine bottom ring of the monofunctional 
FRS derivative allows for the quenching of radical-propagated reactions, and the CHL 
derivative includes an imide functionality on the top ring that can sequester bio-active 
transition metals and prevent the Fenton reaction.  The MFAO combines both the FRS 
and CHL functionalities into one molecule. 
 
Figure 1.3.  MFAO compound scaffolds and their monofunctional and nonfunctional 
analog derivatives.  The first row of compounds shows the scaffolds for the nonfunctional 
parent (NF) and the free radical scavenging (FRS) derivatives, while the second row of 
compounds shows the scaffold for the transition metal chelating (CHL) and multifunctional 
(MFAO) derivatives.  These scaffolds are further elaborated in the last row.  Compared to 
the NF, the monofunctional FRS contains a para-hydroxyl group on the pyrimidine bottom 
ring and the monofunctional CHL contains the two carbonyl groups adjacent to the central 




1.3 Multifunctional Antioxidants are Protective In Vitro and In Vivo After Oral 
Administration 
 
The JHX-series demonstrated protective effects in vitro against ROS in SRA-1 lens 
epithelial cells and ARPE-19 retinal pigmented epithelial cells, both of which are believed 
to be instrumental in the development of cataract and age-related macular degeneration, 
respectively [74].  Furthermore, the oral administration of the JHX MFAOs to Sprague 
Dawley and Long-Evans rats significantly delayed the progression of diabetic cataracts 
and cataracts induced by gamma-irradiation, respectively [75].  Moreover, these 
compounds also protected the retina of dark-adapted Wistar rats against light-induced 
retinal injury, further suggesting that the MFAOs may be effective candidates for 
preventative therapy of age-related macular degeneration [76].   
 
The HK-series also demonstrated protective effects against ROS in various human 
neural cell lines such as the SH-SY5Y neuroblastoma and the ARPE-19 retinal pigmented 
epithelial cells [69].  These compounds prevented manganese-induced mitochondrial 
dysfunction in vitro in the same cell lines and removed zinc from amyloidβ:zinc complexes, 
allowing for the degradation of plaques by matrix metalloproteinase-2 [77].  Furthermore, 
in stoichiometric studies via Job plot (method of continuous variation), the HK-series were 
found to selectively bind redox-active iron, copper, zinc, and manganese, but not calcium 
or magnesium [69].  These results are similar to reported results for the JHX-series [74]. 
 
Little is known of the molecular characteristics required to cross the various 
physiological barriers in the eye.  Dr. Hiroyoshi Kawada conducted preliminary 
biodistribution studies in mice which compared MFAO drug distributions into the lens, 




Figure 1.4.  The JHX and HK series MFAOs.  These compounds combine the 
mechanisms of the free radical scavenging moiety (5-hydroxyl on the bottom ring) and 
metal binding (imide moiety on the top ring) monofunctional analogs into one molecule. 
 
 
compounds were orally administered and, after whole body perfusion, their levels were 
analyzed to investigate drug permeability across the blood-aqueous barrier (BAB), blood-
retinal barrier (BRB), and blood-brain barrier (BBB).  It has been generally assumed that 
drug accumulation in the lens requires a certain level of lipophilicity that also allowed for 
passage into the brain.  However, the results from this study observed the opposite effects 
where lipophilicity was directly proportional with brain levels but inversely proportional with 
lens levels.  The HK-series was found in greater level in the brain than the JHX-series, but 
the JHX-series was found in greater levels in the lens than the HK-series.  Both MFAO 
classes were found in similar levels in the neural retina.  These results confirmed that 
lipophilicity is required for drugs to penetrate the BBB for entry into the brain.  Contrary to 
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previous assumptions, these results also showed that lipophilicity decreases the likelihood 
of a compound to penetrate the BAB and enter the lens.  Finally, these results suggested 
that the mechanisms required for BRB passage extended past simple hydrophilic/lipophilic 
properties of the small molecules. 
 
 
Drug delivery to specific ocular tissues is a major challenge because the factors 
required for the uptake and ocular distributions of drugs remain largely undefined, and our 
preliminary work demonstrated that brain accumulation was not related to lens 
accumulation.  Previous studies investigated drug permeability through these 
physiological barriers as well, however these drugs were administered intravenously [78] 
which presents a significant barrier to their clinical feasibility.  Oral administration is the 
preferred route as it represents the most convenient and non-invasive route of ocular drug 
delivery, while concurrently holding high potential for patient compliance.  Our preliminary 
study was, to our knowledge, the first conducted in examining drug levels in both ocular 
and neural tissues after oral administration of a drug [69].  We have expanded on Dr. 
Kawada’s preliminary results with more detailed studies in rats, whose eyes are larger 
than mice.  In Chapter 2, we demonstrate the distribution of all 24 MFAOs, their 
monofunctional FRS and CHL analogs, and NF parents, to various ocular, neural, and 
visceral tissues including the cornea, iris with the ciliary body (iris/CB), lens, neural retina 
(NR), retinal pigmented epithelium with the choroid (RPE/C), brain, sciatic nerve (SN), 
kidney, and liver. 
 
The MFAOs have also been tested in other neurodegenerative pathologies such 
as blast-induced retinal injury and noise-induced hearing loss.  Both pathologies are 
strongly linked to oxidative stress where inflammation, mitochondrial dysfunction, and 
cellular apoptosis are common [79, 80].  Studies using an acoustic blast overpressure 
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(ABO) model for retinal injury in rats pre-fed with the MFAO JHX-4, or an enriched diet 
containing 2% cholesterol, vitamins C & E, and sodium selenite, found varying degrees of 
protection between the antioxidants.  This study suggests that protective mechanisms are 
dependent on the antioxidant type (JHX-4 as a MFAO or an enriched diet), as well as the 
number of blast exposures (single or double).  Both diets protected against loss of spatial 
frequency and contrast sensitivity to varying extents.  The JHX-4 diet group exhibited 
significant spatial frequency protection in the post-4-month single-blast group (compared 
to control), whereas both diet groups exhibited significant spatial frequency protection 
compared to control in the double-blast group.  Additionally, both diet groups were 
protective of contrast sensitivity for the single-blast group but provided no contrast 
sensitivity protection in the double-blast group [81].  Similarly, studies using a high-
intensity noise exposure system simulating workday noise exposure was employed as a 
model for noise-induced hearing loss (NIHL).  The oral administration of the MFAO HK-2 
prevented the decline of summating potential amplitude, compound action potential 
amplitude, and cochlear hair cell loss of rodents, suggesting neuroprotective effects 
presumably due to ROS quenching [82].  
 
1.4 Mitochondrial Targeting of Multifunctional Antioxidants as a Potential 
Therapeutic Avenue for Ocular and Neural Diseases 
 
Neural tissues depend on mitochondrial function to establish membrane 
excitability and execute the complex processes of neurotransmission and neuroplasticity.  
The retina has one of the highest metabolic demands, and thus, the highest mitochondrial 
density of any tissue in the body [83].  The mitochondria play central roles in ATP 
production, intracellular calcium signaling, and the generation of ROS, all of which are 
increased in the retina.  The majority of intracellular ROS is generated in the mitochondria 
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by the electron transport chain [84].  This generates not only superoxide, but also 
hydrogen peroxide, peroxyl radicals, and hydroxyl radicals (Figure 1.1).  Additionally, the 
mitochondria are a source of iron-sulfur clusters that are used by proteins throughout the 
cell in various critical processes [85].  The post-transcriptional system that mammalian 
cells use to regulate gene expression depends on iron-sulfur cluster-containing proteins 
and environmental signals such as oxygen, free iron levels, and ROS levels [86].  Hence, 
proper mitochondrial function is crucial for neuronal cell homeostasis [87]. 
 
Mitochondria-generated ROS are major mediators of age-associated cellular 
damage.  With age, the antioxidant enzyme activity in the mitochondria decreases [88, 
89].  The subsequent increased levels of ROS can damage aging mitochondria which may 
induce mutations and decrease mitochondrial DNA integrity and functionality.  
Mitochondrial dysfunction has been linked to multiple neurodegenerative pathologies, 
including retinal degenerations.  Mitochondrial dysfunction may also initiate and/or 
contribute to iron dysregulation, which is seen as an increase in free iron concentration 
during the neurodegenerative processes [87, 90].  Because mitochondria are vital 
intracellular organelles for neuronal cell function and survival, many investigators have 
advocated for mitochondrial dysfunction as a target for ocular neurodegenerative diseases 
which include glaucoma and age-related macular degeneration [91-93].  Targeting the 
mitochondria with pharmacological agents that protect against oxidative stress or promote 
the repair of mitochondrial DNA damage offers new therapeutic avenues for the treatment 
of retinal degeneration [94].  Moreover, targeting mitochondria in ocular tissues is not 
limited to neural cells.  Experimental evidence also supports targeting mitochondrial 
dysfunction in retinal pigmented epithelial cells as a strategy for combating age-related 




To combat mitochondrial dysfunction, two main classes of mitochondria-targeted 
compounds have shown promise.  The first class of compounds are called mitochondria-
targeted peptides and contain both natural and synthetic amino acid-based mitochondria 
targeting sequences which carry hydrophobic and positively-charged residues.  An 
example of such a peptide includes a group known as the Szeto-Schiller (SS) series which 
were designed to deliver dimethyl-tyrosine as an antioxidant motif to the mitochondria [95].  
These SS peptides can accumulate at the inner mitochondrial membrane (IMM) and 
readily cross cell membranes in an energy-independent manner, thereby increasing their 
potency as antioxidants [96].  The SS peptides have been reported to protect the 
mitochondria from oxidative damage, suggesting they can scavenge ROS and RNS, and 
inhibit lipid peroxidation due to their aromatic tyrosine residues [97]. 
 
To protect these peptides from enzymatic cleavage, the D-isomer of arginine was 
incorporated.  Furthermore, the peptide amino acid sequence, hydrophobicity, and overall 
charge for efficient mitochondrial penetration were extensively investigated [98].  Based 
on positive pre-clinical results, an SS peptide successfully made its way into clinical trials.  
Elamipretide, also known as SS-31 (Figure 1.5), is a small mitochondrially-targeted 
tetrapeptide with the sequence (D-Arg-dimethylTyr-Lys-Phe-NH2) that has been shown to 
reduce the production of ROS in the IMM  and stabilize cardiolipin, a diphosphatidyl-
glycerol lipid which participates in a variety of mitochondrial survival pathway mechanisms 
[99].  Though Elamipretide has obtained orphan drug designation for use in mitochondrial 





Figure 1.5.  The structure of Elamipretide (also known as SS-31 or MT-131).  It is a small 
mitochondrially-targeted tetrapeptide that has been reported to reduce mitochondrial ROS 




1.4.1  Targeting of Mitochondria through Linkage to Triphenylphosphonium Lipophilic  
Cations 
 
Triphenylphosphonium-based (TPP-based) modifications of molecules for 
targeting mitochondria is not a novel concept.  Abundant literature exists documenting the 
potent biological effects exhibited by small molecules containing TPP [100].  TPP cations 
conjugated to alkyl chain linkers were initially used as probes to study and determine 
mechanisms of coupling the mitochondrial membrane potential and oxidative 
phosphorylation.  The use of TPP-conjugated bio-active molecules was refined by M. 
Murphy when his group delivered TPP-based probes and antioxidants to mitochondria 
[101].  Since Murphy, many groups have synthesized novel mitochondria-targeted cationic 
compounds to traffic into the mitochondrial matrix and/or membranes.  Typically, the 
molecules with active moieties (i.e., free radical scavenging system) are conjugated to a 
linker sequence, generally an alkyl chain, which is conjugated to the lipophilic, charge-
delocalized TPP moiety.  Depending on the length of the linker alkyl chain, the compound’s 
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lipophilicity, cellular uptake, and site of mitochondrial sequestration can be modulated 
[102, 103].  Examples of these molecules are shown in Figure 1.6. 
 
 
Figure 1.6.  Common TPP-derived mitochondrial antioxidants.  Depending on the 
antioxidant, different alkyl chain lengths were found to optimize activity while minimizing 
toxicity.  MitoQ, the mammalian-based ubiquinone derivative, and SkQ1, the plant-based 
plastoquinone derivative, are derivatives of molecules found in the electron transport chain 
and currently in clinical trials.  MitoC3, a vitamin C derivative, and MitoE2, a vitamin E 
derivative, have also been developed but have not progressed past animal studies. 
 
 
Two TPP compounds have shown promise in clinical trials: MitoQ and SkQ1.  
MitoQ, developed by R. Smith and M. Murphy in the 1990s, is the most extensively studied 
and best understood TPP-derived compound.  It is an ubiquinone derivative with a C10-
linker that has been investigated because of its known endogenous antioxidant activity in 
the electron transport chain.  Not only is MitoQ taken up rapidly by mitochondria, which is 
driven by the membrane potential, but nearly all of it is adsorbed to the matrix surface of 
the inner membrane [104-106].  The ubiquinol form of MitoQ is the active antioxidant, 
which is oxidized to the ubiquinone form and then rapidly re-reduced by complex II, 
restoring its antioxidant efficacy [105].  As MitoQ is largely found adsorbed to the 
mitochondrial inner membrane, and its linker chain has been reported to enable its active 
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ubiquinol antioxidant component to penetrate deeply into the membrane core, it was 
anticipated that it may be an effective antioxidant against lipid peroxidation which has been 
confirmed in isolated mitochondria [104].  Clinical trials on MitoQ have demonstrated that 
it can be formulated into an effective pharmaceutical that can be successfully delivered 
orally to humans, including a safety profile of up to a year of use in patients [107].  These 
findings also suggest that orally administered MitoQ and related mitochondria-targeted 
antioxidants may also be applicable to the wide range of human pathologies that involve 
mitochondrial oxidative damage.   
 
SkQ1, developed by V. Skulachev in the 2000s, is a novel compound comprising 
of a plant-derived plastoquinone moiety with a C10-linked TPP head group.  It was 
synthesized for a multi-national collaboration project to study and prevent cellular 
senescence [108].  Studies of SkQ1 showed that it protected the mitochondria from a wide 
array of stressors in various human-derived cells and was able to act as a “rechargeable” 
antioxidant in the mitochondria like MitoQ  [109-114].  Clinical trials of SkQ1 indicated that 
it was safe and efficacious in treating dry eye by increasing corneal tear film stability, 
reducing corneal damage, and alleviating symptoms of dryness, burning, grittiness, and 
blurred vision, in addition to its anti-inflammatory effects [115-117]. 
 
The results from both mechanistic research and clinical trials for MitoQ and SkQ1 
suggest a viable avenue for developing mitochondrially-targeted antioxidants.  Though 
ubiquinone and plastoquinone showed therapeutic merit, they are mono-functional 
antioxidants which only quench ROS through the mechanism of free radical scavenging 
activity.  Furthermore, the phenol moiety, which is present on both MitoQ and SkQ1, is 
prone to auto-oxidation.  Therefore, we investigated the possibility of targeting our MFAOs 
to the mitochondria through conjugation of the TPP lipophilic cation.  We hypothesized 
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that the activity of our MFAOs can be enhanced by directly targeting mitochondrial 
dysfunction, thereby specifically delivering a drug to the greatest source of cellular ROS.  
The multifunctional compounds, especially JHX-4 and HK-2 (Figure 1.4), have shown the 
most therapeutic merit for neural disease pathologies affected by ROS.  The addition of a 
TPP lipophilic cation is likely to increase their efficacy by improving their targeting 
capability directly to the mitochondria, thereby decreasing the necessary dose to achieve 





The following chapters of this dissertation investigate various aspects of the drug 
development process with the MFAOs.  Investigations into the biodistribution of the pre-
existing MFAOs, their monofunctional FRS and CHL analogs, and their NF parents in 
various ocular, neural, and visceral tissues are reported in Chapter 2.  Multiple predictive 
models investigating the biological activity of the 24 compounds (i.e., experimentally 
determined tissue levels) against several calculated physicochemical descriptors were 
developed using both hierarchical cluster analysis (HCA) and quantitative structure activity 
relationship (QSAR) methods, resulting in the first ever published predictive models of 
ocular tissue deliver of orally-administered drugs in Chapter 3.  Molecular modeling 
studies, in vitro lens cultures, and in vitro binding studies in Chapter 4 examine the 
feasibility of oxysterol and MFAO binding against the lens protein αB-crystallin, which is 
reported to play a major role in cataractogenesis.  Finally, progress towards the synthesis 
of the JHX-series triphenylphosphonium (TPP) derivatives and their preliminary in vitro 
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Biodistribution of Multifunctional Antioxidants, Their Monofunctional Free Radical 
Scavenging and Chelating Analogs, and Nonfunctional Parents After Oral 
Administration 
 
2.1  Summary 
 
The tissue distribution of N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-sulfonamide, 
2-(pyrrolidin-1-yl)pyrimidine, 2-(piperidin-1-yl)pyrimidine, and their respective analogs 
possessing either free radical scavenger groups (FRS), chelating groups (CHL), or both 
as a multifunctional antioxidant (MFAO) were administered to 200-gram Sprague Dawley 
rats by mixing 0.05% of each compound into rodent chow.  After 7 days of feeding, the 
rats (n = 8 per group) were terminally perfused with phosphate-buffered saline and the 
biodistribution of these compounds were determined in ocular tissues including the 
cornea, iris with the ciliary body (iris/CB), lens, neural retina (NR), retinal pigmented 
epithelium with the choroid (RPE/C), brain, sciatic nerve (SN), kidney, and liver.  Each 
tissue was extracted, their protein concentration determined using the Bradford assay, 
and drug levels analyzed by HPLC-MS.  Oral administration showed that the 
unmetabolized levels of these compounds were present in all tissues examined.  While no 
obvious trends in the biodistribution data was evident, separating compounds by functional 
group indicated that the highest quantity of monofunctional CHL analogs were present in 
the cornea while the MFAOs, which possesses both CHL and FRS activity, distributed in 






2.2  Introduction 
 
Ocular drug delivery continues to be a major challenge for pharmacologists and 
drug delivery scientists because the main mechanisms for drug distribution and uptake 
into the eye remain largely undefined [1].  The access of drugs to ocular structures through 
the route of systemic administration is greatly hindered by the presence of two 
physiological barriers, the blood-aqueous barrier (BAB) and the blood-retinal barrier 
(BRB), that separate the eye from general circulation.  Successful oral ocular drug delivery 
depends on the ability of the drug to pass through these barriers [2-4].  Unfortunately, this 
often requires high doses of systemically administered drugs in order to reach therapeutic 
concentrations in the internal structures of the eye which can increase potential side 
effects due to systemic toxicity [5].    
 
Topical administration is considered the most suitable route of administration to 
the anterior chamber of the eye.  This is because the ocular surface is easily accessible, 
especially regarding pathologies affecting the anterior segment [6, 7].  However, 
conventional topical ophthalmic formulations have low ocular bioavailability because of 
dilution caused by constant physiologic lacrimal secretion and losses due to rapid 
drainage away from the ocular surface [8].  To improve topical administration in the 
anterior segment, several methods for sustained drug release have been studied such as 
nanoparticles [9-11], nanosuspensions [12-14], liposomes [15-17], dendrimers [18-20], 
hydrogels [21-23], and contact lenses [24-26].  Even with the rise in novel ophthalmic drug 
delivery systems, the basic understanding of major factors associated with drug targeting 




Other common routes of drug delivery to the eye include intravitreal, periocular, 
subretinal, and suprachoroidal injections [27].  However, the invasiveness and risks 
associated with injectable administrations, as well as the diversity of factors affecting 
biodistribution, limit clinical ocular pharmacokinetic research [28].  Appropriate and 
effective patient-compliant treatments are still an unmet medical need.  This is especially 
evident with the aging population through which an increase of irreversible visual 
impairments has been documented such as cataract, glaucoma, and macular 
degeneration [29].   
 
Little is known about the ocular biodistribution of orally-administered drugs.  Our 
laboratory previously developed three orally-active MFAOs and experimentally 
demonstrated that these MFAOs were able to independently scavenge reactive oxygen 
species (ROS) and chelate bio-active transition metals [30, 31], protect the lens against 
ROS generated by gamma irradiation, UV light, and ER stress [32], protect the retina and 
photoreceptor layer against light-induced retinal degeneration in an age-related macular 
degeneration (AMD) rat model [33], and prevent the formation of neurotoxic amyloidβ:zinc 
complexes in the lens, retina, and brain of transgenic Alzheimer’s mice [34].  Recently, 
two of these MFAOs were also shown to protect against blast-induced retinal function loss 
[35] and against noise-induced hearing loss [36].  A preliminary biodistribution study of all 
six MFAOs was conducted in mice to examine levels of drug in the lens, retina, and brain.  
In this study, it was found that the hydrophilic JHX-series of MFAOs distributed in greater 
levels to the lens, while the lipophilic HK-series of MFAOs distributed in greater levels to 
the brain.  Both JHX and HK compounds were observed in similar levels in the retina[37].   
 
This chapter extends these preliminary investigations from mice to Sprague 
Dawley rats.  Not only are the eyes of the rats larger compared to mice, but various tissues 
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of the eye can be more easily dissected and extracted.  In this study, all 24 compounds 
(Figure 2.1) which included the MFAOs, their monofunctional free radical scavengers 
(FRS) and transition metal chelators (CHL), as well as their nonfunctional parents (NF) 
were orally administered at 0.05 wt% in rat chow for seven days. The unmetabolized levels 
of these compounds were measured in various ocular, neural, and visceral tissues 
including the cornea, iris with the ciliary body (iris/CB), lens, neural retina (NR), retinal 
pigmented epithelium with the choroid (RPE/C), brain, sciatic nerve (SN), kidney, and liver.  
Because the JHX and HK drugs have similar structures and functions, it was hypothesized 
that similar trends would be observed between the drug classes to tissues requiring 
penetration through the blood-aqueous barrier (BAB), blood-retinal barrier (BRB), blood-
brain barrier (BBB), and blood-nerve barrier (BNB).  Our results indicated that various 
trends can be identified depending on distribution data division. 
 
2.3  Methods 
 
Animal Care.  All procedures were performed according to the ARVO Statement 
for the Use of Animals in Ophthalmic and Vision Research, as well as the University of 
Nebraska Medical Center Guidelines for Animals in Research. 
 
Bioavailability in Rats.  The bioavailability study was conducted using Sprague 
Dawley rats (male, 200-gram, n = 8 per group, 24 groups) with rat chow containing 0.05 
wt% of one of the 24 MFAO or analog compounds (Figure 2.1).  The compounds, 
dissolved in either acetone or ethanol, were sprayed onto rat chow and mixed, followed 







Figure 2.1.  The 24 orally-active analogs of N,N-dimethyl-4-(pyrimidin-2-yl)piperazine-1-
sulfonamide, 2-(pyrrolidine-1-yl)pyrimidine, and 2-(piperidine-1-yl)pyrimidine.  The 
compounds are separated into their nonfunctional parent (first row), free radical 
scavenging (FRS) analog (second row), chelating analog (third row), and multifunctional 




Rats were housed as follows: either groups of 2 or 3 per cage.  Rats had free 
access to food and water and were kept on a 12-hour day/night cycle.  Food consumption 
studies, measured at the beginning and end of the 7-day feeding period, indicated that 
each rat received an average daily dose of 46.2 ± 2.2 mg drug/kg body weight. 
 
After 7 days, each rat was placed under isoflurane anesthesia followed by a 
terminal trans-cardial perfusion.  The chest wall was opened, and the rib cage was cracked 
open to expose the heart.  The hepatic portal vein was sliced (terminal site of perfusion), 
and a 60-mL syringe filled with 1X phosphate-buffered saline with a 22-gauge needle was 
inserted into the left ventricle and slowly injected.  Upon completion of perfusion, which 
was monitored by bloodless, clear liquid flowing out of the hepatic portal vein, both eyes 
were enucleated followed by removal of the top lobe of the liver, one kidney (randomly), 
and one sciatic nerve (randomly).  The head was then decapitated via guillotine and the 
whole brain was removed.  The brain, kidney, liver, and sciatic nerve were placed in 
labeled 15 mL polypropylene centrifuge tubes and stored at -80 oC until homogenization.  
The eyes of the rats were immediately dissected at the ora serrata to separate the anterior 
and posterior segments.  From the anterior segment, the cornea, iris and ciliary body 
(Iris/CB), and lens were carefully removed.  From the posterior segment, the neural retina 
(NR) and the posterior globe containing the retinal pigmented epithelium with the choroid 
(RPE/C) were carefully removed.  All ocular tissues were placed in labeled 1.5 mL 
Eppendorf tubes and stored at -80 oC until homogenization. 
 
Determination of Drug Levels in the Ocular, Neural, and Visceral Tissues.  
The left and right cornea, iris/CB, NR, RPE/C, and SN of four rats were combined.  These 
combined organs, as well as the left and right lenses, half brain, and segments of the 
kidney and liver were homogenized using ground glass homogenizers in 10 mM acetate 
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buffer, pH 4, and 10 μL of 10 mM JHX-5 or JHX-1 in acetonitrile as an internal standard.  
Total sample volumes were as follows: 1 mL for cornea, iris/CB, and NR; 2 mL for RPE/C, 
SN, and lens; 3 mL for brain, kidney, and liver.  Following centrifugation at 5,000 x g for 
15 minutes (Sorvall RC-5B PLUS, Thermo Fisher Scientific, Waltham, MA) at 25 oC, the 
supernatant was transferred to a clean test tube.  The protein concentrations were 
determined according to Bradford [38] from a 10 μL aliquot directly from the supernatant 
for the cornea, iris/CB, NR, RPE/C, and SN, a 10 μL aliquot to 290 μL dilution of liver 
supernatant, a 10 μL aliquot to 200 μL dilution of lens and kidney supernatant, and a 10 
μL aliquot to 75 μL dilution of brain supernatant.  Dilutions were conducted using double 
distilled water.  The remaining supernatants were then de-proteinized with 1 mL of 20% 
trichloroacetic acid (TCA).  Following additional centrifugation at 15,000 x g for 30 minutes 
at 25 oC, each supernatant was transferred by pipette to a clean conical vial and dried in 
vacuo on Speedvac (Savant Speed Vac Plus SC210A, Thermo Fisher Scientific, Waltham, 
MA) for 5 hours at 25 oC.  Each remaining residue containing both the extracted compound 
and internal standard was dissolved in 200 μL of HPLC-grade acetonitrile, analyzed in 
triplicate by reverse-phase HPLC (HP Agilent Technologies, Series 1100, Santa Clara, 
CA) column (Luna 5 μm, C18, 250 mm x 4 mm, Phenomenex Inc., Torrance, CA), and 
eluted with 75% HPLC-grade aqueous methanol.  The eluent was monitored by UV at 
220, 254, and 280 nm and quantified by ESI-MS in either positive or negative mode on a 
Thermo Finnigan LCQ (Thermo Fisher Scientific, Waltham, MA). 
 
Data Analysis.  The HPLC/MS data was analyzed using the XCalibur 
QualBrowser program (Thermo Fisher Scientific, Waltham, MA) to determine the area 
under the curve.  Samples were quantified against standard curves of the analyzed 
compounds and all analyses were conducted in triplicate.  Final compound concentrations 
were reported in nanograms of drug per milligram of protein (ng drug/mg protein) ± SEM.  
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Linear regression analysis and bar graphs were generated with OriginPro Software 
(OriginPro 2016, OriginLab Co., Northampton, MA).  
 
2.4  Results 
 
Distribution values for these compounds ranged from 0 nanograms of drug per 
milligram of protein (ng drug/mg protein) to nearly 3.7 milligrams of drug per milligram of 
protein (mg drug/mg protein).  The parent HK-15 was undetectable in any ocular tissue or 
the brain, and both parents JHX-1 and JHX-5 were undetectable in the sciatic nerve. The 
levels FRS JHX-6 were found to approach 3.7 mg drug/mg protein in the cornea, while the 
levels of HK-2 exceeded 3.5 mg drug/mg protein in the NR and RPE/C.  The feeding data 
revealed that consumption of HK-15 was 49 mg/kg/day, both JHX-1 and JHX-5 were 50 
mg/kg/day, JHX-6 was 46 mg/kg/day, and HK-2 was 44 mg/kg/day.  The results of 
undetectable HK-15, JHX-1, and JHX-5 were confirmed by colleagues in the Fletcher 
laboratory using reverse-phase HPLC-MS. 
 
The quantified results of the biodistribution for all 24 compounds are summarized 
in Table 2.1.  The data is grouped according to the physiological barriers (blood-aqueous 
barrier [BAB], blood-retinal barrier [BRB], blood-brain barrier [BBB], blood-nerve barrier 
[BNB]) that the compounds were required to traverse in order to accumulate in the tissues 
examined.  While it was expected that similar tissue levels would be seen between the 
JHX and HK compounds, none were observed.  However, it is evident that tissue uptake 
of JHX-6 and HK-2 appear to be much greater than the other compounds.  To investigate 
whether any trends could be identified within each functional family, the compounds 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.1  Distribution of the Nonfunctional Parent (NF) Compounds 
 
The uptake of the parent compounds possessing no antioxidant functional groups 
(NF) in the eye, brain, sciatic nerve, kidney, and liver are shown in Figure 2.2.  Tissue 
uptake was separated according to drug penetration through physiological barriers (BAB, 
BRB, BBB, BNB) or normal tissue circulation (kidney and liver).  While no trends between 
the NFs were apparent, it was clear that the parent compounds JHX-1 and HK-13 were 
found in greatest levels across most tissues.   
 
Across the tissues requiring BAB passage, the following trends were observed.  
The methoxy JHX-5 and HK-11 showed an overall decrease in tissue levels compared to 
their non-methoxy derivatives JHX-1 and HK-9, while HK-15 was absent in both the eye 
and brain.  However, the non-methoxy HK-9 was found in higher levels in the lens 
compared to its methoxy derivative HK-11.  Furthermore, the non-methoxy HK-13 was 
observed to distribute in greatest quantities to the cornea and iris/CB, followed by non-
methoxy compounds JHX-1 and HK-9.  In the lens, JHX-1 was found in highest 
concentrations followed by HK-13 and HK-9.  This data suggests that the HK-13 parent 
scaffold may be superior for developing drugs targeted to the cornea and iris/CB, and the 
JHX-1 scaffold may be superior for developing drugs targeted to the lens. 
 
A similar trend was observed among all methoxy-containing NF compounds 
penetrating the BRB to reach the NR and the RPE/C.  Compared to the non-methoxy-
containing compounds, decreased distribution concentrations was observed with the 
methoxy derivatives.  JHX-1 was found in highest concentration in both the NR and 
RPE/C, while HK-11 was found in lowest concentration.  HK-15 was undetectable in both 
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the NR and RPE/C.  This suggests that JHX-1 may be the superior scaffold for developing 
drugs targeting the NR and RPE/C. 
 
 
Figure 2.2.  Summary of the NF drug levels to ocular, neural, and visceral tissues.  The 
distribution of NF drugs to tissues traversing through the (A) blood-aqueous barrier, (B) 
blood-retinal barrier, or (C) blood-brain and blood-nerve barriers, and (D) directly into 
visceral tissues to reach target tissues.  Drug levels are presented as the log of drug 






For neural tissue penetration through the BBB and the BNB, a similar trend was 
again observed for the parent compounds.  In the brain, the uptake methoxy JHX-5 was 
lower than the non-methoxy JHX-1, and neither JHX-1 or JHX-5 were detected in the SN.  
The methoxy HK-11 had slightly enhanced uptake into both the brain and sciatic nerve 
over the non-methoxy HK-9, and the non-methoxy HK-13 was found in highest levels in 
both the brain and SN.  Again, HK-15 was undetectable in the brain, but present in lowest 
levels in the SN compared to the other NF HK compounds.  This data suggests that the 
HK-13 parent scaffold may be superior for developing small molecules penetrating both 
the central and peripheral nervous system barriers. 
 
For visceral tissues, the uptake of methoxy compounds JHX-5 and HK-15 were 
lower than the non-methoxy compounds JHX-1 and HK-13.  The opposite trend was 
observed between the methoxy HK-11 and the non-methoxy HK-9.  HK-13 is again found 
in highest levels in both the kidney and liver compared to the other NF compounds.  
However, compared to drug levels quantified in the ocular and neural tissues, the NF drug 
concentrations in both the kidney and liver are at least 1 order of magnitude lower.  This 
is not surprising as the main roles of both the kidney and liver are to eliminate and/or 
metabolize drugs.  More polar and hydrophilic drugs are excreted by kidneys, and those 
which are more lipophilic can be metabolized and/or excreted by the liver into the 
gastrointestinal tract through bile [39]. 
 
2.4.2  Distribution of Free Radical Scavenging Compounds 
 
 
The structures and tissue levels of the free radical scavenging compounds (FRS) 
are shown in Figure 2.3.  The difference between the parent (NF) compounds and the 




Figure 2.3.  Summary of the FRS drug levels to ocular, neural, and visceral tissues.  The 
distribution of FRS drugs to tissues traversing through the (A) blood-aqueous barrier, (B) 
blood-retinal barrier, or (C) blood-brain and blood-nerve barriers, and (D) directly into 
visceral tissues to reach target tissues.  Drug levels are presented as the log of drug 




Distribution to tissues requiring BAB penetration showed similar trends between 
the cornea and iris/CB.  The methoxy compounds JHX-6 and HK-12 attained high tissue 
levels compared to their non-methoxy derivatives, and the same trend was observed 
between the methoxy HK-16 and non-methoxy HK-14 in the lens.  Increased tissue levels 
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were observed by all FRS methoxy derivatives compared to their non-methoxy 
counterparts except between methoxy HK-16 and non-methoxy HK-14 in the cornea and 
iris/CB.  Overall, JHX-6 was found in the highest levels among all BAB-related tissues.  
This contrasts with the BAB trend observed by the NFs where the greatest levels observed 
in the cornea and iris/CB were by the non-methoxy HK-13, and in the lens by non-methoxy 
JHX-1.  
 
For drugs crossing the BRB, a similar trend was observed among all FRS 
compounds.  Higher levels of the methoxy compounds JHX-6 and HK-12 were found 
compared to their non-methoxy derivatives JHX-2 and HK-10, and the opposite trend was 
observed between the methoxy HK-16 and the non-methoxy HK-14.  Once again, JHX-6 
demonstrated highest levels among all tissues with the non-methoxy JHX-2 also observed 
in higher levels compared to the HK compounds.  This trend is similar to the observation 
with the NFs.  While the NF non-methoxy JHX-1 was found in greatest levels in both the 
NR and RPE/C, both the FRS non-methoxy JHX-2 and FRS methoxy JHX-6 compounds 
achieved greater tissue levels than the HK compounds. 
 
With respect to BBB and BNB penetration, the methoxy derivatives of all FRS 
compounds achieved higher tissue concentrations in both in the brain and sciatic nerve.  
The methoxy JHX-6 achieved the highest brain levels, while the methoxy HK-16 achieved 
the highest SN levels.  This is surprising since the parent NF scaffolds for these 
compounds, the methoxy compounds JHX-5 and HK-15, respectively, achieved the lowest 
levels in the brain and SN.  This observation suggests that the addition of the para-hydroxy 
moiety may play an important role in BBB and BNB penetration.  These trends may also 
be due to the differences in compound lipophilicity, as it is generally assumed that drugs 




In the visceral tissues, similar trends were observed for the FRS compounds.  
Again, the methoxy compounds JHX-6 and HK-16 achieved higher levels compared to 
their non-methoxy counterparts, but the methoxy HK-12 was observed in lower levels 
compared to the non-methoxy HK-10.  The visceral tissue levels of the NF non-methoxy 
HK-13 were found to be greatest, while the FRS methoxy JHX-6 was observed in greatest 
levels.  Overall FRS levels in visceral tissues were higher than for the NF compounds.  
Interestingly, the non-methoxy HK-10 was observed to distribute in similar levels to certain 
groups of tissues.  Its distribution was observed to not only be similar between the cornea, 
iris/CB, kidney, and liver, but also between the NR, RPE/C, brain, and SN, suggesting that 
HK-10 may have a good balance of both hydrophilic and lipophilic properties. 
 
2.4.3  Distribution of Metal Binding Compounds 
 
The structures of the transition metal binding compounds (CHL) and their tissue 
levels are shown in Figure 2.4.  The difference between the CHL compound and their 
parent analogs are the presence of two carbonyl groups adjacent to the nitrogen 
conjugated to the pyrimidine bottom ring (i.e., an imide functionality).  For the JHX-series, 
this is called a piperazine-2,6-dione moiety; for the five-membered HK-series, a 
succinimide moiety; for the six-membered HK-series, a glutarimide moiety. 
 
In tissues requiring transport through the BAB, the trends appear to be similar for 
the HK compounds.  Lower tissue concentrations are observed for the methoxy derivatives 
compared to their non-methoxy analogs.  For the JHX compounds, this trend was 
observed in the cornea and the lens, but not in the iris/CB.  These trends differed from 
those observed for the NF compounds except in the lens.  The non-methoxy JHX-3 
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achieved the highest levels in the cornea and lens, while the non-methoxy HK-1 achieved 
highest concentrations in the iris/CB. 
 
 
Figure 2.4.  Summary of the CHL drug levels to ocular, neural, and visceral.  The 
distribution of CHL drugs to tissues traversing through the (A) blood-aqueous barrier, (B) 
blood-retinal barrier, or (C) blood-brain and blood-nerve barriers, and (D) directly into 
visceral tissues to reach target tissues.  Drug levels are presented as the log of drug 




In tissues penetrating the BRB, similar trends were observed for the CHLs between 
the NR and RPE/C.  The methoxy compounds JHX-7 and HK-3 were found in lower levels 
than their non-methoxy derivatives JHX-3 and HK-1, while the methoxy HK-7 was found 
in lower levels in the NR, but in higher levels in the RPE/C, compared to its non-methoxy 
HK-5.  These trends were also observed in the NF compounds, though HK-15 was 
undetectable in both the NR and RPE/C.  Compared to the NF compounds which 
demonstrated highest levels of the non-methoxy JHX-1 in the NR and RPE/C, the non-
methoxy HK-1 was observed in highest levels in both the NR and RPE/C. 
 
The observed trends for BBB and BNB passage were similar among HK 
compounds but opposite for JHX compounds.  The non-methoxy HK-1 achieved higher 
levels compared to its methoxy HK-3 in both the brain and SN, and the methoxy HK-7 
achieved higher levels than its non-methoxy HK-5 in both the brain and SN.  The non-
methoxy JHX-3 was found in higher levels in the brain, but in lower levels in the SN, 
compared to the methoxy JHX-7.  The non-methoxy JHX-3 was also observed in highest 
levels in the brain, while the methoxy HK-7 was observed in highest levels in the SN.  
Apart from the observation between the non-methoxy JHX-3 and methoxy JHX-7 in the 
brain, none of the CHL compounds shared the trends observed with their NF parent 
analogs. 
 
In the visceral tissues, kidney levels of the methoxy JHX-7 were markedly higher 
compared to all other CHLs, and both methoxy compounds HK-3 and HK-7 were observed 
in lower levels compared to their non-methoxy derivatives HK-1 and HK-5.  In the liver, 
opposite trends were observed where the level of the methoxy JHX-7 was lower compared 
to the non-methoxy JHX-3, but the levels for both methoxy compounds HK-3 and HK-7 
were higher compared to their non-methoxy derivatives HK-1 and HK-5.  The JHX CHLs 
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followed a similar trend compared to their NF analogs in the liver, but not in the kidney.  
The methoxy derivatives of both HK compounds showed decreased kidney levels but 
increased liver levels compared to their NF analogs.  Compared to their NF analogs, HK-
1 and HK-3 showed similar levels in the liver and HK-5 showed similar levels in the kidney.  
Finally, the NF non-methoxy HK-13 was found in the greatest levels in both the kidney 
and liver, while the methoxy JHX-7 and the non-methoxy JHX-3 were found in greatest 
levels in the kidney and liver, respectively. 
 
2.4.4  Distribution of Multifunctional Compounds 
 
The compounds of greatest interest are the MFAOs because they combine the 
effects of the FRS and CHL compounds into one molecule.  Their structures and tissue 
levels are presented in Figure 2.5. 
 
In tissues requiring BAB penetration, the methoxy compounds JHX-8 and HK-4, 
as well as the non-methoxy compound HK-6, were found in markedly lower levels 
compared to their analogs JHX-4, HK-2, and HK-8, respectively.  Unlike the NF non-
methoxy HK-13, found in greatest levels in the cornea and iris/CB, and NF non-methoxy 
JHX-1 which was found in greatest levels in the lens, the MFAO non-methoxy HK-2 was 
found in the greatest levels in the cornea, while the methoxy HK-8 was found in greatest 
levels in both the iris/CB and the lens.  The same distribution trends were observed in 
tissues requiring BRB penetration to distribute into the NR and the RPE/C.  Though the 
NF non-methoxy JHX-1 was observed in highest levels in both the NR and RPE/C, the 
non-methoxy HK-2 was found in greatest levels in both the NR and RPE/C.  Though the 
trends in greatest tissue uptake between the NFs and the MFAOs are different, the MFAOs 
all appear to exhibit similar distribution trends to both the BAB and the BRB.  This may 
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suggest that the MFAOs all share similar properties which allow for their comparable 
passage through both the BAB and BRB.  
 
 
Figure 2.5.  Summary of the MFAO drug levels to ocular, neural, and visceral tissues.  
The distribution of MFAO drugs to tissues traversing through the (A) blood-aqueous 
barrier, (B) blood-retinal barrier, or (C) blood-brain and blood-nerve barriers, and (D) 
directly into visceral tissues to reach target tissues.  Drug levels are presented as the log 




In the brain, the non-methoxy HK-2 achieved higher levels than the methoxy HK-
4.  In contrast, both the methoxy compounds JHX-8 and HK-8 achieved higher levels 
compared to their non-methoxy derivatives JHX-4 and HK-6.  In the SN, again the non-
methoxy HK-2 achieved higher levels than the methoxy HK-4 and the methoxy JHX-8 
achieved higher levels than its non-methoxy JHX-4.  However, the methoxy HK-8 was 
found in lower levels than its non-methoxy HK-6.  The methoxy compound HK-8 was found 
in greatest overall levels in the brain (though HK-2 was close), while the non-methoxy HK-
2 was found in greatest overall levels in the SN.  The MFAO distribution levels to the brain 
and SN are unexpected because it is thought that the properties of compounds requiring 
passage across the BBB are similar to those required for passage across the BNB due to 
anatomical similarities between these barriers [41].  With the exception of the non-methoxy 
HK-2 and its methoxy HK-4 which distribute in similar levels to both the brain and SN, the 
other MFAOs vary in multiple orders of magnitude. 
 
 
Finally, in the visceral tissues examined, tissue uptake trends are opposite 
between the non-methoxy JHX-4 and methoxy JHX-8 where JHX-8 is observed in higher 
levels in the kidney but in lower levels in the liver.  The non-methoxy HK-2 and methoxy 
HK-4 are observed in similar levels in both the kidney and liver where levels of HK-2 are 
markedly increased compared to HK-4.  The trends between the non-methoxy HK-6 and 
methoxy HK-8 show that the presence of the methoxy group increase tissue levels to both 
the kidney and liver.  Compared to the NF compounds, a similar trend was only observed 








There are multiple routes of drug administration to the body such as subcutaneous, 
intramuscular, and intravenous injections, topical ointments or drops, inhaled aerosols, 
and oral agents.  Each of these routes is known to have a specific purpose, certain 
advantages, and varying absorption, distribution, metabolism, and excretion (ADME) 
profiles [2, 42].  To increase patient compliance, topical and oral dosage forms are the 
major foci of ocular drug delivery even though these routes may suffer from slow and/or 
low drug absorption [43].  Unfortunately, no single route of administration is optimal for all 
drugs [44]. 
 
Though oral drug administration is the most preferred and common drug delivery 
route resulting in the highest patient compliance and decreased cost of care [45], little is 
known about the ocular drug distribution of orally available compounds.  Upon oral 
administration, the efficacy of a small molecule depends on its stability and absorption in 
the gastrointestinal tract, rate of metabolism, and distribution.  Disadvantages associated 
with general oral drug administration include low stability, poor solubility, and low 
membrane permeability which may prevent the uptake of drugs into the bloodstream and 
tissues [46].   
 
This study investigated the levels of unmetabolized drugs distributed to various 
intraocular, neural, and visceral tissues, including the cornea, iris with the ciliary body 
(iris/CB), lens, neural retina (NR), retinal pigmented epithelium with the choroid (RPE/C), 
brain, sciatic nerve (SN), kidney, and liver, and provides a starting point for pharmaceutical 
scientists to identifying the necessary factors for penetrating the BAB, BRB, BBB, and 
BNB.  200-gram Sprague Dawley rats were fed with chow containing 0.05 wt% of one of 
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the 24 compounds (Figure 2.1) for seven days.  The major assumption of this study was 
that after 7 days of oral treatment, steady-state levels of drug would be achieved.  Using 
this method, the average daily dose of all drugs was calculated to be 46.2 ± 2.2 mg/kg/day 
and the unmetabolized drug levels were found to range from 0 ng drug/mg protein to 3.7 
mg drug/mg protein among all tissues examined.  The drug levels achieved in all examined 
tissues are summarized in Table 2.1.  In this table, 17 out of 216 data points had high 
errors, which was defined as an SEM value greater than or equal to 60% of the mean 
value.  All 17 samples with high error were re-analyzed to confirm tissue concentrations.  
This high error could be attributed to several factors including incomplete perfusion, low 
tissue protein concentrations (for example, the cornea), or the small sample size of the 
pooled tissues, and it appears that the high errors occurred primarily with the smaller 
pooled samples (cornea, iris/CB, neural retina, and RPE/C).  Additionally, there were two 
high errors identified in the lens with the FRS JHX-6 and FRS HK-16 where these factors 
may not have a role because the lens is avascular and has a high protein concentration.  
It cannot be ruled out that these errors may be linked to the assumption that steady-state 
drug levels should have been achieved after 7 days without having conducted proper time-
course studies. 
 
Compounds were separated into their functional families (i.e., NF, FRS, CHL, or 
MFAO) and their tissue levels were examined (Figures 2.2 – 2.5, respectively).  In 
addition, the tissues were grouped according to required barrier passage through the BAB, 
BRB, BBB, or BNB, or directly to visceral tissues.  Organs and tissues have layers of 
epithelial cells and endothelial cells which contain tight junctions, forming barriers between 
them and the circulating blood [47].  These tight junctions establish a barrier that directly 
regulates paracellular flux and indirectly regulates transcellular flux.  While these 
structures were thought to be static and largely impermeable, they are dynamic and allow 
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for the transepithelial permeability to small ions, as well as larger molecular flux depending 
on the expression of the tight junction proteins such as occludin and claudins [48-51].   In 
general, small lipophilic molecules are passively diffused transcellularly if they are not 
substrates to any cellular transporter, and paracellular permeability can greatly differ 
between the various diverse tissue barriers, such as the BAB, BRB, BBB, and BNB, 
depending on the expression and composition of tight junction proteins [52]. 
 
The vasculature of the ciliary body is supplied by the anterior ciliary arteries and 
long posterior ciliary arteries, forming the major arterial circle near the root of the iris 
wherefrom branches supply the iris, ciliary body, and the anterior choroid.  The ciliary body 
vasculature is also fenestrated to allow passage of plasma proteins and molecules into 
the stroma as part of aqueous humor production [53].  The BAB is believed to be 
composed of the non-pigmented cell layer of the ciliary epithelium and the endothelial cells 
of the iris blood vessels [54].  Tight junctions are present in the non-pigmented cell layer 
of the ciliary epithelium, suggesting its role as the physical barrier to drug movement 
across the ciliary body [55].   
 
Passage through the BAB in our studies was measured by drug levels in the 
cornea, iris/CB, and lens.  The NF compounds demonstrate that non-methoxy JHX-1 and 
HK-13 distribute in greater quantities to the cornea, iris/CB, and lens than their methoxy 
derivatives and that this same trend is observed in the lens between the non-methoxy HK-
9 and its methoxy derivative HK-11 (Figure 2.2A).  The non-methoxy NFs are inherently 
more lipophilic than their methoxy counterparts.  The distribution of the FRS compounds 
indicate that, with the exception of the non-methoxy HK-14 and its methoxy derivative HK-
16 in the cornea and the iris/CB, the methoxy derivatives achieve higher levels in the 
cornea, iris/CB, and lens compared to their non-methoxy counterparts (Figure 2.3A).  The 
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CHL compounds show that, with the exception of non-methoxy JHX-3 and methoxy JHX-
7 in the iris/CB, all non-methoxy compounds were found in greater concentrations than 
their methoxy derivatives in the cornea, iris/CB, and lens (Figure 2.4A).  Finally, the MFAO 
results show the same trends across all tissues where the non-methoxy compounds JHX-
4 and HK-2 are found in greater concentrations than their methoxy derivatives JHX-8 and 
HK-4, but the methoxy HK-8 was found in greater concentrations than its non-methoxy 
HK-6 (Figure 2.5A).  Of these analogs, the NF non-methoxy HK-13, the FRS methoxy 
JHX-6, the CHL non-methoxy JHX-3, and the MFAO methoxy HK-8 were found to 
penetrate the BAB best as determined by their drug levels in the cornea, iris/CB, and lens.  
The FRS and MFAO results agree with previous reports that less lipophilic/more 
hydrophilic compounds better penetrate the BAB [56].  The investigations of a 400 mg oral 
dose of moxifloxacin and subsequent levels in the aqueous humor [57] comprise one of 
the few studies examining drug penetration across the BAB in humans.  Moxifloxacin 
achieved therapeutic concentrations without any observed or reported patient side effects 
for up to 12 hours.  Though this study confirms penetration of an orally-administered 
prescription antibiotic across the BAB, the factors required for BAB permeability have yet 
to be elucidated.  Another study examining ocular distribution of intravenous-infused drugs 
in Sprague Dawley rats reports that more hydrophilic characteristics are required for BAB 
passage [56].  However, because limited evidence exists in understanding the factors 
required for BAB penetration, these results warrant further investigations. 
 
In the posterior segment of the eye, the blood-retinal barrier (BRB) restricts the 
entry of therapeutic agents from the circulating blood into the retina.  The BRB consists of 
two parts, the inner BRB (iBRB) formed by non-fenestrated retinal capillary endothelial 
cells, and the outer BRB (oBRB) formed by the tight junctions of the retinal pigmented 
epithelial cells with support from Bruch’s membrane that prevent passage of large 
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molecules from the choriocapillaris [58, 59].  Drugs in the bloodstream rapidly equilibrate 
with the extravascular space of the choroid because the choriocapillaris is fenestrated, 
and the RPE limits the permeation of drugs from the choroid to the retina [60].  Unlike the 
BAB where drugs with more hydrophilic characteristics are required for passage, drugs 
penetrating both the inner and outer BRB are reported to exhibit more lipophilic 
characteristics [56, 61].  Unfortunately, few studies have investigated the factors required 
for orally-administered drugs to penetrate the BRB and distribute to the NR or the RPE/C.  
A study conducted in 10 human patients examined the vitreous permeability of an orally-
administered antiviral prodrug, famciclovir (3 x 500 mg) through the BRB.  It was reported 
that these patients were scheduled to undergo an elective pars plana vitrectomy and were 
overall healthy (i.e., BRB was not compromised).  This small lipophilic molecule was found 
to achieve therapeutic concentrations without any observed or reported patient side 
effects [62].  Though in a small patient population, this study provides evidence supporting 
the necessity of lipophilic properties of drugs for BRB passage. 
 
Our BRB results show that, with the NF compounds, the non-methoxy derivatives 
are found in greater levels than methoxy derivatives in both the NR and RPE/C (Figure 
2.2B).  The FRS compounds indicate that the methoxy derivatives JHX-6 and HK-12, but 
not HK-16, are found in greater levels compared to their non-methoxy derivatives in both 
the NR and RPE/C (Figure 2.3B).  The CHL compounds show that all non-methoxy 
derivatives are found in greater levels than the methoxy derivatives in the NR, and the 
same is seen in the RPE/C except between the non-methoxy HK-5 and methoxy HK-7 
(Figure 2.4B).  Finally, the MFAOs demonstrate that the non-methoxy JHX-4 and HK-2, 
and the methoxy HK-8, are found in greater levels than their derivatives in both the NR 
and RPE/C (Figure 2.5B).  Of these analogs, the NF non-methoxy JHX-1, the FRS 
methoxy JHX-6, the CHL non-methoxy HK-1, and the MFAO non-methoxy HK-2 were 
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found to penetrate the BRB best as determined by drug levels in the NR and the RPE/C.  
With the exception of the methoxy FRS JHX-6, the compounds with greater lipophilic 
characteristics were found to penetrate the BRB better, providing further evidence that 
compounds with greater lipophilic properties can better penetrate the BRB [56]. 
 
Few studies exist investigating drug distribution through the BNB into peripheral 
nerves such as the SN.  One recent study from GlaxoSmithKline examined the penetration 
of intravenous-infused small molecule drugs into various peripheral nerves, including the 
sciatic nerve and dorsal root ganglion, and compared their distribution to the CNS (brain 
and spinal cord).  Unlike passage through the BNB which is not well studied, investigations 
of drug permeability through the BBB are well documented, though hampered due to lack 
of robust strategies to mimic the BBB in vitro [63].  It was observed that the sciatic nerve 
is permeable to small molecule drugs with large structural diversity and, in general, most 
small molecule drugs exhibited higher BNB than BBB penetration [40].  With a caveat, our 
study does support GlaxoSmithKline’s study results.  The NF HK-series distributed in 
higher levels to the SN, while the NF JHX-series achieved higher levels to the brain 
(Figure 2.2C).  The FRS HK-series also distributed in higher levels to the SN, while the 
FRS JHX-series achieved higher levels in the brain.  Moreover, all methoxy derivatives 
were found in higher concentrations than the non-methoxy derivatives in both the SN and 
the brain (Figure 2.3C).  The methoxy CHLs JHX-7, HK-3, and HK7 and non-methoxy 
HK-5 achieved higher levels in the SN, while the non-methoxy CHLs JHX-3 and HK-1 
were observed in higher levels in the brain (Figure 2.4C).  Finally, the MFAO non-methoxy 
compounds JHX-4, HK-2, and HK-6, as well as the methoxy JHX-8, distributed in higher 
levels to the SN, while the methoxy compounds HK-4 and HK-8 achieved higher levels in 
the brain (Figure 2.5C).  Of the 24 studied drugs, 16 achieved higher levels in the SN than 
the brain.  These drugs included JHX-4, 5, 6, 7, and HK-2, 3, 5, 6, which inherently 
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possess more hydrophilic properties, and HK-9, 10, 11, 12, 13, 14, 15, 16, which inherently 
possess more lipophilic properties.  This property characterization was based on 
calculated LogP values where a LogP of less than 0 denotes greater hydrophilic 
properties, and a LogP of greater than 0 denotes greater lipophilic properties.  These 
results differ from the reported properties believed to maximize both BNB and BBB 
penetration (i.e., lipophilicity is directly proportional to both BNB and BBB penetration) [40, 
64, 65].  Additionally, the NF non-methoxy HK-13, the FRS methoxy HK-16, the CHL 
methoxy JHX-7, and the MFAO non-methoxy HK-2 achieved greatest levels in the SN and 
are observed to penetrate the BNB best, while the NF non-methoxy HK-13, the FRS 
methoxy JHX-6, the MB non-methoxy JHX-3, and the MFAO methoxy HK-8 achieved 
greatest levels in the brain and penetrate the BBB best.  Further investigations are 
required to elucidate the required factors for penetration through these complex 
physiological barriers [40].  Moreover, though the BBB is one of the most studied 
physiological barrier with overwhelming evidence supporting the claims that lipophilic 
drugs more easily penetrate the BBB [64-66], computational algorithms are being 
employed to further improve BBB drug development and to confirm whether currently 
assumed drug properties for BBB permeation are crucial [67]. 
 
Both the kidney and liver are visceral tissues involved in drug ADME.  The liver is 
responsible for selective uptake, metabolism, and excretion of the majority of drugs 
introduced to the body [68], while the kidney filters and excretes drugs and their 
metabolites [69].  Due to their role in drug elimination, it is no surprise that all drugs were 
found in much lower levels in both the kidney and the liver compared to other target 
tissues.  The trends between the kidney and liver for the NF compounds were similar, 
where the non-methoxy compounds JHX-1 and HK-13, and the methoxy HK-11, were 
found in greater levels than their derivatives (Figure 2.2D).  The opposite trends were 
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observed with the FRS compounds where the methoxy JHX-6 and HK-16, and the non-
methoxy HK-10, were found in greater levels compared to their derivatives in both the 
kidney and liver (Figure 2.3D).  The trends for the CHL compounds were opposite 
between the kidney and liver, where the methoxy JHX-7 and non-methoxy compounds 
HK-1 and HK-5 were found in greater levels than their derivatives in the kidney, but the 
non-methoxy JHX-3 and methoxy compounds HK-3 and HK-7 were found in greater levels 
than their derivatives in the liver (Figure 2.4D).  The MFAO trends show that the non-
methoxy HK-2 and methoxy HK-8 were both found in greater levels in the kidney and liver 
compared to their derivatives, while the methoxy JHX-8 was found in greater levels in the 
kidney and its non-methoxy JHX-4 was found in greater levels in the liver (Figure 2.5D).  
The compounds found in greatest overall concentrations to both the kidney and liver were 
the NF non-methoxy HK-13, the FRS methoxy JHX-6, and the MFAO non-methoxy HK-2.  
The CHL methoxy compound JHX-7 was found in greater levels in the kidney, while the 
non-methoxy JHX-3 was found in greater levels in the liver.  It is well recognized that the 
lipophilicity and extent of metabolism of a drug contribute to liver accumulation [70].  
Moreover, increased hydrophilic properties of a drug contributes to the increase of the 
probability of excretion through the kidneys [69].  Our results indicate that the drugs 
accumulate in the visceral tissues at much lower levels compared to the ocular or neural 
tissues, suggesting that they are effectively excreted and do not strongly target the kidney 
or the liver. 
 
2.6.  Conclusions 
 
We have demonstrated that the unmetabolized compound levels of orally 
administered MFAOs and their analogs can be measured in various intraocular tissues.  
With the exception of HK-15 in ocular tissues and the brain, and JHX-1 and JHX-5 in the 
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SN, the remainder of the compounds were found in all tissues.  Various trends in the 
distribution profiles were identified depending on how the drugs are parsed.  While the 
trends reported here confirm previous findings in our laboratory, further investigations are 
required to understand the pertinent factors of drug passage across the physiological 
barriers required to deliver into target tissues.  Because few attempts have been made to 
study the relationship between oral drug administration, physiological barrier penetration, 
and intraocular drug delivery, I have pursued and conducted modeling studies based on 
the data presented here to identify the physicochemical parameters necessary to predict 
the biological activity of these 24 compounds in ocular, neural, and visceral tissues.  The 
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Developing Predictive Models of Multifunctional Antioxidant Compound 
Distribution and Their Analogs using Hierarchical Cluster Analysis and 
Quantitative Structure Activity Relationship Methods 
 
3.1  Summary 
 
Drug delivery to the eye is a major challenge and distribution to ocular tissues 
includes passage through physiological barriers.  There have been few attempts at 
studying the relationships between drug administration and intraocular drug delivery, but 
none have examined ocular tissue distribution of orally-administered drugs.  Preliminary 
linear regression analysis was conducted on the most abundant compounds found in 
ocular, neural, and visceral tissues presented in Chapter 2 to determine whether their 
observed accumulation can be linked to their calculated physicochemical parameters. 
Several strong correlations were revealed when the whole data set was subjected to 
hierarchical cluster analysis (HCA) and quantitative structure activity relationship (QSAR) 
analysis, paired with linear regression analysis.  The results from these methods have 
identified several previously unknown relationships among the examined compounds and 
identified several physiologically-relevant predictive models to various ocular, neural, and 
visceral tissues.  This is the first published report for the development of predictive models 







3.2  Introduction 
 
Methods to effectively and efficiently handle and analyze the exponential increase 
of data have become increasingly important [1].  Conventionally, data research involves 
data sets with numerous variables that can be handled by multivariate regression 
modeling.  In the area of drug development, various data mining techniques, such as 
hierarchical cluster analysis (HCA), quantitative structural activity relationship analysis 
(QSAR), and linear regression analysis have been applied to understand relationships 
between the intrinsic properties of drugs and how they relate to a drug’s biological activity 
[2, 3]. 
 
3.2.1  Physicochemical Parameters 
 
Physicochemical parameters, also known as molecular descriptors, describe 
various properties of a molecule that are obtained through theoretical calculations.  These 
descriptors are fundamental in computational drug design and discovery because they 
relate the various intrinsic properties of chemicals to their determined biological profiles 
[4, 5].  Over time, molecular descriptors have been improved by various refined 
chemoinformatic methods, and the continuous development of computational tools further 
improves the accuracy of physicochemical descriptors and therefore, computational 
models.  The physiochemical descriptors used in this chapter, and their definitions, are 
summarized in Table 3.1. 
 




Clustering is a fundamental task in data mining whose goal is to discover new 
relationships between data based on a geometric distance measure to determine the 
(dis)similarity between any pair of data points.  It is an invaluable tool for the exploratory 
and unsupervised analysis of multi-dimensional or multivariate data sets which partition 
data into homogeneous subsets, or clusters, to uncover undetermined relationships within 
data sets.  The two most common clustering techniques are “K-means clustering” (KCA) 
and “hierarchical clustering” (HCA).  KCA involves pre-specifying a number of desired 
clusters while HCA allows for a single-nested hierarchy of clusters from which partitions 
can be post-specified.  This allows the HCA algorithm to study relationships between 
clusters not possible with KCA as the HCA is able to test all possible hierarchical 
permutations of a given data set [6]. 
 
HCA has gained popularity in the biomedical sciences, specifically with analyzing 
healthcare and genomics data [7, 8].  HCA attempts to group subjects within proximity into 
clusters using one of two strategies.  The first strategy is agglomerative clustering, or a 
“bottom-up” approach where each data point is treated as its own cluster.  Based on the 
algorithm, data is combined into larger clusters until all data points are part of the same 
cluster.  The second strategy is divisive clustering, or the “top-down” approach which is 
the exact opposite of agglomerative clustering, where all data points are part of one cluster 
and are gradually broken down to individual data points.  The advantages of both methods 
are that no prior knowledge or information about the number of desired clusters is required 
and the methods are simply implemented through the application of mathematical 
algorithms.  One major drawback to HCA, which is used advantageously here, is that this 




Within HCA are multiple distance metric algorithms that may alter the number and 
type of clusters.  The three most common linkage metrics include single-linkage, 
complete-linkage, average-linkage, and the most common geometric distance is 
Euclidean [9].  For the purposes of this study, the linkage metrics complete-linkage and 
average-linkage were paired with Euclidean distance (i.e., the distance of the straight line 
between two points) metric.  The complete-linkage algorithm identifies the maximum 
distance between the furthest data points between two clusters.  At each stage of the 
clustering process, the two clusters with the smallest complete-linkage distance are 
combined.  This allows for the merging of most dissimilar clusters, thereby maximizing the 
probability that the final cluster groups are different and new relationships can be 
identified.  Mathematically, the complete-linkage algorithm is optimally efficient due to its 
rigor [10].  In contrast, the average-linkage algorithm takes the average distance between 
central data points of two clusters (i.e., the cluster centroids).  Here, the two clusters with 
the smallest distance between their centroids are combined.  This linkage metric combines 
the sensitivity of the single-linkage algorithm, which is prone to skewing from outliers, and 
the rigor of complete-linkage, resulting in clusters with average dissimilarity [11].  Both the 
complete-linkage and average-linkage algorithms are most commonly used in HCA. 
 
3.2.3  Quantitative Structure Activity Relationships 
 
Quantitative structure activity relationship (QSAR) models are mathematical 
classifications that relate a set of predictor variables to biological response variables.  In 
QSAR modeling, the goal is to identify molecular properties (i.e., physicochemical 
parameter(s)) important for biological activity (i.e., tissue distribution) [12].  The data 
obtained from QSAR is two-fold: the QSAR model summarizes alleged relationships 
between chemical structures and biological activity in a data set of chemicals, and then it 
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predicts the activity of new chemicals based on the summarized relationship from the 
identified model [13].  Additionally, there are essential steps taken in QSAR to ensure 
maximal efficiency in developing representative models such as data preparation, data 
analysis, and model validation. 
The objective of this study is to determine whether the compound levels observed 
in chapter 2 can be correlated with the molecular attributes of the compounds.  From here, 
the most important relationships between compound properties and their tissue levels can 
be identified to develop predictive models for ocular drug delivery.  Although developing 
these predictive models appears to be a relatively simple task, it has substantial 
applications in understanding how drugs exert different biological responses [14].  Using 
both HCA and QSAR confirms the validity of the models by comparing the similarity of the 
results between the use of two different algorithms. 
 
3.3  Programs and Methods 
 
Programs.  Hierarchical cluster analysis was conducted using the intrinsic 
“Hierarchical Cluster Analysis” algorithm with OriginPro Software (OriginPro 2016, 
OriginLab Co., Northampton, MA).  Quantitative structure activity relationship analysis was 
conducted using the intrinsic “QuaSAR” algorithm with Molecular Operating Environment 
Software (MOE v. 2016.08, Chemical Computing Group, Montreal, Canada). 
 
Data.  The distribution data for this chapter was obtained from Chapter 2 (Table 
2.1).  As is common practice in QSAR, all average drug concentrations (ng drug/mg 
protein ± SEM) were transformed to a logarithm scale, base 10.  A second data set was 
generated by mathematically standardizing the drug levels for each tissue and calculating 
a standardized Z-score.  All values of zero, and Z-scores greater than two standard 
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deviations about the mean (Z-score ≥ 2 or Z-score ≤ -2), were excluded from the data set.  
These included HK-15 in the cornea, iris/CB, lens, and NR; HK-15 and HK-2 in the RPE/C; 
HK-15 and JHX-6 in the brain; JHX-1 and JHX-5 in the SN; and JHX-5 in the liver.  This 
data was also transformed to a logarithm scale, base 10.   
 
To calculate the physicochemical parameters, each of the 24 multifunctional 
antioxidants (MFAOs), their monofunctional free radical scavenging (FRS) and bio-active 
transition metal chelating (CHL) analogs, and their nonfunctional analogs (NF) were 
modeled using “Molecule Builder” in MOETM.  After all 24 compounds were modelled, they 
were added to a molecular database where they were all energy-minimized using Merck’s 
Molecular Forcefield 94x with a gradient of 0.05.  After the minimization procedure, the 
physicochemical parameters for each drug was calculated using the “Calculate 
Descriptors” algorithm in MOETM.  The selected descriptors and their definitions are listed 
in Table 3.1. 
 
Hierarchical Cluster Analysis.  The logged drug distribution data and the 
calculated physicochemical descriptors of the drugs were isolated for each tissue.  The 
data was subject to hierarchical cluster analysis (HCA) for both data sets (all data and 
standardized data) using the “average-linkage” and “complete-linkage” clustering 
algorithms paired with Euclidean distance metric.  The resulting dendrograms, one 
generated per descriptor per tissue, were obtained and each identified group was 
manually separated into their respective clusters.  The clusters chosen for further analysis 
were selected based on meeting Hansch analysis criteria, which requires a minimum of 
5-6 drugs per cluster per calculated descriptor.  The resulting clusters were analyzed by 
linear regression analysis, and all clusters with a Pearson’s correlation coefficient of 
greater than 0.5 (r ≥ 0.5) were identified.  To meet modeling criteria, clusters with a 
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coefficient of determination greater than 0.5 (r2 ≥ 0.5) and a calculated p-value ≤ 0.05 were 
identified and confirmed with quantitative structure activity relationship (QSAR) algorithms 
in MOETM. 
 
Quantitative Structure Activity Relationship Analysis.  Both data sets and their 
calculated physicochemical descriptors were also subject to the “QuaSAR” algorithm in 
MOETM, and the resulting clusters were compared to those from HCA.  All correlations with 
an r2 ≥ 0.5 were validated using the “QuaSAR” intrinsic validation function.  The clusters 
that matched those identified using HCA and passed validation were re-correlated against 
all calculated physicochemical parameters to investigate whether any other relationships 
could be identified between these clusters.   
 
 
3.4  Results 
 
3.4.1  Calculation of Molecular Descriptors 
 
The physicochemical parameters for the 24 compounds consisting of 
multifunctional antioxidants (MFAOs), their monofunctional free radical scavenging (FRS) 
and bio-active transition metal chelating (CHL) analogs, and their nonfunctional parents 
(NF) were modeled using “Molecule Builder” in MOETM.  After all compounds were 
constructed, they were added to a molecular database where they were all energy-
minimized using Merck’s Molecular Forcefield 94x with a gradient of 0.05.  After the 
minimization procedure, the physicochemical parameters for each compound was 
calculated using the “Calculate Descriptors” algorithm in MOETM.  The selected descriptors 








A measure of how easily a molecule's electron cloud is distorted 
by an electric field[15] 
ASA Hydrophilic 
Water accessible surface area calculated using a radius of 1.4 
Angstroms for the water molecule using a polyhedral atomic 
representation 
ASA_H Hydrophobic 
Water accessible surface area of all hydrophobic (|qi| ≤ 0.2) atoms 
where qi denotes the partial charge of atom 'i' 
ASA_P Hydrophilic 
Water accessible surface area of all polar (|qi| ≥ 0.2) atoms where 
qi denotes the partial charge of atom 'i' 
CASA- Hydrophilic 
Water accessible surface area of all atoms with a negative partial 
charge multiplied by the maximum negative partial charge of the 
molecule 
CASA+ Hydrophilic 
Water accessible surface area of all atoms with positive partial 
charge multiplied by the maximum positive partial charge of the 
molecule 
Dipole Hydrophilic Dipole moment calculated from the partial charges of the molecule 
FASA_H Hydrophobic 
Fractional hydrophobic accessible surface area calculated as 
ASA_H / ASA 
FASA_P Hydrophilic 
Fractional polar accessible surface area calculated as ASA_P / 
ASA 
Kier1 Structural 
First kappa shape index: (n-1)2 / m2 where n denotes the number 
of atoms and m is the number of bonds (excluding hydrogens)[16] 
LogP Hydrophobic 
Log of the octanol/water partition coefficient.  This property is 
calculated from a linear atom type model with r2 = 0.931 and 
RMSE = 0.393 on 1,827 molecules[17] 
LogS Hydrophilic 
Log of the aqueous solubility (mol/L).  This property is calculated 
from an atom contribution linear atom type model with r2 = 0.90 on 
ca. 1,200 molecules[18] 
PM3_Dipole Hydrophilic The dipole moment calculated using the PM3 Hamiltonian[19] 
SLogP Hydrophobic 
Log of the octanol/water partition coefficient (including implicit 
hydrogens).  This property is an atomic contribution model that 
calculated logP from the given structure, i.e., the correct 
protonation state.  Results may vary from the logP descriptor.  The 
training set for SLogP was ca. 7,000 structures[20] 
SMR Structural 
Molecular refractivity (including implicit hydrogens).  This property 
is calculated form an 11 descriptor linear model with r2 = 0.997 
and RMSE = 0.168 on 1,947 small molecules[21] 
vsurf_Cp Structural 
Critical packing parameter which measures the steric bulk of the 
molecule. 
vsurf_D1 Hydrophobic A measure of the hydrophobic surface area of a molecule. 
vsurf_G Structural 
Globularity which measures how close the molecular shape 
resembles a perfect sphere. 
vsurf_W1 Hydrophilic A measure of the hydrophilic surface area of a molecule. 
 
Table 3.1.  Definitions of select calculated physicochemical descriptors, which were 
chosen based on literature precedence.  Each of the 24 compounds were modeled and 




3.4.2  Initial Linear Regression Analysis 
 
The biodistribution results from Chapter 2 revealed that there were no obvious 
trends with tissue accumulation.  The compounds were then separated into their functional 
families and it was observed that various compounds in each functional family 
accumulated in highest tissue levels overall.  These compounds included the NFs JHX-1 
and HK-13, the FRS JHX-6, the CHLs JHX-3 and HK-1, and the MFAOs HK-2 and HK-8.  
The relationships between the common calculated physicochemical parameters of these 
compounds and compound tissue levels observed in the cornea, iris with the ciliary body 
(Iris/CB), lens, neural retina (NR), retinal pigmented epithelium with the choroid (RPE/C), 
brain, sciatic nerve (SN), kidney, and liver were investigated.  Two linear correlations were 
conducted with these compounds: one including the NFs JHX-1 and HK-13, and those 
excluding the NFs.  This was done to isolate a data set for only compounds with known 
antioxidant activity.  Initial linear regression analysis was conducted using calculated 
physicochemical parameters that have been most commonly identified in literature, which 
include the partition coefficient (logP), dipole moment (Dipole), kappa shape index (Kier1), 
and the log of predicted aqueous solubility (logS).  The definitions of these calculated 
physicochemical parameters are reported in Table 3.1.  Moderate correlations were 
defined as having an “r” value between ±0.5 and ±0.7, while strong correlations were 
defined as an “r” value between ±0.7 and ±1.0.   
 
When the NF parent compounds were included, initial correlations resulted in three 
moderate correlations between iris/CB and LogS (-0.513), lens and Kier1 (+0.519), and 
brain and Kier1 (+0.505).  These correlations are highlighted in Table 3.2.  However, 
when the parent compounds were excluded and the calculated correlations were focused 
only on compounds with known antioxidant function, six moderate correlations (r between 
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±0.5 and ±0.7) and seven strong correlations (r between ±0.7 and ±1.0) were observed.  
These correlations, reported in Table 3.3, include: cornea with dipole (+0.777) and Kier1 
(+0.797); lens with dipole (+0.810), Kier1 (+0.655), and LogS (-0.653); NR with dipole (-
0.664) and Kier1 (-0.733); RPE/C with LogS (+0.668); brain with dipole (+0.734) and Kier1 
(+0.818); SN with LogS (+0.837); and liver with dipole (+0.542) and Kier1 (+0.535). 
 
 Log P Dipole Kier1 LogS 
Cornea -0.043 0.315 0.464 -0.205 
Iris/CB 0.386 -0.210 -0.073 -0.513 
Lens -0.283 0.396 0.519 -0.252 
N.R. -0.237 -0.014 0.125 0.018 
RPE/C -0.424 0.071 0.192 0.278 
Brain -0.179 0.313 0.505 -0.194 
S.N. 0.440 -0.393 -0.294 -0.240 
Kidney 0.371 -0.100 -0.086 -0.019 
Liver -0.007 0.125 0.257 -0.284 
 
Table 3.2.  Correlation results between the NFs JHX-1 and HK-13, the FRS JHX-6, the 
CHLs JHX-3 and HK-1, and the MFAOs HK-2 and HK-8.  Three moderate correlations 




 Log P Dipole Kier1 LogS 
Cornea -0.309 0.777 0.797 0.419 
Iris/CB 0.337 0.170 0.097 0.377 
Lens 0.303 0.810 0.665 -0.653 
N.R. 0.453 -0.664 -0.733 0.359 
RPE/C 0.029 -0.462 -0.494 0.668 
Brain -0.376 0.734 0.818 0.351 
S.N. -0.158 -0.083 -0.060 0.837 
Kidney 0.293 0.071 -0.010 0.469 
Liver -0.480 0.542 0.535 0.383 
 
Table 3.3.  Correlation results between the functional antioxidants including the FRS JHX-
6, the CHLs JHX-3 and HK-1, and the MFAOs HK-2 and HK-8. Six moderate correlations 
and seven strong correlations were observed, which is more than the data set which 
included the parent NFs (Table 3.2).  Excluding the parent NFs strengthened the 
correlations between lens and Kier1 and brain and Kier1 but did not yield a correlation 




Because these preliminary correlations showed promising results, the linear 
regression analysis was expanded to include additional calculated physicochemical 
parameters: atomic polarizability (Apol), water-accessible surface area (ASA), 
hydrophobic-accessible surface area (ASA_H), polar-accessible surface area (ASA_P), 
semi-empirical parameterized model 3 dipole (PM3_Dipole), atomic-contribution partition 
coefficient (SLogP), and molecular refractivity including correct molecular protonation 
states (SMR).  These parameters are also defined in Table 3.1.  Calculated correlations 
using the data set that included the NF parent compounds yielded 6 more moderate 
correlations and 4 new strong correlations, mainly between the ocular tissues and the 
brain and ASA_H/ASA_P (Table 3.4).  Excluding the NF parent compounds yielded 16 
more moderate correlations and 12 more strong correlations, and all parameters 
examined correlated to at least one tissue (Table 3.5).  These results indicate that 
conducting linear regression analysis between the drug tissue levels and their calculated 
descriptors may lead to the development of predictive tissue uptake models. 
 
  Apol ASA ASA_H ASA_P SLogP PM3_Dipole SMR 
Cornea 0.330 0.391 -0.308 0.647 -0.240 0.142 0.350 
Iris/CB -0.206 -0.155 -0.524 0.197 0.228 -0.320 -0.197 
Lens 0.217 0.317 -0.645 0.801 -0.472 0.401 0.275 
N.R. -0.173 -0.055 -0.874 0.552 -0.331 -0.075 -0.114 
RPE/C -0.091 0.025 -0.818 0.601 -0.483 0.019 -0.029 
Brain 0.323 0.401 -0.377 0.706 -0.371 0.146 0.356 
S.N. -0.287 -0.274 -0.274 -0.110 0.380 -0.548 -0.303 
Kidney -0.098 -0.062 -0.349 0.176 0.300 -0.346 -0.114 
Liver 0.091 0.142 -0.423 0.453 -0.181 0.120 0.118 
 
Table 3.4.  Expanded correlations examining more calculated physicochemical 
parameters continued from Table 3.2.  Linear regression analysis with the parent NFs 
JHX-1 and HK-13, the monofunctional FRS JHX-6, the monofunctional CHLs JHX-3 and 
HK-13, and the MFAOs HK-2 and HK-8 yielded six more moderate correlations and four 





  Apol ASA ASA_H ASA_P SLogP PM3_Dipole SMR 
Cornea 0.833 0.848 0.617 0.912 -0.465 0.479 0.825 
Iris/CB 0.176 0.198 -0.047 0.353 0.319 -0.195 0.147 
Lens 0.599 0.586 0.361 0.679 0.024 0.905 0.595 
N.R. -0.676 -0.658 -0.757 -0.504 0.640 -0.801 -0.696 
RPE/C -0.469 -0.445 -0.657 -0.233 0.194 -0.555 -0.474 
Brain 0.882 0.892 0.840 0.819 -0.516 0.387 0.873 
S.N. 0.007 0.036 -0.169 0.182 -0.064 -0.383 -0.004 
Kidney 0.055 0.079 -0.208 0.282 0.305 -0.244 0.030 
Liver 0.482 0.493 0.190 0.655 -0.589 0.570 0.497 
 
Table 3.5.  Expanded correlations examining more calculated physicochemical 
parameters continued from Table 3.3.  Linear regression analysis with the monofunctional 
FRS JHX-6, the monofunctional CHLs JHX-3 and HK-13, and the MFAOs HK-2 and HK-




3.4.3  Full and Standardized Data Set Linear Regression Analyses 
 
Linear regression analysis was then used to investigate any potential relationships 
between the 24 drug tissue levels and their calculated physicochemical descriptors.  
These results are shown in Table 3.6, where nine moderate correlations (“r” value 
between ±0.5 and ±0.7) were identified.  Relationships included cornea vs. LogP and 
vsurf_Cp; iris/CB vs. vsurf_Cp; NR vs. LogP, LogS, and vsurf_Cp; and RPE/C vs. LogP, 
LogS, and vsurf_Cp. No strong correlations (“r” value between ±0.7 and ±1.0) were 
identified.  Next, the data set was mathematically standardized to exclude any 
experimental concentration zero values or outliers determined by Z-score.  This 
standardized data set was also subject to linear regression analysis against the calculated 
physicochemical descriptors and results are shown in Table 3.7.  Interestingly, no 








Ocular and Visceral Tissues 
Cornea Iris/CB Lens NR RPE/C Brain SN Kidney Liver 
Apol 0.093 0.059 0.050 0.048 0.043 -0.010 -0.229 -0.209 0.041 
ASA 0.092 0.060 0.048 0.066 0.053 -0.020 -0.207 -0.198 0.085 
ASA_H -0.205 -0.214 -0.200 -0.396 -0.316 -0.084 -0.186 -0.234 -0.417 
ASA_P 0.202 0.175 0.154 0.277 0.222 0.024 -0.114 -0.079 0.308 
CASA+ 0.383 0.346 0.242 0.392 0.377 0.080 -0.309 -0.186 0.179 
CASA- 0.386 0.364 0.188 0.370 0.349 0.015 -0.186 -0.220 0.311 
Dipole 0.259 0.212 0.353 0.303 0.297 0.186 -0.322 -0.112 0.123 
FASA_H -0.208 -0.184 -0.203 -0.353 -0.290 -0.041 0.104 0.005 -0.364 
FASA_P 0.208 0.184 0.203 0.353 0.290 0.041 -0.104 -0.005 0.364 
Kier1 0.199 0.163 0.112 0.197 0.165 0.018 -0.184 -0.179 0.203 
LogP -0.518 -0.486 -0.310 -0.565 -0.548 -0.141 0.345 0.127 -0.202 
LogS 0.419 0.402 0.368 0.508 0.519 0.203 -0.369 0.084 -0.069 
PM3 0.137 0.091 0.150 0.148 0.127 0.005 -0.326 -0.266 0.098 
SLogP -0.450 -0.422 -0.259 -0.489 -0.460 -0.092 0.265 0.151 -0.281 
SMR 0.132 0.098 0.071 0.097 0.086 -0.001 -0.231 -0.209 0.081 
vsurf_Cp -0.553 -0.563 -0.466 -0.687 -0.615 -0.470 -0.144 -0.322 -0.434 
vsurf_D1 0.063 0.026 -0.025 -0.005 0.017 0.001 -0.368 -0.230 -0.169 
vsurf_G 0.105 0.089 0.105 0.120 0.101 -0.016 -0.161 -0.188 0.146 
vsurf_W1 0.309 0.267 0.189 0.339 0.301 0.044 -0.243 -0.148 0.248 
 
Table 3.6.  Linear regression analysis of the full data set (all 24 drugs) summarizing the 
resulting Pearson’s correlation coefficients (r-values).  Values between |0.5| and |0.7| are 
highlighted in yellow and indicate moderate correlations and values greater than |0.7| are 
highlighted in green and indicate strong correlations.  Nine moderate correlations were 






Ocular and Visceral Tissues 
Cornea Iris/CB Lens NR RPE/C Brain SN Kidney Liver 
Apol 0.130 0.097 0.070 0.084 0.269 -0.183 0.037 -0.209 0.244 
ASA 0.122 0.091 0.063 0.099 0.249 -0.197 0.028 -0.198 0.286 
ASA_H -0.082 -0.079 -0.108 -0.305 0.043 0.002 0.243 -0.234 -0.328 
ASA_P 0.168 0.135 0.121 0.258 0.230 -0.119 -0.088 -0.079 0.449 
CASA+ 0.333 0.288 0.183 0.344 0.427 -0.185 -0.151 -0.186 0.314 
CASA- 0.343 0.317 0.128 0.324 0.381 -0.194 -0.105 -0.220 0.434 
Dipole 0.204 0.144 0.316 0.255 0.392 -0.056 -0.237 -0.112 0.198 
FASA_H -0.158 -0.125 -0.162 -0.331 -0.203 0.140 0.184 0.005 -0.454 
FASA_P 0.158 0.125 0.162 0.331 0.203 -0.140 -0.184 -0.005 0.454 
Kier1 0.192 0.153 0.094 0.195 0.292 -0.180 -0.040 -0.179 0.374 
LogP -0.426 -0.378 -0.207 -0.479 -0.485 0.136 0.249 0.127 -0.286 
LogS 0.299 0.265 0.270 0.401 0.368 -0.064 -0.271 0.084 -0.059 
PM3 0.115 0.060 0.132 0.128 0.251 -0.098 -0.249 -0.266 0.195 
SLogP -0.365 -0.325 -0.165 -0.409 -0.417 0.177 0.193 0.151 -0.381 
SMR 0.156 0.121 0.079 0.120 0.287 -0.185 0.012 -0.209 0.280 
vsurf_Cp -0.325 -0.290 -0.300 -0.497 -0.363 -0.153 -0.017 -0.322 -0.375 
vsurf_D1 0.119 0.085 0.006 0.048 0.257 -0.134 0.050 -0.230 0.061 
vsurf_G 0.123 0.109 0.115 0.147 0.259 -0.195 0.013 -0.188 0.329 
vsurf_W1 0.269 0.218 0.142 0.308 0.347 -0.195 -0.143 -0.148 0.400 
 
Table 3.7.  Linear regression analysis of the mathematically standardized data sets 
summarizing the resulting Pearson’s correlation coefficients (r-values).  Drugs excluded 
from the data sets included HK-15 in the cornea, iris/CB, lens, and NR; HK-15 and HK-2 
in the RPE/C; HK-15 and JHX-6 in the brain; JHX-1 and JHX-5 in the SN; and JHX-5 in 








Due to the inconclusive results obtained from the linear regression analyses, and 
the absence of strong correlations, cluster analysis was also employed to identify 
additional correlations.  The clusters were calculated using hierarchical cluster analysis 
(HCA), an algorithm that studies the relationships between data by testing all possible 
hierarchical permutations present in a data set, in OriginProTM using the Euclidean (2D 
straight line) distance metric and both average-linkage and complete-linkage clustering, 
the most popular distance metrics in HCA.  This method allows for the minimization of 
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intra-cluster distances while maximizing inter-cluster distances using two different linkage 
criteria. A minimum of 5 drugs in a cluster was required for further analysis. 
 
Figure 3.1 shows an example of the resulting HCA dendrograms for the ocular 
tissues and brain versus the physicochemical parameters Apol (hydrophilic) and Kier1 
(structural).  For each dendrogram (one per tissue per descriptor), the x-axis illustrates an 
arbitrary position of each of the 24 drug levels in 2D space, and the y-axis measures the 
2D geometric distance between each coordinate pair (x = drug level, y = calculated 
descriptor value, or vice-versa).  Drug coordinate pairs in closer proximity to each other 
are represented by linkages closer to the X-axis.  Each subsequent linkage is 
representative of the formation of a larger cluster comprising all previously linked data 
points under.  This process is continued until one final cluster remains.  Each of the color 
coded groups for each tissue indicates a post-process specified cluster.  Clusters with less 
than 5 data points were excluded from further analysis, and clusters with 5 or more data 
points were isolated into their respective groups and analyzed using linear regression 
analysis.  Though many clusters looked similar between tissues and between descriptors, 
their correlations were generally not similar.  The correlation results from the HCA clusters 
were separated into tables containing structural, hydrophilic, and hydrophobic parameters 
for both data sets with both average-linkage and complete-linkage cluster metrics.  Table 
3.8 shows the cluster correlations for the structural parameters of the full data sets, while 
Table 3.9 shows the resulting cluster correlations for the structural parameters of the 
standardized data sets.  Tables 3.12 and 3.13 show the cluster correlations for the 
hydrophilic parameters of the full data set, while Tables 3.14 and 3.15 show the cluster 
correlations for the hydrophilic parameters of the standardized data set.  Finally, Tables 






































































































































































































































































































































































































































































































































































































































set, while Tables 3.18 and 3.19 show the cluster correlations for the hydrophobic 





Full Data Set Using Average-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Kier1 
Cluster 1 0.620 0.650 0.426 0.761 0.372 0.681 -0.094 0.310 0.743 
Cluster 2 -0.344 0.630 0.744 0.059 0.660 0.702 0.403 -0.132 0.289 
Cluster 3 0.769 - -0.575 - - 0.342 0.397 - 0.426 
SMR 
Cluster 1 -0.129 0.335 0.065 -0.460 0.063 0.277 -0.162 0.202 -0.162 
Cluster 2 0.495 -0.752 -0.537 0.048 -0.317 0.670 0.232 -0.701 0.443 
Cluster 3 - -0.124 - - - - - -0.445 - 
vsurf_Cp 
Cluster 1 -0.613 -0.213 -0.427 -0.262 -0.464 0.189 0.256 -0.287 0.371 
Cluster 2 -0.208 0.916 -0.112 0.129 0.226 0.184 0.274 -0.401 0.767 
Cluster 3 0.023 0.119 - - -0.397 - 0.178 - - 
vsurf_G 
Cluster 1 0.468 -0.220 0.320 0.258 -0.316 -0.425 -0.464 0.134 -0.510 
Cluster 2 0.045 0.188 -0.171 0.075 0.290 0.765 -0.490 -0.365 -0.593 
Cluster 3 -0.584 -0.169 - - - - -0.346 -0.393 - 
 
Table 3.8.  Cluster correlations for the structural parameters of the full data set for each 
tissue using the average-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.9).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Kier1  Cornea Cluster 3: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  Iris/CB  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 6, 7, 8, 11, 12, 16 
Kier1  Iris/CB  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  NR  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  NR  Cluster 3: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
Kier1  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 6, 7, 8, 11, 12, 16 
Kier1  Lens  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  Brain  Cluster 1: JHX-1, 2, 3; HK-3, 4, 6, 7, 8, 11, 12, 15, 16 
Kier1  Brain:  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  SN  Cluster 1: JHX-2, 3, 4; HK-3, 4, 8, 15 
SMR  NR  Cluster 2: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
SMR  Brain  Cluster 2: JHX-4, JHX-5, JHX-7, JHX-8, HK-6, HK-15 
SMR  Liver  Cluster 2: HK-3, 6, 7, 11, 12, 15, 16 
Cp  Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 11, 16 
Cp  SN  Cluster 2: JHX-2, 3, 4; HK-1, 3, 4, 6, 8, 9, 10, 11, 14, 15 
G  SN  Cluster 1: JHX-2, 3, 4; HK-1, 3, 4, 6, 8, 9, 10, 11, 14, 15 






Full Data Set Using Complete-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Kier1 
Cluster 1 0.620 0.115 0.426 0.529 0.341 0.681 0.123 -0.302 -0.002 
Cluster 2 -0.344 0.630 0.744 0.695 0.660 0.702 0.403 -0.132 0.289 
Cluster 3 0.769 -0.291 -0.575 -0.503 -0.391 0.342 0.422 -0.045 0.426 
SMR 
Cluster 1 -0.129 -0.063 0.065 -0.460 -0.868 0.277 -0.356 0.212 0.776 
Cluster 2 0.718 -0.248 -0.537 0.048 -0.280 0.670 0.710 -0.400 0.443 
Cluster 3 0.495 -0.696 - - 0.098 - 0.232  -  - 
vsurf_Cp 
Cluster 1 -0.775 0.135 -0.427 -0.367 -0.464 0.189 -0.231 -0.287 0.371 
Cluster 2 -0.170 -0.089 -0.474 -0.178 -0.397 0.184 0.924 -0.401 0.767 
Cluster 3 -0.795  -  -0.406 - -0.609 - 0.178 - - 
vsurf_G 
Cluster 1 0.086 0.172 0.320 0.486 -0.316 -0.425 -0.276 0.134 -0.510 
Cluster 2 0.344 0.225 -0.738 0.075 0.290 0.765 -0.381 0.144 -0.593 
Cluster 3 -0.308  -  0.619 -0.445 - - -0.346  -  - 
 
Table 3.9.  Cluster correlations for the structural parameters of the full data set for each 
tissue using the complete-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.8).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Kier1  Cornea Cluster 3: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  Iris/CB  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  NR  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  NR  Cluster 3: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
Kier1  RPE/C  Cluster 1: JHX-1; HK-3, 4, 6, 7, 11, 12, 16 
Kier1  RPE/C  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  RPE/C  Cluster 3: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
Kier1  Lens  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1  Brain  Cluster 1: JHX-1, 2, 3; HK-3, 4, 6, 7, 8, 11, 12, 15, 16 
Kier1  Brain:  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
SMR  Cornea Cluster 2: JHX-5, 8; HK 4, 15, 16 
SMR  NR  Cluster 2: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
SMR  Brain  Cluster 2: JHX-4, 5, 7, 8; HK-6, 15 
SMR  Kidney  Cluster 2: JHX-2; HK-3, 4, 7, 8, 11, 15, 16 
SMR  SN  Cluster 1: JHX-2, 3, 4, 6, 7, 8; HK-3, 4, 8, 15 
Cp  SN  Cluster 2: JHX-2, 3, 4; HK-1, 3, 4, 6, 8, 9, 10, 11, 14, 15 
G  NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
G  SN  Cluster 1: JHX-2, 3, 4; HK-1, 3, 4, 6, 8, 9, 10, 11, 14, 15 





Standardized Data Set Using Average-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Kier1 
Cluster 1 0.647 0.657 0.462 0.785 0.425 0.572 -0.094 0.310 0.756 
Cluster 2 0.769 0.630 0.744 0.549 0.660 -0.195 0.403 -0.132 0.426 
Cluster 3  -   -   -   -   -   -  0.397  -  0.289 
SMR 
Cluster 1 -0.747 0.209 0.065 0.156 0.063 -0.549 -0.162 0.358 -0.162 
Cluster 2 -0.827 -0.752 -0.537 0.048 -0.116 0.970 0.232 -0.400 -0.263 
Cluster 3 0.495 0.502 - -  -  -  -   -  -0.187 
vsurf_Cp 
Cluster 1 -0.613 -0.213 0.070 -0.100 -0.527 0.253 0.256 -0.353 0.487 
Cluster 2 -0.208 0.916 -0.474 -0.030 0.226 -0.112 0.274 -0.401 0.767 
Cluster 3 0.023 0.119 -0.406 -0.343 -0.397 - 0.178 - - 
vsurf_G 
Cluster 1 0.468 -0.220 0.320 0.486 0.170 -0.017 -0.464 0.134 -0.204 
Cluster 2 0.233 0.188 -0.738 -0.011 0.472 0.498 -0.490 -0.365 -0.593 
Cluster 3 -0.584 -0.169 0.619 0.075 0.452 - -0.346 -0.393 - 
 
Table 3.10.  Cluster correlations for the structural parameters of the standardized data set 
for each tissue using the average-linkage algorithms.  Cells shaded in yellow and green 
are moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.11).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Kier1 Cornea Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 6, 7, 8, 11, 12, 16 
Kier1 Cornea Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 Iris/CB  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 6, 7, 8, 11, 12, 16 
Kier1 Iris/CB  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 NR  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 6, 7, 8, 11, 12, 16 
Kier1 Lens  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 SN  Cluster 1: JHX-2, 3, 4; HK-4, 8 
SMR Cornea Cluster 1: JHX-1; HK-1, 2, 3, 5, 7, 11, 12, 13, 14 
SMR Cornea Cluster 2: HK-4, 6, 9, 10, 16 
SMR NR  Cluster 2: JHX-2, 3, 4, 5, 6, 7, 8; HK-8 
SMR Brain  Cluster 1: JHX-1; HK-1, 2, 3, 4, 5, 9, 10, 11, 12, 13, 14 
Cp Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 11, 16 
Cp SN  Cluster 2/3: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
G NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 






Standardized Data Set Using Complete-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Kier1 
Cluster 1 0.143 -0.010 0.462 0.529 0.281 0.572 0.123 0.310 0.756 
Cluster 2 0.769 0.630 0.744 0.549 0.660 -0.195 0.403 -0.132 0.426 
Cluster 3 -0.257 -0.291 -0.575 -0.183 -0.391  -  0.422  -  0.289 
SMR 
Cluster 1 -0.747 0.190 0.065 0.156 -0.868 0.590 -0.356 -0.429 -0.162 
Cluster 2 -0.827 -0.696 -0.096 0.048 -0.280 0.003 0.710 0.358 -0.263 
Cluster 3 0.495 0.502  -   -  0.443 0.970 0.232 -0.103 -0.187 
vsurf_Cp 
Cluster 1 -0.775 -0.590 -0.314 -0.030 -0.527 0.718 -0.231 -0.353 -0.914 
Cluster 2 -0.293 -0.663 -0.474 0.847 0.226 -0.555 0.924 -0.401 0.096 
Cluster 3 0.023 0.030 -0.406 -0.121 -0.397 -0.112 0.178  -  0.767 
vsurf_G 
Cluster 1 0.086 0.461 0.412 0.486 -0.218 -0.580 -0.276 0.286 -0.410 
Cluster 2 0.430 0.815 -0.738 -0.011 0.472 -0.315 -0.381 -0.531 -0.232 
Cluster 3 -0.584 0.187 0.619 0.075 0.452 0.498 -0.346 0.091 -0.593 
 
Table 3.11.  Cluster correlations for the structural parameters of the standardized data set 
for each tissue using the complete-linkage algorithms.  Cells shaded in yellow and green 
are moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.10).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Kier1 Cornea Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 Iris/CB  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 NR  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 Lens  Cluster 2: HK-1, 2, 5, 9, 10, 13, 14 
Kier1 SN  Cluster 1: JHX-2, 3, 4; HK-4, 8 
SMR Cornea Cluster 1: JHX-1; HK-1, 2, 3, 5, 7, 11, 12, 13, 14 
SMR Cornea Cluster 2: HK-4, 6, 9, 10, 16 
SMR Kidney  Cluster 2: JHX-2; HK-3, 4, 7, 8, 11, 15, 16 
Cp Brain  Cluster 1: JHX-1, 8; HK-3, 4, 9, 10, 12 
Cp SN  Cluster 2/3: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
G Iris/CB  Cluster 2: JHX-2, 3, 4; HK-5, 12, 14 
G NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 








Full Data Set Using Average Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Apol 
Cluster 1 0.345 0.342 0.390 0.502 0.492 0.165 -0.243 -0.032 -0.444 
Cluster 2 -0.063 -0.168 -0.454 -0.476 -0.461 -0.410 -0.161 -0.170 0.105 
Cluster 3 - - - - - - - - - 
ASA 
Cluster 1 0.374 0.380 0.441 0.528 0.535 0.128 -0.328 0.099 -0.423 
Cluster 2 -0.002 -0.128 -0.185 -0.215 -0.344 -0.445 0.077 0.015 -0.074 
Cluster 3 - - - - - - - - - 
ASA_P 
Cluster 1 -0.513 -0.453 -0.361 -0.244 -0.408 -0.507 -0.540 -0.525 -0.550 
Cluster 2 0.578 0.439 0.254 0.185 0.331 0.334 -0.356 0.143 -0.904 
Cluster 3 0.496 0.420 0.176 0.185 -0.066 0.295 0.289 0.582 0.743 
CASA+ 
Cluster 1 0.864 0.937 0.890 0.720 0.573 0.776 0.820 0.891 0.930 
Cluster 2 0.195 0.196 0.520 0.479 0.409 0.473 0.334 0.220 0.089 
Cluster 3 -0.211 -0.061 0.257 0.202 0.447 0.283 -0.134 -0.487 -0.224 
CASA- 
Cluster 1 -0.280 -0.301 -0.158 -0.084 -0.045 -0.264 -0.074 0.318 -0.370 
Cluster 2 -0.463 -0.389 -0.256 -0.270 0.036 -0.157 -0.007 -0.025 0.014 
Cluster 3 - - - - - - - - - 
Dipole 
Cluster 1 0.227 -0.261 0.547 0.346 -0.298 -0.694 -0.332 -0.047 -0.124 
Cluster 2 0.542 -0.116 -0.856 0.210 -0.038 0.675 -0.178 0.030 -0.315 
Cluster 3 -0.692 -0.318 0.715 - - - 0.130 - - 
FASA_P 
Cluster 1 0.450 -0.117 0.244 0.365 -0.283 -0.566 -0.382 0.093 -0.586 
Cluster 2 0.524 -0.196 -0.209 -0.294 0.540 0.477 -0.596 0.612 -0.631 
Cluster 3 -0.379 -0.095 0.567 - - - -0.148 0.299 - 
LogS 
Cluster 1 -0.167 0.153 0.151 0.023 -0.570 -0.408 0.150 -0.220 0.355 
Cluster 2 0.246 0.751 0.391 -0.094 -0.367 0.528 0.446 -0.495 0.305 
Cluster 3 0.912 -0.411 - - - - 0.727 0.305 - 
PM3 
Cluster 1 -0.002 0.459 0.200 -0.091 -0.480 -0.620 -0.480 -0.264 0.165 
Cluster 2 -0.751 0.050 -0.486 -0.327 0.102 0.067 -0.802 -0.724 -0.552 
Cluster 3 -0.239 -0.632 - - -0.227 -0.314 0.808 0.549 -0.419 
vsurf_W1 
Cluster 1 0.190 0.041 0.052 0.102 0.094 -0.036 -0.625 -0.426 -0.813 
Cluster 2 -0.087 -0.151 0.014 -0.053 -0.013 -0.185 0.006 -0.170 -0.418 
Cluster 3 -0.082 -0.064 -0.390 -0.372 -0.420 -0.373 0.104 0.335 0.718 
 
Table 3.12.  Cluster correlations for the hydrophilic parameters of the full data set for each 
tissue using the average-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.13).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Apol  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA  Lens  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA_P Cornea Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
ASA_P Cornea Cluster 2: JHX-2, 3; HK-2, 3, 7, 8, 12, 16 
ASA_P Brain  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
ASA_P Kidney  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
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ASA_P Liver  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
ASA_P SN  Cluster 2: JHX-2, 3; HK-2, 3, 7, 8, 12, 16 
ASA_P SN  Cluster 3: JHX-4, 5, 6, 7, 8; HK-4 
CASA+ Cornea Cluster 1: JHX-1, 2, 3, 5, 6, 7 
CASA+ NR  Cluster 2: HK-1, 5, 7, 9, 10, 11, 12, 13, 14, 15, 16 
CASA+ Brain  Cluster 1: JHX-1, 2, 3, 5, 6, 7 
CASA+ Kidney  Cluster 1: JHX-1, 2, 3, 5, 6, 7 
CASA+ SN  Cluster 1: JHX-1, 2, 3, 5, 6, 7 
Dipole  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
Dipole  Cornea Cluster 3: JHX-5; HK-4, 6, 9, 16 
Dipole  NR  Cluster 1: JHX-1, 5, 8; HK-3, 4, 6, 7, 9, 10, 11, 13, 16 
Dipole  NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
Dipole  Brain  Cluster 1: JHX-1, 7, 8; HK-3, 4, 5, 9, 10, 11, 12, 13, 14 
Dipole  Brain  Cluster 2: JHX-2, 3, 6; HK-1, 2, 7, 8, 16 
FASA_P Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_P NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_P Lens  Cluster 2: JHX-2, 3, 4, 6; HK-1, 2, 8, 14, 16 
FASA_P Brain  Cluster 1: JHX-1, 7, 8; HK-3, 4, 5, 9, 10, 11, 12, 13, 14 
FASA_P Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
FASA_P SN  Cluster 1: JHX-3, 4; HK-1, 3, 6, 9, 10, 11, 14, 15 
FASA_P SN  Cluster 2: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
LogS  Cornea Cluster 3: JHX-5; HK-4, 6, 9, 16 
LogS  Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 16 
LogS  Lens  Cluster 1: JHX-1, 2, 3, 4, 6; HK-1, 2, 8, 14, 16 
LogS  Brain  Cluster 2: JHX-2, 3, 6; HK-1, 2, 7, 8, 16 
PM3_Dipole Cornea Cluster 2: HK-1, 2, 3, 5, 12, 13 
PM3_Dipole Iris/CB  Cluster 3: JHX-2, 3, 4, 6, 7; HK-8 
PM3_Dipole Brain  Cluster 1: JHX-1, 4, 5, 7, 8; HK-3, 4, 11, 12 
PM3_Dipole Liver  Cluster 2: JHX-3, 4, 6, 7, 8; HK-8 
PM3_Dipole Liver  Cluster 3: HK-1, 2, 3, 5, 6, 9, 10, 13, 14 
W1  Kidney  Cluster 1: JHX-1; HK-2, 3, 4, 6, 7, 8, 12, 16 
W1  SN  Cluster 1: JHX-1; HK-2, 3, 4, 6, 7, 8, 12, 16 






Full Data Set Using Complete Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Apol 
Cluster 1 0.345 0.342 0.390 0.502 0.492 0.165 -0.243 -0.032 -0.444 
Cluster 2 -0.063 -0.168 -0.454 -0.476 -0.461 -0.410 -0.161 -0.170 0.105 
Cluster 3 - - - - - - - - - 
ASA 
Cluster 1 0.374 0.380 0.441 0.528 0.535 0.128 -0.328 0.099 -0.423 
Cluster 2 -0.002 -0.128 -0.185 -0.215 -0.344 -0.445 0.077 0.015 -0.074 
Cluster 3 - - - - - - - - - 
ASA_P 
Cluster 1 -0.172 -0.093 0.045 0.129 0.096 0.131 0.106 0.260 0.274 
Cluster 2 -0.013 0.078 -0.087 -0.046 -0.164 -0.235 0.145 0.140 0.641 
Cluster 3  -   -   -   -   -   -   -   -   -  
CASA+ 
Cluster 1 0.305 0.330 0.160 -0.038 0.068 -0.063 0.065 0.677 0.801 
Cluster 2 0.195 0.196 0.520 0.479 0.409 0.473 0.334 0.220 0.089 
Cluster 3 -0.211 -0.061 0.257 0.202 0.447 0.283 -0.134 -0.487 -0.224 
CASA- 
Cluster 1 -0.280 -0.301 -0.158 -0.084 -0.045 -0.264 -0.074 0.318 -0.370 
Cluster 2 -0.463 -0.389 -0.256 -0.270 0.036 -0.157 -0.007 -0.025 0.014 
Cluster 3 - - - - - - - - - 
Dipole 
Cluster 1 0.558 -0.261 0.547 0.443 0.008 -0.443 -0.332 0.146 0.193 
Cluster 2 0.542 -0.116 -0.856 0.210 0.711 0.377 -0.178 -0.188 -0.312 
Cluster 3  -  -0.318 0.715 -0.568 -0.039 - 0.130 - -0.315 
FASA_P 
Cluster 1 0.450 0.356 0.244 0.369 -0.283 -0.566 -0.382 0.093 -0.289 
Cluster 2 0.515 -0.196 -0.209 -0.294 0.540 0.477 -0.596 0.612 0.218 
Cluster 3 0.029 0.318 0.567 0.289 - - -0.148 0.299 - 
LogS 
Cluster 1 -0.246 0.153 -0.430 0.369 -0.081 -0.519 -0.696 0.138 0.371 
Cluster 2 0.246 0.751 0.218 -0.178 0.678 0.377 0.984 0.530 -0.046 
Cluster 3 - -0.411 0.048 - 0.768  -  0.438  -  - 
PM3 
Cluster 1 0.034 -0.006 0.200 0.394 0.558 -0.620 -0.480 -0.264 0.165 
Cluster 2 0.540 -0.484 -0.486 -0.405 -0.227 0.067 -0.802 -0.724 0.459 
Cluster 3 -0.061 -0.141 - - -0.186 -0.314 0.808 0.549 0.747 
vsurf_W1 
Cluster 1 0.219 0.182 0.168 0.083 0.082 -0.113 -0.480 -0.571 -0.800 
Cluster 2 -0.078 -0.070 0.117 -0.001 0.022 -0.161 0.204 -0.097 -0.141 
Cluster 3 -0.082 -0.064 -0.390 -0.372 -0.420 -0.373 0.104 0.335 0.718 
 
Table 3.13.  Cluster correlations for the hydrophilic parameters of the full data set for each 
tissue using the complete-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.12).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Apol  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA  Lens  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 15, 16 
ASA_P SN  Cluster 2: JHX-2, 3, 4, 5, 6, 7, 8; HK-3, 4, 8 
CASA+ NR  Cluster 2: HK-1, 5, 7, 9, 10, 11, 12, 13, 14, 15, 16 
CASA+ SN  Cluster 1: JHX-1, 2, 3, 4, 5, 6, 7, 8 
Dipole  Cornea Cluster 1: JHX-1, 8; HK-3, 6, 7, 9, 10, 11, 12 
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Dipole  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
Dipole  NR  Cluster 1: JHX-1, 5, 8; HK-3, 4, 6, 7, 9, 10, 11, 13, 16 
Dipole  NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
Dipole  Lens  Cluster 2: JHX-5, 8; HK-3, 6, 7, 10, 15 
FASA_P Cornea Cluster 2: JHX-2, 3, 4, 6, 7; HK-1, 2, 5, 8, 13, 14 
FASA_P NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_P Lens  Cluster 2: JHX-2, 3, 4, 6; HK-1, 2, 8, 14, 16 
FASA_P Brain  Cluster 1: JHX-1, 7, 8; HK-3, 4, 5, 9, 10, 11, 12, 13, 14 
FASA_P Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
LogS  Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 16 
LogS  Lens  Cluster 2: JHX-5, 8; HK-3, 6, 10, 15 
LogS  Lens  Cluster 3: JHX-7; HK-4, 5, 7, 9, 11, 12, 13 
LogS  Brain  Cluster 1: JHX-1, 4, 5, 7, 8; HK-3, 4, 6, 9, 10, 11, 12 
LogS  Kidney  Cluster 1: JHX-1, 3, 4, 5, 8; HK-4, 7, 8 
LogS  Liver  Cluster 2: JHX-3, 4, 6, 7, 8; HK-2, 3, 7, 8, 10, 13, 16 
PM3_Dipole Lens  Cluster 1: JHX-1, 5, 7, 8; HK-3, 4, 6, 7, 11, 12, 15 
PM3_Dipole Brain  Cluster 1: JHX-1, 4, 5, 7, 8; HK-3, 4, 11, 12 
PM3_Dipole Liver  Cluster 2: JHX-3, 4, 6, 7, 8; HK-8 
PM3_Dipole Liver  Cluster 3: HK-1, 2, 3, 5, 6, 9, 10, 13, 14 
PM3_Dipole SN  Cluster 3: HK-1, 2, 5, 9, 13 
W1  Liver  Cluster 1: JHX-1; HK-2, 3, 4, 6, 7, 8, 16 
W1  SN  Cluster 1: JHX-1; HK-2, 3, 4, 6, 7, 8, 16 





Standardized Data Set Using Average-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Apol 
Cluster 1 0.448 0.479 0.768 0.766 -0.802 0.236 -0.243 -0.032 -0.306 
Cluster 2 -0.063 -0.168 0.775 -0.317 0.328 -0.410 -0.161 -0.170 0.759 
Cluster 3  -  - -0.454 - -0.461 - - - 0.105 
ASA 
Cluster 1 0.446 0.484 0.583 0.749 0.604 0.135 -0.328 0.099 -0.328 
Cluster 2 -0.002 -0.128 -0.185 -0.247 -0.344 -0.445 0.077 0.015 -0.074 
Cluster 3 - - - - - - - - - 
ASA_P 
Cluster 1 -0.620 -0.497 -0.303 -0.128 -0.358 -0.549 -0.540 -0.525 -0.630 
Cluster 2 0.801 0.439 0.254 0.660 0.611 -0.664 -0.356 -0.317 -0.242 
Cluster 3 0.496 0.420 0.176 0.185 -0.066  -  0.289  -   -  
CASA+ 
Cluster 1 0.864 0.937 0.890 0.720 0.573 0.677 0.820 0.640 0.440 
Cluster 2 0.073 0.069 0.527 0.289 0.366 0.620 0.334 0.220 0.089 
Cluster 3 -0.211 -0.061 0.257  -  0.447 0.283 -0.134 -0.487 -0.224 
CASA- 
Cluster 1 -0.280 -0.301 -0.158 -0.439 -0.045 -0.264 -0.074 0.318 -0.370 
Cluster 2 -0.401 -0.298 -0.083 -0.075 0.335 0.228 -0.007 -0.025 0.014 
Cluster 3 - - - - - - - - - 
Dipole 
Cluster 1 0.227 -0.261 0.547 0.443 0.008 -0.443 -0.332 -0.047 -0.124 
Cluster 2 0.542 -0.116 -0.856 -0.385 0.667 0.595 -0.178 0.034 -0.315 
Cluster 3 -0.692 -0.318 0.715 0.099 0.701 - 0.130 0.497  -  
FASA_P 
Cluster 1 0.450 -0.117 0.321 0.369 -0.069 -0.305 -0.382 0.093 -0.586 
Cluster 2 0.524 -0.196 -0.209 -0.019 0.047 0.076 -0.596 0.612 -0.631 
Cluster 3 -0.379 -0.095 0.567 -0.294 0.750 - -0.148 0.299 - 
LogS 
Cluster 1 -0.167 0.153 -0.098 0.815 -0.081 -0.107 0.150 -0.220 0.355 
Cluster 2 0.168 0.751 -0.153 -0.331 0.307 0.507 0.446 -0.495 0.305 
Cluster 3 0.912 0.072  -  - 0.768  -  0.727 0.305 - 
PM3 
Cluster 1 -0.002 0.459 0.200 0.281 -0.480 -0.620 -0.480 -0.152 -0.552 
Cluster 2 -0.412 0.050 -0.486 -0.327 -0.589 0.603 -0.802 -0.724 -0.492 
Cluster 3 -0.394 -0.632 - - -0.227 -0.314 0.808 0.549  -  
vsurf_W1 
Cluster 1 0.219 0.182 0.168 0.513 0.082 -0.113 -0.625 -0.426 0.797 
Cluster 2 0.241 0.245 0.449 0.402 0.311 0.196 0.006 -0.170 0.305 
Cluster 3 -0.082 -0.064 -0.390 -0.372 -0.420 -0.519 0.104 0.171 -0.799 
 
Table 3.14.  Cluster correlations for the hydrophilic parameters of the standardized data 
set for each tissue using the average-linkage algorithms.  Cells shaded in yellow and green 
are moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.15).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
Apol  NR  Cluster 2: HK-3, 4, 7, 8, 12 
Apol  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
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Apol  Lens  Cluster 1: JHX-1, 2, 3, 4; HK-8, 16 
ASA  NR  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA  Lens  Cluster 1 JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA_P Cornea Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14 
ASA_P Cornea Cluster 2: JHX-2, 3; HK-2, 3, 7, 8, 12, 15, 16 
ASA_P Brain  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14 
ASA_P Brain  Cluster 2: JHX-2, 3, 4, 5; HK-2, 3, 4, 7, 8, 12, 16 
ASA_P Kidney  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
ASA_P Liver  Cluster 1: JHX-1; HK-1, 5, 6, 10, 11, 14, 15 
ASA_P SN  Cluster 1: JHX-2, 3; HK-2, 3, 4, 6, 7, 8, 12, 16 
CASA+ Brain  Cluster 2: HK-1, 5, 7, 9, 10, 11, 12, 13, 14, 16 
CASA+ Kidney  Cluster 1: JHX-1, 2, 3, 5, 6, 7 
Dipole  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
Dipole  Cornea Cluster 3: JHX-5; HK-4, 6, 9, 16 
Dipole  NR  Cluster 1: JHX-1, 5, 8; HK-3, 4, 6, 7, 9, 10, 11, 13, 16 
Dipole  NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
Dipole  Lens  Cluster 3: JHX-3, 6; HK-1, 2, 8, 16 
FASA_P Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_P NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_P Lens  Cluster 3: JHX-3, 6; HK-1, 2, 8, 16 
FASA_P Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
FASA_P SN  Cluster 1: JHX-3, 4; HK-1, 3, 6, 9, 10, 11, 14, 15 
FASA_P SN  Cluster 2: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
LogS  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
LogS  Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 16 
LogS  Lens  Cluster 3: JHX-7; HK-4, 5, 7, 9, 11, 12, 13 
PM3_Dipole Iris/CB  Cluster 3: JHX-2, 3, 4, 6, 7; HK-8 
PM3_Dipole Brain  Cluster 1: JHX-1, 4, 5, 7, 8; HK-3, 4, 11, 12 
PM3_Dipole Liver  Cluster 2: JHX-3, 4, 6, 7, 8; HK-8 
PM3_Dipole Liver  Cluster 3: HK-1, 2, 3, 5, 6, 9, 10, 13, 14 
W1  Kidney  Cluster 1: JHX-1; HK-2, 3, 4, 6, 7, 8, 12, 16 






Standardized Data Set Using Complete Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
Apol 
Cluster 1 0.448 0.479 0.560 0.766 -0.802 -0.325 -0.243 -0.032 -0.284 
Cluster 2 -0.063 -0.168 -0.454 -0.317 0.328 -0.410 -0.161 -0.170 0.105 
Cluster 3 -  -   -   -  -0.461  -  -  -   -  
ASA 
Cluster 1 0.446 0.484 0.583 0.749 0.604 0.135 -0.328 0.099 -0.328 
Cluster 2 -0.002 -0.128 -0.185 -0.247 -0.344 -0.445 0.077 0.015 -0.074 
Cluster 3 -  -   -   -   -   -  -  -   -  
ASA_P 
Cluster 1 -0.275 -0.178 0.020 -0.089 0.083 0.142 0.106 0.260 -0.600 
Cluster 2 -0.013 -0.149 -0.136 -0.105 0.021 -0.764 0.145 0.009 0.805 
Cluster 3  -   -   -   -   -   -   -   -  -0.242 
CASA+ 
Cluster 1 0.864 0.937 0.890 0.720 0.573 0.677 0.065 0.562 0.440 
Cluster 2 0.073 0.069 0.527 0.515 0.366 0.620 0.334 0.220 0.089 
Cluster 3 -0.211 -0.061 0.257  -  0.447 0.283 -0.134 -0.487 -0.224 
CASA- 
Cluster 1 -0.280 -0.301 -0.158 -0.439 -0.045 -0.264 -0.074 0.318 -0.370 
Cluster 2 -0.401 -0.298 -0.083 -0.075 0.335 0.228 -0.007 -0.025 0.014 
Cluster 3 -  -   -   -   -   -  -  -   -  
Dipole 
Cluster 1 0.558 -0.261 0.680 0.443 0.008 -0.443 -0.332 -0.360 -0.312 
Cluster 2 0.542 -0.116 -0.856 -0.385 0.667 0.377 -0.178 -0.188 -0.315 
Cluster 3  -  -0.318 0.715 0.099 -0.901  -  0.130  -   -  
FASA_P 
Cluster 1 0.450 0.356 0.321 0.369 -0.283 -0.305 -0.382 0.093 -0.006 
Cluster 2 0.524 0.828 -0.209 -0.019  -  0.076 -0.596 0.612 0.417 
Cluster 3 -0.379 0.200 0.567 -0.294 0.750  -  -0.148 0.299 0.728 
LogS 
Cluster 1 -0.167 0.153 -0.430 -0.270 0.682 0.557 -0.696 0.138 0.371 
Cluster 2 0.912 0.751 0.218 -0.106 -0.081 0.227 0.984 -0.220 -0.046 
Cluster 3 -0.621 -0.411 0.048 -0.178 -0.379  -  0.438 -0.257  -  
PM3 
Cluster 1 0.034 -0.632 0.200 0.120 0.472 -0.620 -0.480 -0.152 0.780 
Cluster 2 -0.412 -0.484 -0.486 -0.900 -0.227 0.603 -0.802 -0.724 0.747 
Cluster 3 -0.157 -0.172  -  -0.405 0.102 -0.445 0.808 0.549  -  
vsurf_W1 
Cluster 1 0.219 0.182 0.168 0.780 0.082 -0.113 -0.480 0.505 0.219 
Cluster 2 0.241 0.245 0.449 0.171 0.311 0.196 0.204 0.465  -  
Cluster 3 -0.082 -0.064 -0.390 -0.372 -0.420 -0.519 0.104  -   -  
 
Table 3.15.  Cluster correlations for the hydrophilic parameters of the standardized data 
set for each tissue using the complete-linkage algorithms.  Cells shaded in yellow and 
green are moderate and strong cluster correlations, and cells shaded in blue are identical 
cluster correlations between both average-linkage and complete-linkage algorithms 
(Table 3.14).  Additionally, cells shaded in pink are eliminated cluster correlations due to 
a non-linear distribution of data points.  The drugs in each accepted cluster are listed 
below. 
 
Apol  NR  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
Apol  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
Apol  Lens  Cluster 1: JHX-1, 2, 3, 4; HK-8, 16 
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ASA  NR  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA  RPE/C  Cluster 1: JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA  Lens  Cluster 1 JHX-1, 2, 3, 4; HK-3, 4, 7, 8, 11, 12, 16 
ASA_P Brain  Cluster 1: JHX-1; HK-1, 2, 5, 6, 7, 10, 11, 12, 14, 16 
ASA_P SN  Cluster 1: JHX-2, 3; HK-2, 3, 6, 7, 8, 12, 16 
CASA+ Brain  Cluster 2: HK-1, 5, 7, 9, 10, 11, 12, 13, 14, 16 
Dipole  Cornea Cluster 1: JHX-1, 8; HK-3, 6, 7, 9, 10, 11, 12 
Dipole  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
Dipole  NR  Cluster 1: JHX-1, 5, 8; HK-3, 4, 7, 9, 13 
Dipole  NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
Dipole  Lens  Cluster 3: JHX-2, 4; HK-1, 2, 16 
FASA_P Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_P Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 16 
FASA_P NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_P Lens  Cluster 3: JHX-3, 6; HK-1, 2, 8, 16 
FASA_P Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
LogS  Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
LogS  Cornea Cluster 3: JHX-4, 7; HK-1, 5, 8, 13, 14 
LogS  Iris/CB  Cluster 2: JHX-5; HK-4, 6, 9, 16 
LogS  Lens  Cluster 1: JHX-1, 2, 4; HK-4, 5, 9, 12, 13, 14 
LogS  Kidney  Cluster 1: JHX-1, 3, 4, 5, 8; HK-4, 7, 8 
LogS  Kidney  Cluster 2: JHX-6, 7; HK-2, 10, 12 
PM3_Dipole Iris/CB  Cluster 3: JHX-2, 3, 4, 6, 7; HK-8 
PM3_Dipole RPE/C  Cluster 2: JHX-2, 3, 4, 6; HK-8 
PM3_Dipole Brain  Cluster 1: JHX-1, 4, 5, 7, 8; HK-3, 4, 11, 12 
PM3_Dipole Liver  Cluster 2: JHX-3, 4, 6, 7, 8; HK-8 
PM3_Dipole Liver  Cluster 3: HK-1, 2, 3, 5, 6, 9, 10, 13, 14 








Full Data Set Using Average-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
ASA_H 
Cluster 1 0.014 -0.015 0.083 0.291 0.473 0.447 -0.136 -0.241 -0.115 
Cluster 2 0.096 0.037 -0.275 -0.375 -0.095 -0.229 -0.665 0.006 -0.663 
Cluster 3 - - - - - - - - - 
FASA_H 
Cluster 1 -0.450 0.117 -0.244 -0.365 0.283 0.566 0.382 -0.093 0.586 
Cluster 2 -0.524 0.196 0.209 0.294 -0.540 -0.477 0.596 -0.612 0.631 
Cluster 3 0.379 0.095 -0.567 - - - 0.148 -0.299 - 
LogP 
Cluster 1 0.259 -0.987 -0.523 0.462 -0.764 -0.275 -0.163 0.240 0.676 
Cluster 2 0.177 -0.304 -0.345 0.243 0.565 -0.200 0.586 0.745 0.478 
Cluster 3 -0.355 0.688 0.606 - - - 0.113 0.199 - 
SLogP 
Cluster 1 0.069 0.002 -0.114 0.625 0.566 -0.093 0.876 0.356 0.213 
Cluster 2 0.182 0.420 0.796 0.326 0.492 -0.543 0.098 -0.636 0.572 
Cluster 3 -0.188 - - - -0.516 - - 0.451 - 
vsurf_D1 
Cluster 1 -0.302 -0.173 -0.090 -0.072 0.067 -0.157 -0.127 -0.376 -0.405 
Cluster 2 -0.305 -0.290 -0.305 -0.218 0.025 -0.348 -0.392 -0.365 -0.440 
Cluster 3 0.031 0.127 -0.079 -0.158 0.183 0.196 -0.141 -0.139 0.068 
 
Table 3.16.  Cluster correlations for the hydrophobic parameters of the full data set for 
each tissue using the average-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.17).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
FASA_H Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_H NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_H Lens  Cluster 2: JHX-2, 3, 4, 6; HK-1, 2, 8, 14, 16 
FASA_H Brain  Cluster 1: JHX-1, 7, 8; HK-3, 4, 5, 9, 10, 11, 12, 13, 14 
FASA_H Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
FASA_H SN  Cluster 1: JHX-3, 4; HK-1, 3, 6, 9, 10, 11, 14, 15 
FASA_H SN  Cluster 2: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
LogP  Iris/CB  Cluster 1: JHX-1, 5, 8; HK-4, 6 
LogP  Iris/CB  Cluster 3: JHX-2, 3, 4, 6, 7; HK-1, 2 
LogP  NR  Cluster 3: JHX-2, 3, 4, 6, 7; HK-1, 2, 8 
LogP  Lens  Cluster 1: JHX-1, 2, 3, 4, 5, 7, 8 
LogP  Lens  Cluster 2: HK-3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 16 
LogP  Kidney  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10, 12, 13 
LogP  Liver  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10 
SLogP  NR  Cluster 2: JHX-2, 3, 4, 6, 7, 8; HK-1, 2, 8 
SLogP  RPE/C  Cluster 1: JHX-1, 2, 3, 4, 6, 7, 8; HK-1, 2, 8 
SLogP  Brain  Cluster 2: HK-1, 2, 5, 7, 8, 9, 10, 11, 12, 13, 14, 16 
SLogP  Kidney  Cluster 1: JHX-1; HK-1, 3, 4, 5, 6, 7, 8 
SLogP  Liver  Cluster 2: HK-2, 3, 7, 8, 10 






Full Data Set Using Complete-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
ASA_H 
Cluster 1 -0.296 -0.348 0.083 -0.452 -0.554 0.447 -0.262 -0.635 -0.115 
Cluster 2 -0.110 -0.116 -0.275 -0.201 -0.187 -0.229 0.434 0.026 -0.663 
Cluster 3 - - - - - - - - - 
FASA_H 
Cluster 1 -0.450 -0.356 -0.244 -0.369 0.283 0.566 0.382 -0.093 0.289 
Cluster 2 -0.515 0.196 0.209 0.294 -0.540 -0.477 0.596 -0.612 -0.218 
Cluster 3 -0.029 -0.338 -0.567 -0.289 - - 0.148 -0.299 - 
LogP 
Cluster 1 0.214 0.375 0.583 0.646 -0.073 -0.275 0.031 0.240 -0.204 
Cluster 2 0.142 0.492 -0.587 -0.243 -0.448 -0.277 -0.195 0.745 -0.251 
Cluster 3 -0.269   -0.144 - -0.388 0.215 0.554 0.199 - 
SLogP 
Cluster 1 -0.081 -0.343 -0.114 0.335 -0.146 -0.093 -0.056 0.503 0.593 
Cluster 2 -0.619 0.169 0.796 0.326 0.239 -0.543 -0.499 -0.417 0.572 
Cluster 3 -0.141 - - -  -  -  -  0.427 - 
vsurf_D1 
Cluster 1 -0.302 -0.173 -0.090 -0.072 0.067 -0.157 -0.127 -0.376 -0.405 
Cluster 2 -0.156 -0.205 -0.374 -0.255 -0.126 -0.231 -0.302 0.388 -0.065 
Cluster 3 0.246 0.249 -0.010 -0.084 0.159 0.415 0.235 -0.008 -0.073 
 
Table 3.17.  Cluster correlations for the hydrophobic parameters of the full data set for 
each tissue using the complete-linkage algorithms.  Cells shaded in yellow and green are 
moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.16).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
ASA_H Lens  Cluster 1: JHX-1, 2, 3, 5, 6, 7; HK-9, 11, 13, 14, 15, 16 
ASA_H Liver  Cluster 1: JHX-1, 2, 3, 5, 6, 7; HK-9, 11, 13, 14, 15, 16 
FASA_H Cornea Cluster 2: JHX-2, 3, 4, 6, 7; HK-1, 2, 5, 8, 13, 14 
FASA_H NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_H Lens  Cluster 2: JHX-1, 5, 7, 8; HK-4, 5, 7, 9, 10, 11, 12, 13 
FASA_H Brain  Cluster 1: JHX-1, 7, 8; HK-3, 4, 5, 9, 10, 11, 12, 13, 14 
FASA_H Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
LogP  NR  Cluster 1: JHX-1, 2, 3, 4, 6, 7, 8; HK-1, 2 
LogP  NR  Cluster 2: JHX-5; HK-3, 4, 6, 9, 10, 11, 13, 16 
LogP  RPE/C  Cluster 1: JHX-1, 2, 3, 4, 6, 7; HK-1, 2 
LogP  Kidney  Cluster 3: JHX-3, 4, 5, 8; HK-3, 4, 9, 11, 15, 16 
LogP  Liver  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10 
SLogP  Cornea Cluster 1: JHX-1, 2, 3, 4, 7, 8 
SLogP  NR  Cluster 2: JHX-2, 3, 4, 6, 7, 8; HK-1, 2, 8 
SLogP  Brain  Cluster 2: HK-1, 2, 5, 7, 8, 9, 10, 11, 12, 13, 14, 16 
SLogP  Liver  Cluster 1: JHX-1, 2, 5; HK-1, 4, 6 










Standardized Data Set Using Average-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
ASA_H 
Cluster 1 0.014 -0.015 0.083 -0.371 0.473 0.314 0.136 -0.241 -0.115 
Cluster 2 0.096 0.037 -0.275 0.651 -0.095 -0.229 -0.665 0.006 -0.281 
Cluster 3 - - - 0.393 - - - - - 
FASA_H 
Cluster 1 -0.450 0.117 -0.321 -0.369 0.069 0.305 0.382 -0.093 0.586 
Cluster 2 -0.524 0.196 0.209 0.019 -0.047 -0.076 0.596 -0.612 0.631 
Cluster 3 0.379 0.095 -0.567 0.294 -0.750 - 0.148 -0.299 - 
LogP 
Cluster 1 0.259 -0.987 -0.523 -0.254 -0.764 -0.275 -0.163 0.240 -0.084 
Cluster 2 -0.355 -0.449 -0.345 0.243 0.407 -0.200 0.586 0.745 -0.251 
Cluster 3 0.263 0.688 0.606 -  -   -  0.113 0.199 - 
SLogP 
Cluster 1 0.069 0.169 -0.114 0.171 0.566 -0.093 0.876 0.356 0.474 
Cluster 2 0.182 0.420 0.811 0.326 0.086 -0.543 0.098 -0.636 -0.286 
Cluster 3 -0.188 - - - 0.492 -  -  0.451 - 
vsurf_D1 
Cluster 1 -0.302 -0.173 -0.090 0.757 0.067 0.202 -0.127 0.226 -0.440 
Cluster 2 0.199 0.168 -0.045 0.193 0.163 0.415 -0.392 -0.365 0.068 
Cluster 3 0.246 0.249 -0.010  -  0.159  -  -0.141 -0.139  -  
 
Table 3.18.  Cluster correlations for the hydrophobic parameters of the standardized data 
set for each tissue using the average-linkage algorithms.  Cells shaded in yellow and green 
are moderate and strong cluster correlations, and cells shaded in blue are identical cluster 
correlations between both average-linkage and complete-linkage algorithms (Table 3.19).  
Additionally, cells shaded in pink are eliminated cluster correlations due to a non-linear 
distribution of data points.  The drugs in each accepted cluster are listed below. 
 
FASA_H Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_H NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_H Lens  Cluster 3: JHX-3, 6; HK-1, 2, 8, 16 
FASA_H Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
FASA_H SN  Cluster 1: JHX-3, 4; HK-1, 3, 6, 9, 10, 11, 14, 15 
FASA_H SN  Cluster 2: JHX-6, 7, 8; HK-2, 5, 7, 12, 13, 16 
LogP  Iris/CB  Cluster 1: JHX-1, 5, 8; HK-4, 6 
LogP  Iris/CB  Cluster 3: JHX-2, 3, 4, 6, 7; HK-1, 2 
LogP  NR  Cluster 3: JHX-2, 3, 4, 6, 7; HK-1, 2, 8 
LogP  Lens  Cluster 1: JHX-1, 3, 4, 5, 7, 8 
LogP  Kidney  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10, 12, 13 
LogP  Liver  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10 
SLogP  NR  Cluster 2: JHX-2, 3, 4, 6, 7; HK-1, 2, 8 
SLogP  Brain  Cluster 2: HK-1, 2, 5, 7, 8, 9, 10, 11, 12, 13, 14, 16 
SLogP  Kidney  Cluster 1: JHX-1; HK-1, 3, 4, 5, 6, 7, 8 







Standardized Data Set Using Complete-Linkage Algorithm 
Cornea Iris/CB NR RPE/C Lens Brain Kidney Liver SN 
ASA_H 
Cluster 1 -0.338 -0.400 0.083 -0.371 -0.215 0.314 -0.262 -0.717 0.073 
Cluster 2 -0.110 -0.116 -0.275 0.651 -0.187 -0.229 0.434 0.026 -0.360 
Cluster 3 -  -   -  0.393  -   -  -  -  -0.281 
FASA_H 
Cluster 1 -0.450 -0.356 -0.321 -0.369 0.283 0.305 0.382 -0.093 0.006 
Cluster 2 -0.524 -0.828 0.209 0.019  -  -0.076 0.596 -0.612 -0.417 
Cluster 3 0.379 -0.200 -0.567 0.294 -0.750  -  0.148 -0.299 -0.728 
LogP 
Cluster 1 0.214 0.375 0.583 0.537 -0.764 -0.275 0.031 0.240 -0.084 
Cluster 2 0.142 -0.716 -0.587 -0.243 -0.448 -0.404 -0.195 0.745 -0.251 
Cluster 3 0.299 -0.019 -0.144  -  0.369 0.405 0.554 0.199  -  
SLogP 
Cluster 1 0.069 -0.343 0.620 0.335 -0.004 -0.093 -0.056 0.434 0.667 
Cluster 2 0.182 0.169 0.485 -0.740 0.475 -0.543 -0.499 -0.417 0.986 
Cluster 3 -0.188  -  0.300 -0.431  -   -   -  0.427  -  
vsurf_D1 
Cluster 1 -0.302 -0.173 -0.090 -0.072 0.067 0.202 -0.127 0.226 -0.815 
Cluster 2 0.199 0.168 -0.045 0.187 0.163 0.415 -0.302 -0.188 0.069 
Cluster 3 0.246 0.249 -0.010  -  0.159  -  0.235 0.872 -0.073 
 
Table 3.19.  Cluster correlations for the hydrophobic parameters of the standardized data 
set for each tissue using the complete-linkage algorithms.  Cells shaded in yellow and 
green are moderate and strong cluster correlations, and cells shaded in blue are identical 
cluster correlations between both average-linkage and complete-linkage algorithms 
(Table 3.18).  Additionally, cells shaded in pink are eliminated cluster correlations due to 
a non-linear distribution of data points.  The drugs in each accepted cluster are listed 
below. 
 
FASA_H Cornea Cluster 2: JHX-2, 3, 4, 7; HK-1, 2, 5, 8, 13, 14 
FASA_H Iris/CB  Cluster 2: JHX-2, 3, 4; HK-5, 12, 14 
FASA_H NR  Cluster 3: JHX-3, 4, 7; HK-5, 12, 14 
FASA_H Lens  Cluster 3: JHX-3, 6; HK-1, 2, 8, 16 
FASA_H Kidney  Cluster 2: JHX-2; HK-1, 3, 4, 5, 6, 7, 8, 13, 14, 16 
LogP  NR  Cluster 1: JHX-1, 2, 3, 4, 6, 7, 8; HK-1, 2 
LogP  Lens  Cluster 1: JHX-1, 3, 4, 5, 7, 8 
LogP  Kidney  Cluster 3: JHX-3, 4, 5, 8; HK-3, 4, 9, 11, 15, 16 
LogP  Liver  Cluster 2: HK-1, 3, 4, 5, 6, 7, 8, 10 
SLogP  NR  Cluster 1: JHX-1, 5; HK-3, 4, 5, 6, 7, 12, 14 
SLogP  Brain  Cluster 2: HK-1, 2, 5, 7, 8, 9, 10, 11, 12, 13, 14, 16 
SLogP  SN  Cluster 2: HK-5, 7, 12, 13, 16 





All cluster correlations shown in Tables 3.8 to 3.19 represent the linear relationship 
between the clustered drugs using Pearson’s r-value where an r-value between ±0.5 and 
±0.7 denotes a moderate correlation and an r-value between ±0.7 and ±1.0 denotes a 
strong correlation.  These metrics are common statistical cut-offs which here denote the 
strength of the linear relationship between the drug tissue levels and their calculated 
physicochemical descriptors.  In order to develop the most accurate and predictable 
models for the tissue distribution of these drugs from these clusters, all correlation values 
which resulted in an r2 ≤ 0.5 (i.e., |r| < 0.707) were excluded.  Thus, only strong correlations 
were considered for model development.  P-values were also calculated for these cluster 
correlations and clusters with a p-value > 0.05 were also excluded.  A model with a 
significant p-value (i.e., p < 0.05) is more likely to be meaningful because this supports 
the notion that the changes observed between the drug tissue levels and the calculated 
physicochemical descriptors are more likely to be directly related.  The final clustered 
linear correlations are shown in Figures 3.2 to 3.10.  
 
In Figure 3.2, the clustered correlations for the cornea are reported.  Four positive 
correlations were calculated for the cornea, where the log concentrations of drugs found 
in the cornea were positively correlated with the hydrophilic parameters CASA+ (r2 = 
+0.746, p = 0.026), ASA_P (r2 = +0.641, p = 0.009), and LogS (r2 = +0.831, p = 0.031), 
and the structural parameter SMR (r2 = +0.515, p = 0.017).  These results suggest that 
larger, polar, and hydrophilic compounds possessing are more likely to distribute into the 
cornea. 
 
In Figure 3.3, the clustered correlations for the iris/CB are reported.  Three positive 
and two negative correlations were calculated.  The log concentrations of drugs found in 
the iris/CB were positively correlated with the hydrophilic parameter FASA_P (r2 = +0.685, 
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p = 0.042) and the structural parameter vsurf_G (r2 = 0.664, p = 0.048), and negatively 
correlated with hydrophobic parameters FASA_H (r2 = -0.685, p = 0.042) and LogP (r2 = 
-0.974, p = 0.002).   This suggests that globular, polar, and hydrophilic compounds are 




Figure 3.2.  Linear regression models between physicochemical descriptors and drug 
levels in the cornea where (A) corresponds to Cluster 1 between cornea and CASA+ in 
Table 3.12, (B) corresponds to the Cluster 2 between cornea and ASA_P in Table 3.14, 
(C) corresponds to Cluster 2 between cornea and SMR in Table 3.9, and (D) corresponds 
to Cluster 3 between cornea and LogS in Table 3.14.   The hydrophilic parameters ASA_P, 
and LogS, and the structural parameter SMR, were all positively correlated with drug 
levels in the cornea and exhibit both an r2 ≥ 0.5 and p < 0.05, indicating strong relationships 
between these descriptors and drug levels in the cornea.  These results suggest that 








Figure 3.3.  Linear regression models between physicochemical descriptors and drug 
levels in the iris/CB where (A) corresponds to Cluster 2 between iris/CB and FASA_H in 
Table 3.19, (B) corresponds to Cluster 2 between iris/CB and FASA_P in Table 3.15, (C) 
corresponds to Cluster 1 between iris/CB and LogP in both Table 3.16 and Table 3.18, 
and (D) corresponds to Cluster 2 between iris/CB and vsurf_G in Table 3.11.  The 
hydrophilic parameters FASA_P and LogS, and the structural parameter vsurf_G, were 
positively correlated, while the hydrophobic parameter LogP was negatively correlated, 
with drug levels in the iris/CB.  All of these correlations exhibit an r2 ≥ 0.5 and p < 0.05, 
indicating a strong relationship between these descriptors and drug levels in the iris/CB.  
These results suggest that globular, polar, and hydrophilic compounds are more likely to 




In Figure 3.4, the clustered correlations for the lens are reported where two 
positive and two negative correlations were found.  The log concentrations of drugs found 
in the lens were positively correlated with the hydrophilic parameters FASA_P (r2 = 
+0.562, p = 0.047) and LogS (r2 = +0.589, p = 0.026), and negatively correlated with 
hydrophobic parameters FASA_H (r2 = -0.562, p = 0.047) and LogP (r2 = -0.583, p = 
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0.045).  This data suggests that more polar, hydrophilic compounds are more likely to 




Figure 3.4.  Linear regression models between physicochemical descriptors and drug 
levels in the lens where (A) corresponds to Cluster 3 between lens and FASA_H in Tables 
3.18 and 3.19, (B) corresponds to Cluster 2 between lens and FASA_P in Tables 3.14 
and 3.15, (C) corresponds to Cluster 1 between lens and LogP in Tables 3.16 and 3.18, 
and (D) corresponds to Cluster 3 between lens and LogS in Tables 3.13 and 3.14.  The 
hydrophilic parameters FASA_P and LogS were positively correlated, while the 
hydrophobic parameter FASA_H and LogP were negatively correlated, with drug levels in 
the lens.  All of these correlations exhibit an r2 ≥ 0.5 and p < 0.05, indicating a strong 
relationship between these descriptors and drug levels in the lens.  These results suggest 




In Figure 3.5, the clustered correlations for the neural retina (NR) are reported.  
Three positive correlations were found, with two correlations of the same parameter.  The 
log concentrations of drugs found in the NR were positively correlated with the 
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hydrophobic parameter SLogP (r2 = +0.633, p = 0.010; r2 = +0.657, p = 0.015) and the 
structural parameter Kier1 (r2 = +0.554, p = 0.046).  This suggests that compounds which 




Figure 3.5.  Linear regression models between physicochemical descriptors and drug 
levels in the NR where (A) corresponds to Cluster 2 between NR and SLogP in Tables 
3.16 and 3.17, (B) corresponds to Cluster 2 between NR and SLogP in Table 3.18, and 
(C) corresponds to Cluster 2 between NR and Kier1 in Tables 3.8, 3.9, 3.10, and 3.11.  
The hydrophobic parameter SLogP, which resulted in two models, and the structural 
parameter Kier1 were both positively correlated with drug levels in the NR.  All of these 
correlations exhibit an r2 ≥ 0.5 and p < 0.05, indicating a strong relationship between these 
descriptors and drug levels in the NR.  These results suggest that larger, branched, and 




In Figure 3.6, the clustered correlations for the RPE/C are reported where four 
positive correlations were identified.  The log concentrations of drugs found in the RPE/PS 
were positively correlated with the hydrophilic parameters Apol (r2 = +0.587, p = 0.006), 
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ASA (r2 = +0.561, p = 0.047), LogS (r2 = +0.664, p = 0.044), and vsurf_W1 (r2 = +0.608, 
p = 0.037).  This suggests that compounds which are more water soluble, polar, and 




Figure 3.6.  Linear regression models between physicochemical descriptors and drug 
levels in the RPE/C where (A) corresponds to Cluster 1 between RPE/C and Apol in 
Tables 3.14 and 3.15, (B) corresponds to Cluster 1 between RPE/C and ASA in Tables 
3.14 and 3.15, (C) corresponds to Cluster 3 between RPE/C and LogS in Table 3.14, and 
(D) corresponds to Cluster 1 between RPE/C and vsurf_W1 in Table 3.15.  The hydrophilic 
parameters Apol, ASA, LogS, and vsurf_W1 are all positively correlated with drug levels 
in the RPE/C.  All of these correlations exhibit an r2 ≥ 0.5 and p < 0.05, indicating a strong 
relationship between these descriptors and drug levels in the RPE/C.  These results 








The single cluster correlation for the brain is shown in Figure 3.7, where drug 
concentration in the brain is positively correlated with the structural parameter vsurf_Cp 
(r2 = +0.515, p = 0.050), suggesting that compounds which are more micellar in shape 





Figure 3.7.  Linear regression model between physicochemical descriptors and drug 
levels in the brain where (A) corresponds to Cluster 1 between brain and vsurf_Cp in 
Table 3.11.  The structural parameter vsurf_Cp is positively correlated with drug levels in 
the brain and exhibits an r2 ≥ 0.5 and p < 0.05, indicating a strong relationship between 
vsurf_Cp and drug levels in the RPE/C.  This result suggests that compounds resembling 




The cluster correlations for the sciatic nerve (SN) are reported in Figure 3.8 where 
two positive and two negative correlations were identified.  The log concentrations of drugs 
found in the SN were positively correlated with the hydrophobic parameter SLogP (r2 = 
+0.972, p = 0.002) and the structural parameter vsurf_Cp (r2 = +0.588, p = 0.016), and 
negatively correlated with hydrophilic parameters ASA_P (r2 = -0.817, p = 0.002) and 
vsurf_W1 (r2 = -0.661, p = 0.008).  These results suggest that compounds which are less 







Figure 3.8.  Linear regression models between physicochemical descriptors and drug 
levels in the SN where (A) corresponds to Cluster 2 between SN and ASA_P in Table 
3.12, (B) corresponds to Cluster 2 between SN and SLogP in Table 3.19, (C) corresponds 
to Cluster 2 between SN and vsurf_Cp in Tables 3.8, 3.9, and 3.10, as well as Cluster 3 
between SN and vsurf_Cp in Table 3.11, and (D) corresponds to Cluster 1 between SN 
and vsurf_W1 in Table 3.12.  The hydrophilic parameters ASA_P and vsurf_W1 are 
negatively correlated, while the hydrophobic parameter SLogP and structural parameters 
Kier1 and vsurf_Cp are positively correlated, with drug levels in the SN.  All of these 
correlations exhibit an r2 ≥ 0.5 and p < 0.05, indicating a strong relationship between these 
descriptors and drug levels in the SN.  These results suggest that less polar and more 





Figure 3.9 reports the cluster correlations for the kidney where two positive 
correlations were identified.  The log concentrations of drugs found in the kidney were 
positively correlated with the hydrophilic parameters CASA+ (r2 = +0.672, p = 0.046) and 
SMR (r2 = +0.504, p = 0.048).  This suggests that larger polar compounds with a greater 







Figure 3.9.  Linear regression models between physicochemical descriptors and drug 
levels in the kidney where (A) corresponds to Cluster 1 between kidney and CASA+ in 
Table 3.12, and (B) corresponds to Cluster 2 between kidney and SMR in Table 3.9.  The 
hydrophilic parameter CASA+ and the structural parameter SMR are both positively 
correlated with drug levels in the kidney.  Both of these correlations exhibit an r2 ≥ 0.5 and 
p < 0.05, indicating a strong relationship between these descriptors and drug levels in the 
kidney.  These results suggest that larger hydrophilic compounds with a greater positively-




The cluster correlations for the liver are reported in Figure 3.10 where one positive 
correlation and one negative correlation was identified.  The log concentrations of drugs 
found in the liver were positively correlated with the hydrophobic parameter LogP (r2 = 
+0.555, p = 0.034) and negatively correlated with the hydrophilic parameter PM3_Dipole 
(r2 = -0.524, p = 0.049).  This suggests that more hydrophobic, less polar molecules are 





Figure 3.10.  Linear regression models between physicochemical descriptors and drug 
levels in the Liver where (A) corresponds to Cluster 2 between liver and PM3_Dipole in 
Tables 3.12, 3.13, 3.14, and 3.15, and (B) corresponds to Cluster 2 between liver and 
LogP in Tables 3.16, 3.17, 3.18, and 3.19.  The hydrophilic parameter PM3_Dipole is 
negatively correlated, and the hydrophobic parameter LogP is positively correlated, with 
drug levels in the liver.  Both of these correlations exhibit an r2 ≥ 0.5 and p < 0.05, indicating 
a strong relationship between these descriptors and drug levels in the liver.  These results 
suggest hydrophobic compounds are more likely to distribute into the liver. 
 
 
3.4.5  Confirmation of HCA Clusters using QSAR Algorithms 
 
Initial efforts at investigating predictive models for drug delivery upon oral 
distribution using HCA and linear regression analysis led to the identification of multiple 
relationships between the calculated physicochemical parameters and drug levels in 
various ocular, neural, and visceral tissues (Figures 3.2 through 3.10).  To investigate the 
accuracy of these models, the same data were subject to the “QuaSAR” algorithm in 
MOETM.  Although many of the same cluster correlations were identified, some were 
excluded due to different p-values, suggesting the statistical methods between OriginPro 
and MOE may be different.  Results using the MOETM “QuaSAR” algorithm are shown in 
Table 3.20 along with the calculated mean absolute error (MAE), root mean square error 
(RMSE), cross-validated root mean square error (XRMSE), and cross-validated coefficient 
of determination (Xr2).  Clusters matching those calculated by HCA are indicated (*). 
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Tissue Drugs in Cluster Measured Parameter r2 MAE RMSE XRMSE Xr2 
Cornea* JHX: 2,3; HK: 2,3,7,8,12,15,16 ASA_P 0.643 0.853 1.127 1.407 0.452 
Cornea* JHX: 1,2,3,5,6,7 CASA+ 0.747 0.648 0.773 1.411 0.365 
Cornea* JHX: 5; HK: 4,6,9,16 LogS 0.833 0.139 0.155 0.246 0.597 
IrisCB JHX: 1,2,3,5,6,7 CASA+ 0.878 0.275 0.351 0.648 0.653 
IrisCB* JHX: 2,3,4; HK: 5,12,14 FASA_P 0.685 0.140 0.205 0.256 0.536 
IrisCB JHX: 2,3,4; HK: 5,12,14 LogP -0.934 0.081 0.094 0.135 0.868 
IrisCB* JHX: 2,3,4; HK: 5,12,14 vsurf_G 0.663 0.151 0.212 0.276 0.465 
IrisCB* JHX: 1,5,8; HK: 4,6 LogP -0.973 0.074 0.092 0.169 0.917 
Lens* JHX: 1,2,3,4,5,7,8 LogP -0.586 0.481 0.594 0.780 0.372 
Lens* JHX: 7; HK: 4,5,7,9,11,12,13 LogS 0.591 0.143 0.168 0.245 0.240 
NR* JHX: 2,3,4,6,7,8; HK: 1,2,8 SLogP1 0.633 0.416 0.524 0.721 0.372 
NR* JHX: 2,3,4,6,7; HK: 1,2,8 SLogP2 0.656 0.267 0.355 0.506 0.383 
RPE/C* JHX: 1,2,3,4; HK: 3,4,7,8,11,12,16 Apol 0.588 0.451 0.607 0.693 0.469 
RPE/C* JHX: 1,2,3,4; HK: 3,4,7,8,11,12,16 ASA 0.561 0.491 0.626 0.725 0.424 
RPE/C JHX: 1,2,3,4; HK: 3,4,7,8,11,12,16 vsurf_W1 0.608 0.562 0.663 0.800 0.335 
SN* JHX: 2,3; HK: 2,3,7,8,12,16 ASA_P -0.817 0.373 0.505 0.681 0.696 
SN JHX: 2,3; HK: 2,3,7,8,12,16 Kier1 -0.557 0.720 0.785 1.014 0.357 
SN* HK: 5,7,12,13,16 SLogP 0.972 0.033 0.041 0.063 0.937 
SN* JHX: 6,7,8; HK: 2,5,7,12,13,16 vsurf_Cp 0.588 0.125 0.157 0.191 0.424 
SN* JHX: 1; HK: 2,3,4,6,7,8,12,16 vsurf_W11 -0.661 0.737 0.842 1.075 0.473 
SN JHX: 1; HK: 2,3,4,6,7,8,16 vsurf_W12 -0.639 0.747 0.864 1.124 0.419 
SN HK: 2,3,4,6,7,8,12,16 vsurf_W13 -0.639 0.527 0.646 0.766 0.504 
Kidney* JHX: 1,2,3,5,6,7 CASA+ 0.673 0.489 0.557 0.897 0.334 
Kidney* JHX: 2; HK: 3,4,7,8,11,15,16 SMR 0.504 0.202 0.247 0.330 0.297 
Liver* HK: 1,3,4,5,6,7,8,10 LogP 0.555 0.300 0.386 0.493 0.340 
Table 3.20.  Cross-validated linear regression models obtained with the MOETM QuaSAR 
algorithm, many of which are the same as those obtained using OriginProTM HCA 
algorithm and subsequent linear regression analysis (indicated with *).  The clusters that 
were not identified by MOETM that were identified by OriginProTM include cornea vs. SMR, 
NR vs. Kier1, and brain vs. vsurf_Cp.  However, a few clusters were identified by MOETM 
that were not identified by OriginProTM, including iris/CB vs. CASA+, iris/CB vs. LogP, 
RPE/C vs. vsurf_W1, SN vs. Kier1, and SN vs. vsurf_W1.  An r2 value with a (-) sign 








Could these determined clusters, which were identified using two different 
mathematical approaches with OriginProTM and MOETM, be correlated with other 
physicochemical descriptors?  To investigate this possibility, the “QuaSAR” algorithm in 
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MOETM was again employed.  All identified cluster correlations in Table 3.20 were re-
evaluated against all physicochemical descriptors (Table 3.1) to confirm whether these 
clusters can be used to further identify relationships between tissue drug levels and the 
calculated physicochemical descriptors.  The results in Tables 3.21 through 3.28 report 
the newly calculated clusters where clusters highlighted in green were accepted and 
clusters highlighted in red were rejected by the internal validation algorithm.  The rejection 
criteria included the resulting calculations with a weak cross-validated coefficient of 
determination (Xr2 < 0.5), a large cross-validated error (XRMSE ≥ 1.2), or a non-linear 
distribution of data points. 
 
The results from the validated cornea cluster correlations (Table 3.20, cornea) are 
presented in Table 3.21, where the extended relationships between cornea and ASA_P, 
CASA+, and LogS clusters were examined.  The clusters were initially chosen based on 
their calculated r2 values, and then subjected to the internal cross-validation algorithm.  
For the cornea, this yielded four acceptable clustered correlations: FASA_H (Xr2 = -0.647), 
FASA_P (Xr2 = +0.647), vsurf_Cp (Xr2 = +0.631), and LogS (Xr2 = +0.597).  The graphed 
results of these extended QSAR models are shown in Figure 3.11. 
 
The results from the validated iris/CB cluster correlations (Table 3.20, iris/CB) are 
presented in Table 3.22, where the extended relationships between iris/CB and CASA+, 
FASA_H, FASA_P, and LogP clusters were examined.  The clusters were initially chosen 
based on calculated r2 values, and then subjected to the internal cross-validation 
algorithm.  For the iris/CB, this yielded eight acceptable clustered correlations: vsurf_Cp 
(Xr2 = +0.660), ASA (Xr2 = +0.536), ASA_P (Xr2 = +0.609), CASA- (Xr2 = +0.949), 
FASA_H (Xr2 = -0.536), FASA_P (Xr2 = +0.536), Kier1 (r2 = +0.815), and LogP (Xr2 = 





Parameter Drugs in Cluster 
Measured 
Parameter r2 MAE RMSE XRMSE Xr2 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
FASA_H -0.752 0.775 0.939 1.126 0.647 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
FASA_P 0.752 0.775 0.939 1.126 0.647 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
LogP -0.671 0.983 1.082 1.446 0.459 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
SLogP -0.684 0.939 1.06 1.547 0.431 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
vsurf_Cp 0.597 0.882 1.197 4.25 0.505 
Cornea ASA_P 
JHX: 2,3; HK: 
2,3,7,8,12,15,16 
vsurf_W1 0.533 1.073 1.289 1.654 0.289 
Cornea CASA+ JHX: 1,2,3,5,6,7 ASA_H -0.538 0.884 1.045 1.58 0.175 
Cornea CASA+ JHX: 1,2,3,5,6,7 vsurf_Cp 0.784 0.586 0.714 0.941 0.631 
Cornea LogS 
JHX: 5; HK: 
4,6,9,16 
LogS 0.833 0.139 0.155 0.246 0.597 
 
Table 3.21.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the cornea.  An r2 value with a (-) sign 
indicates a negative correlation.  The clusters in green (4) were accepted, and the clusters 
in pink (5) were rejected due to Xr2 < 0.5, XRMSE ≥ 1.2, or a non-linear distribution of data 
points.  The accepted clusters are shown in Figure 3.11.   
 
Figure 3.11.  Cross-validated linear regression models between physicochemical 
descriptors and drug levels in the cornea where (A) and (B) correspond to the new 
FASA_H and vsurf_Cp cluster correlations identified from Cluster 1 between cornea and 
CASA+ in Table 3.14, (C) corresponds to the new FASA_P cluster correlation identified 
from Cluster 1 between cornea and CASA+ in Table 3.14, and (D) corresponds to the 
validated Cluster 3 between cornea and LogS in Table 3.14.  These results suggest that 
non-micellar hydrophilic compounds are more likely to distribute into the cornea, which 









Parameter r2 MAE RMSE XRMSE Xr2 
IrisCB CASA+ JHX: 1,2,3,5,6,7 ASA_H 0.672 0.456 0.577 0.845 0.39 
IrisCB CASA+ JHX: 1,2,3,5,6,7 CASA+ 0.878 0.275 0.351 0.648 0.653 
IrisCB CASA+ JHX: 1,2,3,5,6,7 vsurf_Cp 0.777 0.348 0.475 0.685 0.660 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
Apol 0.708 0.182 0.198 0.284 0.474 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
ASA 0.729 0.16 0.191 0.26 0.536 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
ASA_P 0.74 0.13 0.187 0.234 0.609 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
CASA+ 0.939 0.062 0.09 0.128 0.879 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
CASA- 0.972 0.048 0.061 0.089 0.949 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
FASA_H -0.685 0.144 0.205 0.256 0.536 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
FASA_P 0.685 0.14 0.205 0.256 0.536 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
Kier1 0.897 0.093 0.117 0.161 0.815 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
LogP -0.934 0.081 0.094 0.135 0.868 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
PM3_Dipole 0.624 0.19 0.224 0.298 0.399 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
SLogP -0.982 0.045 0.049 0.077 0.957 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
SMR 0.796 0.144 0.165 0.233 0.625 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 
vsurf_G 0.663 0.151 0.212 0.276 0.465 
IrisCB FASA_H/_P 
JHX: 2,3,4;  
HK: 5,12,14 




CASA+ 0.706 0.269 0.307 0.442 0.471 
IrisCB LogP 
JHX: 1,5,8;  
HK: 4,6 
Dipole 0.551 0.322 0.38 0.915 0.215 
IrisCB LogP 
JHX: 1,5,8;  
HK: 4,6 
LogP -0.973 0.074 0.092 0.169 0.917 
IrisCB LogP 
JHX: 1,5,8;  
HK: 4,6 
SLogP -0.569 0.28 0.372 0.642 0.325 
 
Table 3.22.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the iris/CB.  An r2 value with a (-) sign 
indicates a negative correlation.  The clusters in green (8) were accepted, and the clusters 
in pink (13) were rejected due to Xr2 < 0.5, XRMSE ≥ 1.2, or a non-linear distribution of 





Figure 3.12.  Cross-validated linear regression models between physicochemical 
descriptors and drug levels in the iris/CB where (A) corresponds to a newly identified 
vsurf_Cp cluster correlation between iris/CB and CASA+, (B) through (G) correspond to 
the new calculated ASA, ASA_P, CASA-, ASA_H, FASA_P, and Kier1 clusters from 
iris/CB and FASA_H in Table 3.19 or FASA_P in Table 3.15, and (H) corresponds to the 
validated Cluster 1 between iris/CB and LogP in Table 3.18.  These results suggest that 
globular, hydrophilic compounds are more likely to distribute into the iris/CB, which agrees 
with the trends observed and reported for the iris/CB using HCA in Figure 3.3. 
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The results from the validated lens cluster correlations (Table 3.20, lens) are 
presented in Table 3.23, where it is shown that one new cluster correlations was identified 





Parameter Drugs in Cluster 
Measured 
Parameter r2 MAE RMSE XRMSE Xr2 
Lens LogP JHX: 1,2,3,4,5,7,8 vsurf_D1 -0.545 0.506 0.622 0.799 0.309 
 
Table 3.23.  Extended and cross-validated QSAR model relating to the measured 
parameters with clustered drug tissue levels in the lens.  An r2 value with a (-) sign 





The results from the validated NR cluster correlations (Table 3.20, NR) are 
presented in Table 3.24, where the extended relationships between NR and SLogP were 
examined.  The difference between the clusters for SLogP1 and SLogP2 is the presence 
or absence of compound JHX-8.  Though many clusters were identified based on r2 value, 
only CASA-1 (Xr2 = -0.509) and CASA-2 (Xr2 = -0.636) were identified, suggesting that the 
cluster without JHX-8 yielded a stronger relationship between drug levels in the NR and 
the calculated physicochemical parameters.  The graphed results of these identified 






Parameter Drugs in Cluster 
Measured 
Parameter r2 MAE RMSE XRMSE Xr2 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 Apol -0.509 0.444 0.606 0.797 0.228 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 ASA -0.552 0.432 0.579 0.770 0.273 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 ASA_P -0.656 0.398 0.508 0.697 0.397 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 CASA+ -0.559 0.449 0.574 0.737 0.317 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 CASA- -0.710 0.373 0.466 0.619 0.509 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 Kier1 -0.682 0.379 0.488 0.656 0.456 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 SMR -0.555 0.423 0.577 0.758 0.289 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 vsurf_G -0.623 0.381 0.532 0.721 0.36 
NR SLogP1 
JHX: 2,3,4,6,7,8; 
HK: 1,2,8 vsurf_W1 -0.676 0.382 0.493 0.687 0.436 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 Apol -0.501 0.356 0.428 0.592 0.175 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 ASA -0.519 0.344 0.42 0.581 0.198 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 ASA_P -0.506 0.336 0.426 0.56 0.239 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 CASA+ -0.566 0.358 0.399 0.525 0.301 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 CASA- -0.793 0.190 0.276 0.371 0.636 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 Kier1 -0.652 0.284 0.358 0.478 0.419 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 PM3_Dipole -0.506 0.392 0.426 0.555 0.267 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 SMR -0.547 0.341 0.408 0.558 0.243 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 vsurf_G -0.595 0.323 0.386 0.54 0.299 
NR SLogP2 
JHX: 2,3,4,6,7; 
HK: 1,2,8 vsurf_W1 -0.666 0.325 0.350 0.479 0.440 
 
Table 3.24.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the NR.  An r2 value with a (-) sign indicates 
a negative correlation.  The clusters in green (2) were accepted, and the clusters in pink 
(17) were rejected either due to Xr2 < 0.5, XRMSE ≥ 1.2, or a non-linear distribution of 





Figure 3.13.  Cross-validated linear regression models between physicochemical 
descriptors and drug levels in the NR where (A) corresponds to the newly calculated 
CASA- clusters from Cluster 2 between NR and SLogP in Tables 3.16 and 3.17, and (B) 
corresponds to the newly calculated cluster from Cluster 2 between NR and SLogP in 
Table 3.18.  These results suggest that hydrophilic molecules with less negatively charged 
surface area are more likely to distribute into the NR, which support the trends observe 
and reported in Figure 3.5 demonstrating larger hydrophobic molecules are more likely to 




The results from the validated RPE/C cluster correlations (Table 3.20, RPE/C) are 
presented in Table 3.25, where the extended relationships between RPE/C and Apol, 
ASA, and vsurf_W1 were examined.  No clustered correlations were identified from the 
ASA and vsurf_W1 clusters because no new relationships were identified with an r2 ≥ 0.5.  
The Apol clusters were initially chosen based on r2 values, and then subject to the internal 
cross-validation algorithm.  For the RPE/C, this yielded three acceptable clustered 
correlations with Dipole (Xr2 = +0.584), PM3_Dipole (Xr2 = +0.690) and SMR  (Xr2 = 






Parameter Drugs in Cluster 
Measured 
Parameter r2 MAE RMSE XRMSE Xr2 
RPE/C Apol 
JHX: 1,2,3,4;  
HK: 3,4,7,8,11,12,16 
ASA 0.561 0.491 0.626 0.725 0.424 
RPE/C Apol 
JHX: 1,2,3,4;  
HK: 3,4,7,8,11,12,16 




Kier1 0.552 0.577 0.633 0.773 0.381 
RPE/C Apol 
JHX: 1,2,3,4;  
HK: 3,4,7,8,11,12,16 
PM3_Dipole 0.775 0.328 0.448 0.531 0.69 
RPE/C Apol 
JHX: 1,2,3,4;  
HK: 3,4,7,8,11,12,16 
SMR 0.651 0.435 0.558 0.647 0.539 
RPE/C Apol 
JHX: 1,2,3,4;  
HK: 3,4,7,8,11,12,16 
vsurf_W1 0.608 0.562 0.663 0.800 0.335 
 
Table 3.25.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the RPE/C.  An r2 value with a (-) sign 
indicates a negative correlation.  The clusters in green (3) were accepted, and the clusters 






Figure 3.14.  Cross-validated linear regression models between physicochemical 
descriptors and drug levels in the RPE/C where (A) through (C) corresponds to the newly 
calculated Dipole, PM3_Dipole, and SMR clusters from Cluster 1 between RPE/C and 
Apol in Tables 3.14 and 3.15.  These results suggest that larger, polar hydrophilic 
molecules are more likely to distribute into the RPE/C, supporting the trends observed and 
reported for the RPE/C in Figure 3.6 demonstrating more polar hydrophilic molecules are 





The results from the validated SN cluster correlations (Table 3.20, SN) are 
presented in Table 3.26, where the extended relationships between SN and ASA_P, 
SLogP, vsurf_Cp, and three different vsurf_W1 clusters were examined.  The clusters 
were accepted based on initial r2 values and subjected to the internal cross-validation 
algorithm. For the SN, this yielded six acceptable clustered correlations with ASA_P (Xr2 
= -0.696), vsurf_W1 (Xr2 = -0.600; Xr2 = -0.504), ASA_H (Xr2 = +0.654), SLogP (Xr2 = 
+0.937), and vsurf_Cp (Xr2 = +0.596).  The graphed results of these extended QSAR 
models are shown in Figure 3.15. 
 
The results from the validated kidney cluster correlations (Table 3.20, kidney) are 
presented in Table 3.27, where the extended relationships between kidney and SMR were 
examined.  The clusters were initially accepted based on r2 values, and then subject to 
the internal cross-validation algorithm.  This yielded one acceptable clustered correlation 
between the kidney and Kier1 (Xr2 = +0.656).  The graphed result of this extended QSAR 
models is shown in Figure 3.16. 
 
Finally, the results from the validated liver cluster correlations (Table 3.20, liver) 
are presented in Table 3.28, where the extended relationships between liver and LogP 







Drugs in Cluster 
Measured 
Parameter 
r2 MAE RMSE XRMSE Xr2 
SN ASA_P 
JHX: 2,3;  
HK: 2,3,7,8,12,16 
ASA_P -0.817 0.373 0.505 0.681 0.696 
SN ASA_P 
JHX: 2,3;  
HK: 2,3,7,8,12,16 
CASA+ -0.529 0.702 0.809 1.006 0.318 
SN ASA_P 
JHX: 2,3;  
HK: 2,3,7,8,12,16 
Kier1 -0.557 0.720 0.785 1.014 0.357 
SN ASA_P 
JHX: 2,3;  
HK: 2,3,7,8,12,16 
vsurf_W1 -0.742 0.531 0.599 0.762 0.600 
SN SLogP HK: 5,7,12,13,16 ASA_H 0.836 0.094 0.100 0.188 0.654 
SN SLogP HK: 5,7,12,13,16 CASA+ -0.562 0.119 0.164 0.211 0.298 
SN SLogP HK: 5,7,12,13,16 CASA- -0.856 0.090 0.094 0.169 0.608 
SN SLogP HK: 5,7,12,13,16 LogP 0.700 0.115 0.136 0.199 0.486 
SN SLogP HK: 5,7,12,13,16 SLogP 0.972 0.033 0.041 0.063 0.937 
SN SLogP HK: 5,7,12,13,16 vsurf_Cp 0.772 0.100 0.118 0.225 0.596 
SN vsurf_Cp 
JHX: 6,7,8;  
HK: 2,5,7,12,13,16 
CASA- -0.512 0.146 0.171 0.215 0.278 
SN vsurf_Cp 
JHX: 6,7,8;  
HK: 2,5,7,12,13,16 
SLogP 0.520 0.144 0.169 0.209 0.295 
SN vsurf_Cp 
JHX: 6,7,8;  
HK: 2,5,7,12,13,16 
vsurf_Cp 0.588 0.125 0.157 0.191 0.424 
SN vsurf_Cp 
JHX: 6,7,8;  
HK: 2,5,7,12,13,16 
vsurf_W1 -0.517 0.143 0.170 0.216 0.257 
SN vsurf_W11 
JHX: 1;  
HK: 2,3,4,6,7,8,12,16 
CASA+ -0.727 0.661 0.755 1.082 0.622 
SN vsurf_W11 
JHX: 1;  
HK: 2,3,4,6,7,8,12,16 
CASA- -0.630 0.697 0.879 1.109 0.432 
SN vsurf_W11 
JHX: 1;  
HK: 2,3,4,6,7,8,12,16 
SLogP 0.537 0.708 0.983 1.292 0.257 
SN vsurf_W12 
JHX: 1;  
HK: 2,3,4,6,7,8,16 




CASA- -0.602 0.748 0.908 1.302 0.342 
SN vsurf_W13 HK: 2,3,4,6,7,8,12,16 CASA+ -0.507 0.565 0.755 0.913 0.307 
SN vsurf_W13 HK: 2,3,4,6,7,8,12,16 vsurf_W1 -0.639 0.527 0.646 0.766 0.504 
 
Table 3.26.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the SN.  An r2 value with a (-) sign indicates 
a negative correlation.  The clusters in green (6) were accepted, and the clusters in pink 





Figure 3.15.  Cross-validated linear regression models between physicochemical 
descriptors and drug levels in the SN where (A) and (B) correspond to the newly calculated 
ASA_P and vsurf_W1 clusters from Cluster 2 between SN and ASA_P in Tables 3.12, (C) 
through (E) correspond to the validated SLogP cluster and new calculated ASA_H and 
vsurf_P clusters from Cluster 2 between SN and SLogP in Table 3.19,and (F) corresponds 
to the validated vsurf_W1 cluster from Cluster 1 between SN and vsurf_W1 in Table 3.12.  
These results suggest that hydrophobic molecules with micellar-shape are more likely to 








Drugs in Cluster 
Measured 
Parameter 
r2 MAE RMSE XRMSE Xr2 
Kidney SMR 
JHX: 2;  
HK: 3,4,7,8,11,15,16 
Dipole 0.648 0.17 0.208 0.257 0.49 
Kidney SMR 
JHX: 2;  
HK: 3,4,7,8,11,15,16 
Kier1 0.753 0.128 0.174 0.207 0.656 
Kidney SMR 
JHX: 2;  
HK: 3,4,7,8,11,15,16 
PM3_Dipole 0.62 0.182 0.216 0.265 0.451 
Kidney SMR 





0.203 0.231 0.297 0.353 
Kidney SMR 
JHX: 2;  
HK: 3,4,7,8,11,15,16 
vsurf_W1 0.58 0.198 0.227 0.278 0.393 
 
Table 3.27.  Extended and cross-validated QSAR models relating to the measured 
parameters with clustered drug tissue levels in the kidney.  An r2 value with a (-) sign 
indicates a negative correlation.  The cluster in green (1) was accepted, and the clusters 





Figure 3.16.  Cross-validated linear regression model between physicochemical 
descriptor Kier1 and drug levels in the Kidney where (A) corresponds to the newly 
calculated Kier1 cluster from Cluster 2 between kidney and SMR in Table 3.9.  This result 
suggests that larger, more branched molecules are more likely to distribute into the kidney, 
which supports the trends observed and reported in Figure 3.9 that indicate larger, polar 








Drugs in Cluster 
Measured 
Parameter 
r2 MAE RMSE XRMSE Xr2 
Liver LogP HK: 1,3,4,5,6,7,8,10 vsurf_Cp 0.525 0.299 0.399 0.502 0.288 
 
Table 3.28.  Extended and cross-validated QSAR model relating to the measured 
parameter vsurf_Cp with clustered drug tissue levels in the liver.  An r2 value with a (-) 
sign indicates a negative correlation.  The identified cluster in pink was rejected due to an 




3.5  Discussion 
 
3.5.1  Initial Linear Regression Analysis 
 
The possibility that predictive models of drug distribution using the 24 orally-active 
multifunctional antioxidants (MFAO), their monofunctional free radical scavengers (FRS) 
and bio-active transition metal chelators (CHL), and their nonfunctional parent (NF) 
analogs, could be developed was investigated.  Initially, the results for the compounds 
found in the greatest concentrations per functional family were plotted against the 
calculated physicochemical parameters of those compounds, followed by linear 
regression analysis.  These compounds included the NFs JHX-1 and HK-13, the FRS 
JHX-6, the CHLs JHX-3 and HK-1, and the MFAOs HK-2 and HK-8.  The calculated 
physicochemical parameters each represent a general molecular attribute and are 
categorized as lipophilic, hydrophilic, or structural terms, which are used to develop 
physiologically-relevant modeling equations [22].  The classifications of each for each 
physicochemical parameter are reported in Table 3.1. 
 
The preliminary correlations reported in Tables 3.2 to 3.5 are meaningless without 
understanding the general properties of molecules required to pass through tissues [23].  
Just like the calculated physicochemical parameters are assigned a property, so are the 
physiological barriers in tissues which also possess different degrees of lipophilicity or 
hydrophilicity.  With the preliminary correlation data set including the NF compound (no 
antioxidant activity), two strong correlations (“r” value between ±0.7 and ±1.0) which 
followed physiologically-known trends were observed: lens with ASA_P (r = +0.801) and 
RPE/C with ASA_H (r = -0.818).  The data set excluding NFs found 10 strong correlations 
following physiologically-known trends: cornea with Dipole (r = +0.777), Apol (r = +0.833),   
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ASA (r = +0.848), ASA_P (r = +0.912), and SMR (r = +0.825); lens with Dipole (r = +0.810) 
and PM3_Dipole (r = +0.905); NR with PM3_Dipole (r = -0.801); brain with ASA_H (r = 
+0.840) and Kier1 (r = +0.818).  Due to the identification of many correlations which 
followed physiologically-known trends, it appeared that the creation of predictive models 
was plausible [14].   
 
Linear regression analysis of the full data set suggested that there may be some 
relationships between the 24 compounds and various calculated physicochemical 
descriptors (Table 3.6), and unfortunately the linear regression analysis on the 
mathematically standardized data set provided more questions rather than answers as no 
moderate correlations nor strong correlations were identified (Table 3.7).  Hence, attention 
was turned towards two common data mining techniques, hierarchical cluster analysis 
(HCA) followed by linear regression analysis and quantitative structure activity relationship 
(QSAR) analysis, to investigate whether it was possible to elucidate unknown relationships 
between the drug levels found in tissues and their calculated physicochemical descriptors.  
These two techniques were applied to confirm whether using different strategic 
approaches resulted in similar clusters and/or correlation outcomes. 
 
3.5.2  Clustered Correlations and Cluster Confirmations using QSAR Algorithms 
 
HCA was conducted on both data sets using average-linkage and complete-
linkage distance measures with the Euclidean distance metric.  The HCA method 
employed here is called agglomerative clustering, also known as a “bottom-up” approach, 
where each data point in 2D space (i.e., an (x,y) coordinate where x = tissue level of drug 
and y = calculated physicochemical parameter of drug, or vice-versa) is treated as its own 
individual cluster.  Based on the linkage algorithm, each of the points are successively 
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combined until one large cluster with all data points remains.  For cluster analysis, the 
linkage algorithm is important because it can be used to help understand the 
(dis)similarities between cluster groups.  Both complete-linkage and average-linkage 
measures were used.  The complete-linkage measure is an algorithm which merges the 
points of two clusters with the smallest maximum distance, which has been shown to 
maximize the probability that the most dissimilar clusters will be identified through its 
sensitivity to outliers [24].  In contrast, the average-linkage measure is a combined 
algorithm using aspects of both complete-linkage and single-linkage measures to create 
a balanced group of clusters, though more weight is given to the complete-linkage 
algorithm [25].  These two linkage algorithms are the most popular distance metrics in 
hierarchical clustering.  The single-linkage measure was not used due to its tendency to 
compact data sets into very similar groups [26].  Additionally, the distance metric chosen 
for clustering was Euclidean distance because it measures the 2D linear distance between 
two clusters. 
 
For both the full and standardized data sets, the drug levels for each tissue were 
plotted against the calculated physicochemical parameter of the drugs.  These were then 
subject to HCA using both average-linkage and complete-linkage algorithms.  An example 
of the results from these algorithm calculations are illustrated in Figure 3.1 which shows 
two model groups of dendrograms for the Apol and Kier1 parameters.  Each dendrogram 
chart represents the clustered data of the specified tissue’s drug levels and the calculated 
physicochemical parameter of the drugs.  The different colors within each dendrogram 
(i.e., red, green, blue, cyan, purple) represent a unique cluster of compounds identified by 
the algorithm within a specific data set.  Any clusters containing less than 5 drugs were 
excluded from further analysis because such clusters do not meet the minimum Hansch 
analysis criteria of 5-6 drugs per cluster per descriptor [23].  Though these dendrograms 
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may look similar between tissues, this did not indicate that the same drugs were clustered 
together, nor that the correlations of these clusters were similar.  Each calculated cluster 
identified by HCA analysis that met Hansch analysis criteria was further subject to linear 
regression analysis, and the results for all clustered correlations are shown in Tables 3.8 
to 3.11 for structural parameters, Tables 3.12 to 3.15 for hydrophilic parameters, and 
tables 3.16 to 3.19 for hydrophobic parameters. 
 
 The clustered correlation values (i.e., Pearson’s r-value) for the full data set of the 
structural parameters using average-linkage and complete-linkage algorithms, 
respectively, are shown in Tables 3.8 and 3.9.  Each of these clustered correlations were 
graphed and those with a non-linear distribution of data points (i.e., data points localized 
at two extremes) were eliminated.  Though many clusters did not appear to indicate even 
modest relationships, there were a large number of clusters which appeared to suggest 
robust relationships.  Clusters highlighted in yellow indicate a moderate correlation (“r” 
value between ±0.5 and ±0.7), while clusters highlighted in green indicate a strong 
correlation (“r” value between ±0.7 and ±1.0) for the respective linkage algorithms.  
Clusters highlighted in blue were found to be identical clusters between both average-
linkage and complete-algorithms for that tissue/descriptor cluster set, and clusters 
highlighted in pink were eliminated due to a non-linear distribution of data points.  This 
method was also applied to the standardized data set of the structural parameters (Tables 
3.10 and 3.11) and both data sets of the hydrophilic and hydrophobic parameters (3.12 to 
3.19). 
 
For cluster correlations to have any predictive merit, two major criteria must be 
met.  The first criterion is that the r2 value, also known as the coefficient of determination, 
must meet or exceed a value of 0.5.  The r2 value is a statistical measure of the strength 
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of the regression prediction and the degree of influence both variables have on each other 
[27].  In the case of an r2 value of 0.5, this means that 50% of the variation in the 
correlation/model is due to the variability between the measured variables, while 50% of 
the variation is attributed to external factors.  Because greater r2 values suggest model 
robustness, all correlations with Pearson’s r-values with an absolute value less than 0.707 
were eliminated.  The second criterion is that the p-value of the cluster correlations must 
be less than 0.05.  The p-value is statistically defined as the probability, under a specified 
statistical model, that the statistical summary of the data would be equal to or more 
extreme than its observed value [28].  A predictive model with a calculated p-value of less 
than 0.05 also suggests greater model robustness.  The final clustered correlations by 
means of HCA and linear regression analysis that meet these two criteria are presented, 
per tissue, in Figures 3.2 to 3.10. 
 
3.5.2a.  Blood-Aqueous Barrier Penetration 
 
For a drug in systemic circulation to distribute into the cornea, iris/CB, or lens, it 
must penetrate the blood-aqueous barrier (BAB), a network of tight junctions in the non-
pigmented epithelium of the ciliary process and the endothelial cells in the iris vasculature 
[29].  These cell layers prevent drug entry into aqueous humor and the intraocular tissues 
of the anterior segment  due to the presence of tight junctions which regulate solute 
passage [30, 31].  The clustered correlations for the cornea, iris/CB, and lens are shown 
in Figures 3.2, 3.3, and 3.4, respectively.   
 
The vasculature of the ciliary body is supplied by the anterior ciliary arteries and 
the long posterior ciliary arteries, forming the major arterial circle near the root of the iris 
wherefrom branches supply the iris, ciliary body, and the anterior choroid.  The ciliary body 
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vasculature is also fenestrated to allow passage of plasma proteins and molecules into 
the stroma as part of aqueous humor production [32].  The non-pigmented cell layer of the 
ciliary epithelium, and the endothelial cells of iris blood vessels, are believed to make up 
the blood-aqueous barrier (BAB).  Tight junctions are present in the non-pigmented cell 
layer of the ciliary epithelium, suggesting its role as the physical barrier to drug movement 
across the ciliary body [33].  Therefore, distribution of drugs to the cornea and lens require 
transit through the iris/CB.  According to Figure 3.3, parameters strongly correlated with 
iris/CB drug levels include the hydrophilic parameter FASA_P, the structural parameter 
vsurf_G, and the hydrophobic parameters FASA_H and LogP.  All hydrophilic and 
structural parameters are positively correlated, and all hydrophobic parameters negatively 
correlated, with iris/CB drug levels, suggesting that globular hydrophilic drugs with a 
greater polar surface area have a greater probability of distributing into the iris/CB. 
 
Upon transit through the iris/CB, the drugs enter circulation of the aqueous humor 
which flows from the ciliary body, into the anterior chamber, and out through the trabecular 
meshwork and Schlemm’s canal.  During aqueous circulation, the drugs can distribute to 
the lens through the lens epithelial cells.  Drug distribution to isolated lenses have been 
extensively studied with various compounds such as pilocarpine [34], dexamethasone 
[35], epinephrine [35], and timolol [36], and suggest that lipophilic drugs are able to 
distribute into the lens.  One comprehensive study with 13 small molecule xenobiotics and 
amino acids investigated in vitro drug partition through rabbit lenses and linked lipophilicity 
with increased lens uptake rate, suggesting that lipophilic drugs penetrate the lens better 
than more polar, hydrophilic compounds [37].  Another study investigated various drugs 
and dyes and found consistent distribution to the lens capsule, epithelium, and cortex of 
the porcine lens, but not to the lens nucleus [38]; these findings agree with other reported 




Unfortunately, drug distribution studies to the lens are limited in literature and it is 
difficult to assess what factors contribute to overall lens uptake.  It was initially assumed 
that more lipophilic drug characteristics were desired in order to penetrate into the lens.  
The opposite was observed in our studies, both in a preliminary distribution study in mice 
by Kawada and my distribution study in rats (Chapter 2).  The lens distribution results 
herein (Figure 3.4) reveal that the hydrophilic parameters FASA_P and LogS are 
positively correlated with lens distribution, while the hydrophobic parameter LogP is 
negatively correlated with lens distribution.  This is a similar trend to the one observed in 
the iris/CB, where it was also observed that hydrophilic drugs with a greater polar surface 
area have a higher likelihood of distributing to the iris/CB.  It is possible that a balance of 
lipophilic and hydrophilic characteristics are required for lens distribution, but future 
investigations must be done to determine whether this is the case. 
 
From aqueous circulation, drugs may also enter the cornea through the corneal 
endothelial cells.  Few oral drug treatments have been shown to deliver to the diseased 
cornea such as miltefosine [40], cyclosporin [41], tetracycline [42], and prednisolone [43].  
However, studies comparing the effects of different routes of administration on corneal 
drug delivery are limited, especially since the most convenient route for treating corneal 
ailments is by topical application; scarce are models predicting corneal permeability upon 
oral distribution.  Araki-Sasaki and colleagues demonstrated in healthy rabbits that 
corticosteroids reached the cornea in higher concentrations upon topical application 
(dexamethasone) than upon oral administration (prednisolone).  Though this was 
expected, it was also found that both oral and topical administration of these 
corticosteroids resulted in similar distributions to the conjunctiva [44].   Furthermore, 
Sharma and colleagues developed a novel QSPR model using molecular descriptors to 
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predict the penetration of nine fluoroquinolones, though this was based on topical 
administration and corneal predictability was found to be unachievable [45].  Whether 
hydrophilicity or lipophilicity is a greater factor in corneal permeation remains to be 
determined as results continue to be conflicting and based solely on topical formulations 
[45-49].  Our results indicate that corneal drug levels are positively correlated with the 
hydrophilic parameters CASA+, ASA_P, and LogS, and the structural parameter SMR.  
SMR is an indirect measure of molecular size (i.e., larger SMR suggests to greater 
molecular size) and is strongly correlated with hydrophilicity and polarizability.  These 
data, reported in Figure 3.2, suggest that larger, polar, hydrophilic molecules with a 
greater positively-charged surface area have a greater likelihood of distributing into the 
cornea.  These findings agree with other reported hydrophilic trends for corneal drug 
penetration through different routes of administration [50, 51]. 
 
3.5.2b.  Blood-Retinal Barrier Penetration 
 
For drugs in systemic circulation to distribute into the neural retina or retinal 
pigmented epithelium and choroid (RPE/C), they must penetrate the blood-retinal barrier 
(BRB).  Like the BAB in the anterior segment, the BRB is the major barrier of ocular drug 
delivery to the posterior segment from the blood.  By means of tight junctions, the BRB 
regulates fluids and molecular movement between the ocular vascular beds and retinal 
tissues, prevents leakage of macromolecules and other potentially harmful agents into the 
retina, and maintains the microenvironment of the retina [52].  The BRB consists of two 
parts, the inner BRB (iBRB) formed by non-fenestrated retinal capillary endothelial cells, 
and the outer BRB (oBRB) formed by the tight junctions of the retinal pigmented epithelial 
cells with support from Bruch’s membrane that prevent passage of large molecules from 
the choriocapillaris [53].  The clustered correlations for the neural retina (NR) and retinal 
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pigmented epithelium with choroid (RPE/C) are shown in Figures 3.5 and 3.6, 
respectively. 
 
The RPE comprises the oBRB and is situated between the retinal photoreceptors 
and choroid. It has several essential functions, namely absorbing scattered light, 
phagocytosis of photoreceptor outer segment membranes, and maintaining the 
homeostasis between the neural retina and circulating blood.  Due to its large surface 
area, the RPE is considered an important route of passage of small molecular weight 
drugs, especially in their elimination [54], because small molecules may cross the RPE 
both transcellularly and paracellularly [55].  Though drugs may cross the RPE by passive 
diffusion and/or active transport, evidence suggests that passive permeability is the main 
mechanism of drug distribution across the BRB [56-58].  It has been shown that drugs in 
the bloodstream rapidly equilibrate with the extravascular space of the choroid because 
the choriocapillaris is fenestrated, and the RPE limits the permeation of drugs from the 
choroid to the retina [59, 60].  Additionally, the inward permeability of more hydrophilic 
drugs, such as the beta blockers atenolol and nadolol, were found to penetrate greater 
than the more hydrophobic drugs pindolol, metoprolol, timolol, and betaxolol [31, 61, 62].  
In agreement with these reports, the cluster correlations for the RPE/C (Figure 3.6) 
illustrate positive correlations between RPE/C drug levels and the hydrophilic parameters 
Apol, ASA, LogS, and vsurf_W1, indicating that large, polar, hydrophilic drugs with a 
greater polar surface area are more likely to distribute to the RPE/C. 
 
Consequently, the iBRB prevents the free diffusion of substances between the 
neural retina (NR) and the circulating endoneurial blood [63].  Transcellular transport by 
retinal capillary endothelial cells is required for a variety of low molecular weight 
compounds such as amino acids and D-glucose [64, 65].  When a drug is administered 
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systemically, it must pass the iBRB to reach therapeutic levels in the neural retina.  Drug 
penetration across the iBRB depends on various factors including plasma protein binding 
of the drug, plasma concentration of the drug, and the drug’s volume of distribution 
(pharmacokinetic parameter representing a drug’s tendency to remain in plasma or 
distribute to a tissue) [66].  It is well-known that hydrophilic molecules are impermeable 
through the iBRB and, in general, drugs with more lipophilic characteristics penetrate the 
iBRB better.  The data in Figure 3.5 agree with this general presumption, where it is 
reported that drug levels in the NR are positively correlated with the hydrophobic 
parameter SLogP and the structural parameter Kier1, indicating that larger, branched, 
hydrophobic molecules are more likely to distribute into the NR. 
 
3.5.2c.  Blood-Brain and Blood-Nerve Barrier Penetration 
 
The blood-brain barrier (BBB) and blood-nerve barrier (BNB) constitute a complex 
interface between the blood, the central nervous system (CNS), and the peripheral 
nervous system (PNS).  The BBB protects the brain by controlling molecule exchange 
from the blood and regulates the transmigration of immune cells.  It is mainly composed 
of brain microvascular endothelial cells, pericytes, astrocytes, and basement membranes 
[67, 68].  Like the BAB and BRB, the BBB is comprised of tight junctions.  The BNB has a 
similar structure to the BBB except that it lacks supporting astrocytes [69].  Despite the 
lack of astrocytes, reports indicate that the BNB has similar properties to the BBB which 
suggests that the specific structural components of the basement membrane at the BNB 
affects barrier function [69, 70].  Both the BBB and BNB play crucial roles in maintaining 




Molecules cross the BBB both paracellularly and transcellularly.  For the 
paracellular pathway, ions and solutes use concentration gradients to pass the BBB by 
passive diffusion.  The transcellular pathway includes passive diffusion and transcytosis.  
Physicochemical factors that influence BBB permeability include molecular weight, 
charge, hydrophobicity, surface activity, and relative molecular size [72], yet the BBB 
prevents entry into the brain of most drugs from the blood.  While it is assumed that small 
molecules are freely transported across the BBB, ca. 98% are not; however, almost all 
drugs for the brain in the clinic are highly lipid soluble small molecules with a molecular 
weight < 400 Da [73-75].  Unfortunately, only one cluster correlation was identified for the 
brain.  The data presented in Figure 3.7 shows that drug concentration in the brain is 
positively correlated with vsurf_Cp, a structural parameter which measures micellar 
shape of molecules.  Molecular structure has not been well documented for BBB passage, 
nor used in predictive BBB models. 
 
The PNS and CNS constantly transmit signals between each other which is critical 
for normal human sensory and motor function.  To ensure proper function of peripheral 
nerves, the maintenance of homeostasis is required for the endoneurial environment.  This 
is endowed by the presence of the BNB which is located at the innermost layer of the 
perineurium and at the endoneurial microvessels within the nerve fascicles in the PNS 
[76, 77].  The tight junctions between the endothelial cells and pericytes in the endoneurial 
vasculature isolate the endoneurium from the blood, thereby preventing uncontrollable 
leakage of molecules and ions from the circulatory system to the peripheral nerves.  
Evidence from various physiological and morphological studies indicates that BNB 
exchange occurs predominantly through endoneurial capillaries and that perineurial 
passage constitutes a minor route [78-81].  For drug targets located in peripheral nerves, 
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the BNB can be problematic because of its potential to restrict or prevent drugs from 
reaching their site of action [81, 82].   
 
Little is known about the impact of the blood-nerve barrier (BNB) on drug 
distribution into peripheral nerves.  Previous studies indicate that the distal trunks of 
peripheral nerves, such as the sciatic nerve, are relatively impermeable to hydrophilic 
small molecules and many large molecules due to limited intercellular diffusion [83-85].  
Despite some basic drug passage studies, a systematic and quantitative evaluation of the 
distribution of small molecule drugs into peripheral nerves is still absent.  Compared to 
BBB penetration, the physicochemical and transport properties governing the drug 
distribution into peripheral nerves remains largely unexplored.  One recent study from 
GlaxoSmithKline by Liu and colleagues shows that the sciatic nerve is more permeable to 
small, lipophilic molecules with structural diversity compared to the BBB [86].  Our reported 
cluster correlations in Figure 3.8 support this finding and show that SN concentration is 
positively correlated with the hydrophobic parameter SLogP and the structural parameters 
Kier1 and vsurf_Cp, and negatively correlated with the hydrophilic parameters ASA_P 
and vsurf_W1.  This suggests that large, branched, micelle-like hydrophobic molecules 
are more likely to distribute into the SN. 
 
3.5.2d.  Peripheral Tissue Distribution 
 
The liver and kidneys are two vital organs responsible for the metabolism and 
excretion of drugs, respectively.  However, there is a lack of site-specific delivery of drugs 
to both hepatocytes and nephrons [87, 88].  Most discussions concerning the liver and 
kidney come from a toxicological perspective, such as drug-induced liver injury and drug-
induced kidney injury, as these organs are rarely the direct targets of therapeutic drugs 
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[89-91].  As a result, there are limited, if any, models for drug distribution to the liver and 
kidney.  Figures 3.9 and 3.10 illustrate the predictive cluster correlations of the MFAOs 
and their analogs to the kidney and liver, respectively.  It was observed that drug 
concentration in the kidney is positively correlated with the hydrophilic parameter CASA+ 
and the structural parameter SMR, while the liver is negatively correlated with the 
hydrophilic parameter PM3_Dipole and positively correlated with the hydrophobic 
parameter LogP.  These reports indicate that larger, polar, hydrophilic drugs with a larger 
positively-charged surface area are more likely to distribute into the kidney, and that more 
nonpolar hydrophobic drugs preferentially distribute into the liver.  These results support 
the general known trends of drug distribution in the body.  The liver is the primary site of 
metabolism and contains the necessary enzymes to metabolize drugs [92].  Most drugs 
are lipophilic, and upon oral administration they eventually reach the liver and readily 
undergo first-pass metabolism to increase their hydrophilicity [93].  These modifications 
are necessary for excretion by the kidneys, since the kidneys cannot efficiently filter and 
excrete lipophilic drugs [94].  However, drugs can also be excreted from the liver into bile 
which get released into the gastrointestinal tract, where drugs can then be reabsorbed into 
systematic circulation. 
 
3.5.2e.  Verification of HCA Clustered Correlations 
 
To verify the HCA clustered correlations, the data sets were also subject to the 
intrinsic “QuaSAR” algorithm in MOETM.  Most of the clustered correlations identified by 
OriginProTM were also identified with MOETM. Though a few correlations were eliminated 
due to p-value exclusion criteria (i.e., p > 0.05), a few new correlations were identified.  
These resulting clustered correlations are shown in Table 3.20 along with the drugs in the 
clusters, the mean average error (MAE), the root-mean standard error (RMSE), cross-
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validated RMSE (XRMSE) and cross-validated r2 (Xr2) values.  Unlike the results from 
HCA analysis using OriginProTM, no models were found for the brain.  This approach 
validated the HCA methods of analysis by means of a more mathematically rigorous 
algorithm and was able to eliminate less robust models. 
 
3.5.3  Extended Linear Regression Using QSAR-Derived Clustered Correlations 
 
Could these determined clusters, which were identified using two different 
mathematical approaches with OriginProTM and MOETM, be correlated with other 
physicochemical descriptors?  To investigate this possibility, the “QuaSAR” algorithm in 
MOETM was employed.  All identified cluster correlations in Table 3.20 were re-evaluated 
against all physicochemical descriptors (Table 3.1) to confirm whether these clusters can 
be used to further identify relationships between tissue drug levels and the calculated 
physicochemical descriptors.  The results in Tables 3.21 through 3.28 report the identified 
clusters where clusters highlighted in green were accepted and clusters highlighted in red 
were rejected by the internal validation algorithm.  The rejection criteria included the 
resulting calculations with a weak cross-validated coefficient of determination (Xr2 < 0.5), 
a large cross-validated error (XRMSE ≥ 1.2), or a non-linear distribution of data points.   
 
The accepted clusters after intrinsic cross-validation for the cornea, iris/CB, NR, 
RPE/C, SN, and kidney are reported in Figures 3.11 to 3.16.  These models agree with 
the reported HCA trends for the cornea (Figure 3.2), iris/CB (Figure 3.3), NR (Figure 3.5), 
RPE/C (Figure 3.6), SN (Figure 3.8), and kidney (Figure 3.9).  No models were identified 
for the lens, brain, or liver, but these results indicated that there are multiple 
physicochemical descriptors that can be used to develop predictive models for drug 
distribution to various tissues.  Though many of the parameters used herein have been 
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commonly used in QSAR and computational studies, many of them have not been widely 
accepted or standardized since they cannot be validated experimentally.  For example, 
the hydrophobic parameter LogP is the partition coefficient of a drug which can be 
determined experimentally by measuring its concentration in octanol vs. water.  However, 
a structural parameter like Kier1 or a hydrophilic parameter like CASA+ cannot be 
determined experimentally as their values are based on theoretical calculations. 
 
Using the QuaSAR algorithms, four predictive models were identified for the 
cornea as reported in Figure 3.11.  Drug levels in the cornea were found to be a function 
of FASA_H (r2 = -0.752), vsurf_Cp (r2 = -0.785), FASA_P (r2 = +0.752), and LogS (r2 = 
+0.831).  Just like the results from HCA (Figure 3.2), these models show that increased 
hydrophilicity of a drug increases the probability of drug distribution to the cornea.  The 
same trend is observed in the iris/CB in Figure 3.12 where iris/CB drug levels were found 
to be a function of vsurf_Cp (r2 = -0.777), ASA (r2 = +0.729), ASA_P (r2 = +0.740), CASA- 
(r2 = +0.972), FASA_H (r2 = -0.685), FASA_P (r2 = +0.685), Kier1 (r2 = +0.897), LogP (r2 
= -0.973), and SLogP (r2 = -0.982).  These predictive models also agree with the 
calculated HCA results (Figure 3.3), further supporting the premise that more hydrophilic 
compounds are required to permeate the BAB and deliver to tissues of the anterior 
segment. 
 
Two predictive models were identified for the NR as reported in Figure 3.13.  Both 
models identified a negative correlation between NR drug levels and the hydrophilic 
parameter CASA- (r2 = -0.710; r2 = -0.793).  Though this model is different compared to 
calculated HCA results (Figure 3.5), which found positive correlations between the 
hydrophobic parameter SLogP and the structural parameter Kier1, the same overall trend 
was identified where molecules with more lipophilic properties are more likely to distribute 
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into the NR.  Additionally, Figure 3.14 demonstrated the positive correlation between 
RPE/C drug levels and the hydrophilic parameters Dipole (r2 = +0.681), PM3_Dipole (r2 
= +0.775), and SMR (r2 = +0.651), while HCA calculations showed positive correlation 
between RPE/C and the hydrophilic parameters Apol, ASA, LogS, and vsurf_W1 (Figure 
3.6).  These results support the calculated HCA results, demonstrating that drugs with 
greater hydrophilic characteristics are more likely to distribute into the RPE/C.  These 
models suggest that compounds possessing hydrophilic characteristics are more likely to 
pass the oBRB and distribute to the RPE/C, while compounds with lipophilic properties 
are required for iBRB passage for delivering to the NR. 
 
No predictive models were identified for the brain using the MOETM QuaSAR 
algorithm.  In contrast, all calculated predictive models using the QuaSAR algorithm for 
the SN are shown in Figure 3.15.  SN drug levels are positively correlated with the 
hydrophobic parameters ASA_H (r2 = +0.836) and SLogP (r2 = +0.972) and the structural 
parameter vsurf_Cp (r2 = +0.772), and negatively correlated with the hydrophilic 
parameters ASA_P (r2 = -0.817) and vsurf_W1 (r2 = -0.639).  Interestingly, the identified 
parameters and their trends are very similar to those seen in the calculated HCA cluster 
correlations  (Figure 3.8), suggesting that these cluster correlations may have strong 
predictability.  Since drug distribution to the SN and peripheral nerves is underexplored, 
this is one of the first predictive models for SN drug distribution which suggests that drugs 
with more lipophilic characteristics that resemble a micellar shape are more likely to pass 
the BNB and deliver to the SN. 
 
Finally, there was only one predictive model identified for the visceral tissues.  
Unlike the HCA cluster correlations which showed kidney drug distribution positively 
correlated to CASA+ and SMR (Figure 3.10), Figure 3.17 reported one positive 
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correlation between kidney drug levels and the structural parameter Kier1 (r2 = 0.753).  
These models agrees with each other and suggest that larger, branched, hydrophilic drugs 
with a greater positively-charged surface area are more likely to distribute to the kidney. 
 
3.6  Conclusion 
 
Both Hierarchical Cluster Analysis (HCA) and Quantitative Structure Activity 
Relationship (QSAR) analysis algorithms were employed herein to determine whether 
predictive models could be created for 24 orally-administered multifunctional antioxidants 
(MFAOs), their monofunctional free radical scavenging (FRS) and bio-active transition 
metal chelating (CHL) analogs, and their nonfunctional (NF) analogs.  Using both 
methods, multiple correlative relationships with several similar, if not identical, trends were 
identified.  More importantly, the present results agree with observations of the 
requirement of lipophilic or hydrophilic drug passage through the various physiological 
barriers such as the BAB, BRB, BBB, and BNB, and their respective tissues.  This study 
not only demonstrates the feasibility of developing predictive models for the oral 
administration of compounds into the ocular, neural, and visceral tissue, but also provides 
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Failure of Oxysterols such as Lanosterol to Restore Lens Clarity from Cataract 
 
4.1  Summary 
 
The paradigm that cataracts are irreversible and that vision from cataracts can only 
be restored through surgery has recently been challenged by reports that oxysterols, such 
as lanosterol and 25-hydroxycholesterol, can restore vision by binding to the αB-crystallin 
chaperone protein to dissolve or disaggregate lenticular opacities.  To confirm this 
premise, in vitro rat lens studies along with in vitro human lens protein solubilization 
studies were conducted.  Cataracts were induced in viable rat lenses cultured for 48 hours 
in TC-199 bicarbonate media through physical trauma, 10 mM ouabain as Na+/K+ ATPase 
ion transport inhibitor, or 1 mM of an experimental compound that induces water influx into 
the lens.  Subsequent 48-hour incubation with 15 mM of lanosterol liposomes failed to 
either reverse these lens opacities or prevent the further progression of cataracts to the 
nuclear stage.  Similarly, 3-day incubation of 47-year-old human lenses in media 
containing 0.20 mM lanosterol, or 60-year-old human lenses in 0.25 and 0.50 mM 25-
hydroxycholesterol, failed to increase the levels of soluble lens proteins or decrease the 
levels of insoluble lens proteins.  These binding studies were followed up with in 
silico docking studies of lanosterol, 25-hydroxycholesterol, and ATP as a control to two 
wild type (2WJ7 and 2KLR) and one R120G mutant (2Y1Z) αB-crystallins using 
MOETM (Molecular Operating Environment) and Schrödinger’s Maestro software.  Results 
confirmed that, compared to ATP, both oxysterols failed to reach the acceptable threshold 
binding scores for good predictive binding to the αB-crystallins.  Additional in silico studies 
were also conducted on six novel multifunctional antioxidants which exhibited superior 
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binding compared to the oxysterols.  In summary, all three studies failed to provide 
evidence that lanosterol or 25-hydroxycholesterol have either anti-cataractogenic activity 
or bind aggregated lens protein to dissolve cataracts.  This study has already been 
published, but the additional MFAO results and discussions were added for this thesis [1]. 
 
4.2  Introduction 
 
The ocular lens is a transparent organ whose function is to focus light onto the 
retina.  It is composed of epithelial cells that are enclosed in a thick capsule formed from 
epithelial basement membrane [2].  At its anterior surface, the lens contains a single layer 
of proliferating epithelial cells.  As these cells reach the equator, they elongate and 
differentiate into fiber cells that then make up the bulk of the lens.  These elongated fiber 
cells become completely internalized with their ends joined by collagen at sutures that run 
from the lens center to anterior and posterior poles.  The lens grows throughout life with 
new fiber cells continually laid on top of the older fiber cells so that the fiber cell depth 
within the lens is directly related to the age and stage of lens development [3-5].  The 
transparent lens is unique because this “enclosed bag of regularly ordered cells and 
proteins” has evolved into an internal micro-circulatory system composed of ions that are 
coupled to fluid movement that causes the lens to demonstrate behavior similar to that of 
a single cell [6-8]. 
 
The lens is transparent because light scattering within the lens is minimized.  It 
lacks blood vessels that can scatter and absorb light as well as light scattering cellular 
organelles such as nuclei, mitochondria, and endoplasmic reticula that are removed during 
differentiation of the epithelial cells into fiber cells.  Light scattering is further minimized by 
the specialized organization and composition of the tightly packed fiber cells which contain 
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structural crystallin proteins that also assist in maintaining the proper refractive index in 
the lens [9, 10].  Since the lens fiber cells lack the capacity for protein turnover and repair, 
specific antioxidant defenses and protein chaperones are present within these fiber cells 
to protect lens proteins from post-translational changes and aggregation [9, 11-14].  
Among these are the small heat shock protein (sHSP) α-crystallins with chaperone-like 
activity that play a central role in maintaining lens transparency by trapping the denaturing 
or unfolding proteins responsible for light scattering in the highly ordered lens fibers [15-
18]. 
 
Cataracts develop from the loss of lens transparency associated with increased 
light scattering and changes in refractive properties.  The protective lens antioxidant 
defenses and the molecular chaperone reserves of α-crystallin decrease with age so that 
the aging lens can no longer adequately protect itself from post-translational modifications 
of lens proteins.  This leads to increased light scattering as a function of protein 
aggregation of post-translationally modified structural proteins which has been 
experimentally and clinically established in pre-cataractous lenses by dynamic light 
scattering [15, 19, 20].  Since this aggregation and denaturation of lens proteins appears 
irreversible, the surgical removal of the opaque lens is currently the only treatment for 
restoring vision loss from cataracts [14].  As a result, the development of anti-cataract 
agents has primarily focused on supplementing the lens with biochemical intermediates 
or redox agents to reduce or prevent the post-translational modifications that eventually 
result in irreversible changes in lens protein structure and aggregation.  An exception is 
the pharmacological prevention of diabetic cataracts where a specific enzyme that initiates 




The paradigm that vision can only be restored through cataract surgery has 
recently been challenged by Zhao et al. [24] and Makley et al. [25]  It is reported that 
interaction of lanosterol or 25-hydroxycholesterol with α-crystallin chaperones enhance 
the ability of these chaperones to restore lens clarity by increasing their ability to physically 
dissolve protein aggregates and/or the denatured amyloid-like fibril proteins present in 
cataractous lenses.  These reports have subsequently been expanded to include 
dissolving aggregated proteins in cataracts from two additional congenital mouse models 
[26, 27].  The striking possibility of a non-surgical cataract removal has received worldwide 
coverage by the news media and encouraged investigators to focus on developing anti-
cataract drugs that reverse rather than prevent cataract formation.  It has also led to the 
commercialization of lanosterol eye drops [28-30].  However, the ability of these 
compounds to restore lens clarity has not been independently confirmed.  For example, a 
recent report has shown that culturing lens nuclei from 40 age-related cataractous human 
lenses with 25 mM lanosterol for 6 days at room temperature failed to either dissolve the 
aggregated proteins or restore the clarity of the lens nuclei [31].  Similarly, clinically 
administering eye drops containing 5 mM lanosterol dissolved in olive oil two times daily 
for the first week, followed by three times daily for the next seven weeks, to a patient with 
idiopathic unilateral juvenile nuclear cataracts failed to produce any relevant clinical effect 
in reversing either the cataract or halting the progressive worsening of visual acuity with 
an increasing of myopic shift [32].  Triparanol, an inhibitor of the conversion of lanosterol 
to cholesterol, has also been shown to not only induce cataract formation, but also 
increase tissue lanosterol levels [33-35].  The presence of 25-hydroxycholesterol in human 
lenses has also been linked to the presence rather than absence of cataracts [36].  
 
To clarify these contrasting findings, we pursued a series of in vitro studies to 
evaluate whether oxysterols such as lanosterol or 25-hydroxycholesterol can reverse 
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experimentally induced cataracts or to re-dissolve aggregated lens crystallin proteins.  We 
also explored if either oxysterol adequately bound to αB-crystallin chaperones at the 
molecular level in silico.  In addition, six novel multifunctional antioxidants (MFAOs) were 
also examined in silico since previous studies from our laboratory have indicated that a 
parent MFAO analog, JHX-1, was able to significantly delay in the advanced progression 
of sugar cataract formation in vivo without sorbitol dehydrogenase or aldose reductase 
inhibition, suggesting it may have inherent chaperone activity [37].   
 
4.3  Materials and Methods 
 
All procedures involving live animals were performed in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and the 
Association for Research in Vision and Ophthalmology Statement for the Use of Animals 
in Ophthalmic and Vision Research and approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Nebraska Medical Center.  Human lenses 
were obtained from donor eyes from the Saving Sight Eye Bank, Kansas City, MO and 
stored at −85 °C prior to use. 
 
In Vitro Lenses Culture Studies.  Eyes from young (125 g, 5-week old) Sprague 
Dawley rats were immediately enucleated upon death from carbon dioxide asphyxiation.  
The intact lens from each eye was removed by careful dissection from a posterior 
approach and cultured as previously described in sterile TC-199 bicarbonate media 
containing 30 mM fructose and 20 U/mL of penicillin-streptomycin in a humidified incubator 




Following overnight pre-incubation to ensure intact lenses were not damaged 
during dissection, all clear lenses were transferred into 24-well culture plates containing 
2 mL of the standard culture media for 48 hours according to the following 4 groups (6 
lenses/group).  The first group served as the untreated control, while each lens in the 
second group was squeezed at the equator with forceps to induce blunt trauma opacities. 
In the third group, opacities were induced by addition of 10 mM of the Na+/K+ ATPase 
inhibitor, ouabain, and in the fourth group opacities were induced by culture with 1 mM of 
an experimental toxic glycoprotein chaperone that induces osmotic cataract.  After 
48 hours, the culture media for each lens was replaced with fresh TC-199 bicarbonate 
media containing 15 mM of lanosterol liposomes and the lenses were cultured for an 
additional 48 hours.  At the end of the second 48-hour culture period, each lens was 
carefully washed with PBS solution and transferred to culture plates containing PBS 
solution.  The appearance of each lens was immediately photo-documented by placing 
the lens over a light source containing a grid.  Each photograph was then standardized by 
adjusting the pixel densities of each outer grid line to a standard value.  
 
Liposome Preparation.  Lanosterol (Alpha Chem) was dissolved in a 250 mL 
round bottom flask containing acetonitrile and the solvent was removed under vacuum in 
a rotary evaporator.  The resulting glassine layer of lanosterol coating the inner surface of 
the round bottom flask was then removed by scraping with a spatula, followed by addition 
of an appropriate amount of TC-199 bicarbonate media to give a 15 mM solution.  The 
lanosterol sheets were converted to liposomes by sonication using a micro homogenizer 
tip (MISONIX Fisher Scientific Sonicator Ultrasonic Processor XL) until the solution 
appeared homogenous (ca. 5 minutes).  Equal aliquots of 2 mL were pipetted into the 24-




Solubilization of proteins from human lens fragments with lanosterol.  Two 
human lenses from a 47-year-old donor were cut through the center into four equal 
quadrants and weighed.  One piece from each lens tissue was placed in PBS media 
composed of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.5 mM KH2PO4, pH 7.4, 
containing 0.03% sodium azide.  Lanosterol dissolved in 12.5 µL of ethanol was then 
added to some of the lens pieces in PBS to give a 0.20 mM lanosterol test solution in a 
total volume of 500 µL.  All lens pieces, with or without lanosterol, were incubated at 37 °C 
in the dark for 72 hours and then homogenized.  The soluble and insoluble protein fractions 
were separated by centrifugation at 13,000 rpm for 20 minutes at room temperature in an 
Eppendorf centrifuge.  The protein content of the soluble protein in the supernatant was 
determined using the Bio-Rad Protein Assay (Hercules, CA).  Control samples were 
similarly prepared using only 12.5 µL ethanol (These studies were conducted by Dr. 
Sharma’s group from the University of Missouri, Columbia).  
 
Solubilization of proteins from human lens fragments with 25-
hydroxycholesterol.  Six frozen lenses from 60-year-old donors were each cut into three 
equal pie shapes with each sample composed of two pie shapes from different lenses.  
These nine samples were each immersed into 500 µL of PBS containing 0.03% sodium 
azide and 10% ethanol containing either 0.0, 0.25 or 0.50 mM of 25-hydroxycholesterol.  
The samples were then incubated at 37 °C for 72 hours in the dark.  Following incubation, 
the samples were homogenized, and the water-soluble fraction was separated from the 
insoluble fractions by centrifugation at 13,000 rpm for 20 min at room temperature.  The 
water-insoluble fractions were treated with 100 µL of 0.1 M NaOH for 2 hours to solubilize 
the proteins.  The protein content in all samples was measured using the Bio-Rad Protein 
Assay.  Samples incubated only with 10% ethanol served as controls (These studies were 




Solubilization of proteins from human lens homogenates with lanosterol.  
Attempts to solubilize lens proteins by lanosterol and 25-hydroxycholesterol were also 
carried out using lens homogenates prepared from 72-year-old human lenses.  Tissue 
homogenates containing 0.25 and 1.0 mg protein in 0.5 mL PBS (containing protease 
inhibitor cocktail) and oxysterols at a final concentration of 0, 100, or 200 µM were 
incubated at 37 °C for 24 hours.  At the end of the incubation, the tubes were centrifuged 
at 13,000 rpm for 15 min at 4 °C.  The protein content in soluble and insoluble fractions 
was measured using Bio-Rad protein assay reagent.  These experiments were conducted 
three times separately using homogenates prepared from a pair of lenses (These studies 
were conducted by Dr. Sharma’s group from the University of Missouri, Columbia, MO). 
 
Molecular Modeling Studies.  The Chemical Computing Group’s Molecular 
Operating Environment 2016 (MOE) and Schrödinger LLC’s program, Maestro 11, were 
used for this study.  The structures (Figure 4.1) of ATP, 25-hydroxycholesterol, lanosterol, 
JHX-4, JHX-8, HK-2, HK-4, HK-6, and HK-8 were built and minimized in MOE [41].  To 
investigate the binding activities of these three compounds to αB-crystallins, docking 
studies were conducted using MOE’s internal dock and Schrödinger’s Glide dock [42].  
The target proteins were three resolved model αB-crystallins (cryAB) obtained from the 
Protein Data Bank (PDB): a human wild type dimer 2WJ7 [43], a human wild type αB-
crystallin 2KLR [44], and a R120G mutant, 2Y1Z [45]. 
 
All three proteins, wildtype 2WJ7, wildtype 2KLR, and R120G mutant 2Y1Z, were 
uploaded from the PDB into MOE.  The first cryAB examined was the wildtype 2WJ7 used 
by Makley et al. [25]  The dimer containing chains A/B was isolated for binding studies, 
and residues ASP 46 and ARG 57 on this protein were identified to be synonymous with 
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residues ASP 109 and ARG 120 described in Makley et al. [25]  These residues are 
located at the dimer interface where the carboxylic group of ASP 46 on one chain and the 




Figure 4.1.  Structures of molecules used in the docking studies with the human cryAB 
wildtypes, 2WJ7 and 2KLR, and the R120G mutant, 2Y1Z.  These molecules were 




protein’s stability.  Salt bridges are defined as noncovalent hydrogen bonds or electrostatic 
interactions between two ionized sites with distances ≤ 4.0 Å.  Despite the absence of a 
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ligand, the dimer also contains water molecules.  2WJ7 was prepared, corrected, and 
protonated using the Protonate3D function which runs an optimization routine to determine 
overall lowest potential energy configuration for the protein’s side chains.  Next, the protein 
backbone was selected, inverted, and minimized using Amber14:EHT forcefield with a 
0.05 gradient, followed by an unrestricted minimization using the same forcefield and 
gradient.  In this mathematical process of energy minimization, the potential energy 
surface minimum of the protein is determined by changing the geometry of the protein in 
a step-wise fashion until a local or global minimum is reached.  The slope of this step-wise 
change is defined as the gradient, and the minimization is terminated when the slope 
change is less than the specified threshold of 0.05.  During the energy minimization, the 
protein structure was stabilized by retaining water molecules attached to the protein so 
that major 3D configurational perturbations were avoided.  These water molecules were 
then removed for the docking experiments.  A similar process was used for the other two 
cryABs, wildtype 2KLR and mutant 2Y1Z.  The same proteins were then imported into 
Maestro and re-prepared using the Protein Preparation Wizard.  Proteins were pre-
processed with original hydrogens removed and water molecules beyond 5 Å from het 
groups deleted.  Next, the proteins were refined and optimized, followed by a backbone-
constrained minimization of side chains and an unconstrained minimization with the 
OPLS3e forcefield. 
 
Docking Studies.  Two binding pockets were defined for the docking studies.  The 
first binding pocket was at the dimer interface binding site as defined by Makley et al. [25] 
on wildtype 2WJ7.  2WJ7 is an apoprotein without any ligand binding information, and 
Makley et al. did not specify ligand binding residues.  We identified PHE 55 on the “A” 
chain of 2WJ7 as the centroid for the binding pocket and extended the docking space by 
25 Å on each side.  We defined the same binding pocket for the 2KLR wildtype, and PHE 
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118 was identified as the centroid for the R120G mutant dimer, 2Y1Z.  The second binding 
pocket was the binding site for ATP that was experimentally determined and defined by 
Ghosh et al. [46] in the β4-β8 groove.  ATP binds to an amino acid sequence part of a 
Walker-B ATP-binding motif which contains the cryAB sequence 
82KHFSPEELKVKVLGD96.  This motif has also been found in several ATP-binding 
proteins, including HSP90 and HSP104 [47, 48].  Furthermore, the Walker-B motif is highly 
conserved in the α-crystallin core domain of the sHSP family.  
 
The MOETM docking studies were conducted using the “Triangle Matcher” 
placement method with the flexible “Induced Fit” placement algorithm which simulates 
physiological conditions by allowing the residues in the receptor pocket and the ligand to 
freely perturb.  The output from this method was a London ΔG binding score, and predicted 
Kd values were calculated based on the following equation: 
 
Kd (unit, μM) = e (docking score*1000 / (1.98*298.15)) / 10-6 (eq. 1) 
 
The Maestro docking studies were conducted using Glide Dock by first defining 
the binding pocket using the Glide Grid Generation method using centroids identified 
above for all three proteins: wildtypes 2WJ7 and 2KLR, and the R120G mutant 2Y1Z.  
This was followed by Glide dock with the Extra Precision (XP) scoring function.  The 
docking scores of each protein-ligand docked complex were expressed in kcal/mol, with 
a value of -9 kcal/mol approximated to an IC50 or Kd in the high nM/low μM.  A more 











Organ Culture Studies.  The new paradigm suggests that lanosterol and other 
oxysterols can clear cataracts, presumably by boosting the α-crystallin’s chaperone 
activity to dissolve the light scattering, denatured, aggregated lens proteins responsible 
for opacification.  Since transparency and biochemical viability can be maintained for up 
to two weeks, lens organ culture has become a valuable technique in investigating the 
mechanisms of both lens homeostasis and cataractogenesis [49, 50].  Therefore, lens 
culture studies were conducted to investigate the ability of lanosterol to reduce lens 
opacities.  Cataracts were experimentally induced with blunt trauma, by ATPase ion 
transport inhibition with 10 mM of ouabain, or by osmotic stress induced with 1 mM of a 
toxic experimental compound that induces water influx into the lens.  Untreated lenses 
were used as the control.  Within 48 hours of culture, all the lenses developed opacities 
except the control untreated group.  As illustrated in Figure 4.2, trauma-induced cataracts 
appeared as localized opacities that varied because of the levels of blunt physical trauma 
applied, while the ouabain-treated lenses developed cortical opacities and the osmotic 
inducer produced dramatic refractive index changes associated with significant lens 
swelling.  All lenses were then transferred to similar TC-199 bicarbonate media containing 
15 mM of lanosterol liposomes.  Incubation for an additional 48 hours in the lanosterol 
liposome media resulted in an apparent penetration of the amber liposomes into the 
lenses as noted by the slight color changes, especially around the nucleus as all treated 
lenses progressed to the mature nuclear cataract stage.  Over the 48-hour period, there 
was also liposome clumping at the surface of the collagen capsule, which was difficult to 
rinse off presumably because of the sticky nature of the liposomes.  While transparency 
in the control lenses appeared to be minimally affected, lanosterol failed to reverse 
opacities or halt the progression of cataracts in all treated lenses.  In fact, lens opacities 
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in all treated lenses exposed to lanosterol progressed to the more advanced mature 
cataract stage with apparent nuclear involvement. 
 
Protein Binding Studies.  The described lens culture studies suggest that 
lanosterol either inadequately binds to lens proteins or that the chaperone activity of the 
assumed bound lanosterol to α-crystallin complex is not adequate to reverse or alter the 
progression of cataracts as previously proposed.  To evaluate this possibility, two lenses 
from a 47-year-old human were equally divided into 4 pie shaped portions and incubated 
in the dark for 3 days at 37 °C in media containing 0.2 mM lanosterol dissolved in 10% 
ethanol.  As shown in Figure 4.3, incubation with lanosterol did not result in either an 
anticipated increase in the level of soluble lens proteins or decrease the levels of insoluble 
proteins.  This indicates that lanosterol failed to solubilize the insoluble lens proteins 
present in the cataractous lens.  Similar results were obtained with three lenses from 70-
year-old humans analyzed separately (data not shown). 
 
Since in our experiments lanosterol failed to increase soluble protein levels, the 
binding studies were expanded to include 25-hydroxycholesterol whose binding power 
has been reported to be superior to that of lanosterol [25].  For these studies, 6 frozen 
lenses from three 60-year-old donors were each cut into three equal pie shaped 
fragments, thawed and incubated in the dark for 3 days at 37 °C in media containing either 
0.0, 0.25 or 0.50 mM of 25-hydroxycholesterol.  For each group, two pieces from different 
lenses were combined for each experiment.  The percentage of protein in soluble and 










































































































































































































































































































































































































Figure 4.3.  Change in protein levels from 47-year-old human lens fragments after 3 days 
incubation at 37 °C in media containing 0.20 mM lanosterol.  There is no change in the 
levels of proteins in the soluble and insoluble fractions with or without the presence of 




As summarized in Figure 4.4, no significant difference in soluble protein levels (p-
value of 0.79, by ANOVA single factor analysis) was observed between the non-treated 
and 25-hydroxycholesterol-treated lenses.  If the aggregated proteins were solubilized, 
then the levels of proteins in the insoluble fractions should have been lowered in the 25-
hydroxycholesterol treated lenses.  Instead, the insoluble protein levels in the control and 







Figure 4.4. Change in soluble/insoluble protein levels of 60-year-old human lens 
homogenate after 3 days incubation at 37 °C in media containing either 0.0, 0.25 or 
0.50 mM of 25-hydroxycholesterol.  There is no change in the levels of proteins in the 




The lack of binding demonstrated by both oxysterols could possibly be due to the 
failure of both oxysterols to adequately penetrate the lens fibers in the incubated lens 
fragments. To investigate this possibility, protein solubilization studies with 100 and 
200 µM concentrations of lanosterol and 25-hydroxycholesterol were carried out with lens 
homogenates of 0.5 and 2.0 mg/mL protein concentrations in PBS (containing protease 
inhibitor cocktail) prepared from 72-year-old human lenses. Changes in the soluble protein 
levels after 24-hour incubation at 37 °C are illustrated in Figure 4.5. The results confirm 
that lanosterol and 25-hydroxycholesterol do not affect lens protein solubilization when 






Figure 4.5.  The solubility of human lens proteins in the presence of (A) lanosterol and 
(B) 25-hydroxycholesterol. Tissue homogenates from 72-year-old human lenses 
containing 0.5 or 2.0 mg protein in 1.0 mL of PBS were incubated with 0.0, 100 and 200 µM 
lanosterol or 25-hydroxycholesterol at 37 °C for 24 hours. The values shown are the 
percentage of protein remaining in the soluble fraction after incubation. N = 3 ± S.D. and 




Molecular Modeling Studies.  Since both oxysterols failed to increase the 
anticipated soluble protein levels in lenses or lens homogenates where age-related protein 
denaturation had occurred, this suggests that oxysterol binding to the crystallin 
chaperones may be inadequate. Therefore, additional in silico studies to gain insight into 
chaperone binding to lanosterol and 25-hydroxycholesterol at the molecular level were 
conducted. As specified in the Method Section, lanosterol and 25-hydroxycholesterol were 
docked to three small αB-crystallins heat shock chaperones, two human wild type 
dimers, 2WJ7 [43] and 2KLR [44], and an ARG120GLY mutant, 2Y1Z [45]. As an internal 
control, ATP, which has been reported to bind these αB-crystallins, was also examined.  
Additionally, the novel MFAOs were investigated because the parent scaffold of these 
compounds was observed to have anti-cataract activity without aldose reductase or 
sorbitol dehydrogenase activity in vivo [37].  Molecular modeling and docking studies were 
conducted using MOE dock and Schrödinger Glide dock standard docking methods. The 
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appropriate binding modes were determined by docking the ligands to two potential 
pockets, an ATP pocket and the dimer interface. The top five docked poses were collected 
and the best docking scores along with predicted Kd values are presented. The MOE dock 
scores are reported as London ΔG binding scores which generally indicate that a value of 
−12.00 corresponds to the low nM range and a dissociation constant, Kd, of 
−12.3 kcal/mol, a value of −8.00 corresponds to the low µM range and a Kd of 
−8.2 kcal/mol, and a value of −4.00 corresponds to the low mM range and a Kd of 
−4.1 kcal/mol. 
 
The MOETM docking results summarized in Table 4.1 demonstrate good binding 
of ATP to the ATP binding pocket in wildtypes 2WJ7 and 2KLR (ca. −12.0 kcal/mol). This 
indicates that the methods employed successfully predicted the expected feasible 
nanomolar range binding of ATP to its binding pocket on these chaperones. However, 
ATP binding to mutant 2Y1Z appeared to be slightly weaker as observed by the higher 
docking score (−9.82 kcal/mol), though still with high affinity. In contrast, the results of the 
oxysterols suggested weak binding to the dimer interface containing the PHE centroid in 
the wildtype 2WJ7, with lanosterol (−4.33 kcal/mol) and 25-hydroxycholesterol 
(−6.75 kcal/mol) binding with much lower affinity. Compared to the oxysterols, the MFAOs 
all exhibited much stronger binding to the 2WJ7 dimer interface. The binding of the bulkier 
and slightly larger MFAOs JHX-4 (-11.62 kcal/mol) and JHX-8 (-13.08 kcal/mol) to the 
2WJ7 dimer interface was stronger than the HK series. However, HK-2 (-9.11 kcal/mol), 
HK-4 (-9.80 kcal/mol), HK-6 (-9.18 kcal/mol), and HK-8 (-10.10 kcal/mol) also bound 
stronger than the oxysterols. The methoxy derivatives JHX-8, HK-4, and HK-8 all exhibited 
stronger binding than the non-methoxy derivatives, suggesting the added bulkiness of the 
methoxy groups on the pyrimidine bottom ring in addition to their smaller size may help to 
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increase binding affinity at the dimer interface.  Against the 2KLR wildtype, the slightly 
bulkier methoxy compounds JHX-8 (-10.15 kcal/mol) and HK-4 (-8.71 kcal/mol) exhibited 
slightly stronger binding than their non-methoxy derivatives JHX-4 (-9.71 kcal/mol) and 
HK-2 (-7.92 kcal/mol). However, the non-methoxy HK-4 (-8.71 kcal/mol) bound slightly 
stronger than the methoxy HK-8 (-8.36 kcal/mol).  Against the mutant 2Y1Z, JHX-4 (-9.79 
kcal/mol) and JHX-8 (-10.26 kcal/mol) were found to bind tighter than HK-2 (-6.08 
kcal/mol), HK-4 (-7.91 kcal/mol), HK-6 (-5.92 kcal/mol), and HK-8 (-7.86 kcal/mol), 
suggesting the size of the JHX-series is better for binding to the 2Y1Z mutant model. 
Comparatively, the results for lanosterol (+2.34 kcal/mol; +17.80 kcal/mol) and 25-
hydroxycholesterol (+0.11 kcal/mol; +11.33 kcal/mol) at both 2KLR and 2Y1Z dimer 
interfaces, respectively, predict that no binding is anticipated.  The positive docking scores 
suggest unfavorable binding which is most likely due to the size and hydrophobicity of the 
oxysterols.  All MFAOs are shown to bind well at all dimer interfaces and the data suggest 
that they are small enough to successfully bind to the closed groove of 2Y1Z.   
 
Compounds 
2WJ7 Wildtype 2KLR Wildtype 2Y1Z Mutant 
Best Kd (Pred) Best Kd (Pred) Best Kd (Pred) 
ATP -12.72 438.78 pM -11.48 3.59 nM -9.82 59.66 nM 
25-Hydroxycholesterol -6.75 10.82 μM 0.11 n.d. 11.33 n.d. 
Lanosterol -4.33 652.44 μM 2.34 n.d. 17.80 n.d. 
JHX-4 -11.62 2.84 nM -9.71 72.01 nM -9.79 63.31 nM 
JHX-8 -13.08 239.99 pM -10.15 34.30 nM -10.26 28.41 nM 
HK-2 -9.11 198.87 nM -7.92 1.49 μM -6.08 33.77 μM 
HK-4 -9.80 62.05 nM -8.71 390.78 nM -7.91 1.51 μM 
HK-6 -9.18 177.53 nM -8.29 792.02 nM -5.92 44.43 μM 
HK-8 -10.10 37.36 nM -8.36 712.49 nM -7.86 1.65 μM 
 
Table 4.1.  MOETM docking scores of all compounds (Figure 4.1) to the dimer interface 
on PHE 55 of wildtypes, 2WJ7 and 2KLR, and the R120G mutant, 2Y1Z.  ATP was docked 
to the ATP binding pocket of each protein as the internal control.  Positive binding scores 






In order to verify these docking results, a similar strategy was employed using 
Schrodinger’s Maestro and these results are summarized in Table 4.2.  Compared to 
MOETM, the Maestro docking scores and predicted Kd values were more positive and 
comparable to reported experimental data of both ATP and the oxysterols.  ATP again 
showed good binding at the ATP binding site of wildtype 2WJ7 (-8.23 kcal/mol).  
Surprisingly, the binding of ATP to wildtype 2KLR was weaker (-5.57 kcal/mol) compared 
to 2WJ7, and binding of ATP to mutant 2Y1Z was stronger (-9.65 kcal/mol) than to both 
wildtypes 2WJ7 and 2KLR.  Both oxysterols demonstrated weak binding to all dimer 
interfaces with strength of binding decreasing from 2WJ7 > 2KLR > 2Y1Z.  Lanosterol 
was shown to bind weakly to the wildtypes 2WJ7 (-3.33 kcal/mol) and 2KLR (-1.54 
kcal/mol), and no docking information could be extracted for 2Y1Z (n.d.).  On the other 
hand, 25-hydroxycholesterol bound stronger than lanosterol to 2WJ7 (-4.40 kcal/mol), 
2KLR (-3.96 kcal/mol), and 2Y1Z (-2.87 kcal/mol), albeit poorly.  This trend follows the 
MOETM results, though no feasible docking poses were found for both oxysterols on 2KLR 
or 2Y1Z.  Unlike the MOETM results of MFAOs docked to the 2WJ7 dimer interface, the  
 
Compounds 
2WJ7 Wildtype 2KLR Wildtype 2Y1Z Mutant 
Best Kd (Pred) Best Kd (Pred) Best Kd (Pred) 
ATP -8.23 881.90 nM -5.57 79.86 μM -9.65 79.57 nM 
25-Hydroxycholesterol -4.40 579.49 μM -3.96 1.22 mM -2.87 7.74 mM 
Lanosterol -3.33 3.55 mM -1.54 73.63 mM n.d. n.d. 
JHX-4 -7.36 3.85 μM -4.27 722.24 μM n.d. n.d. 
JHX-8 -6.49 16.81 μM n.d. n.d. n.d. n.d. 
HK-2 -7.39 3.66 μM -5.78 55.95 μM -5.84 50.54 μM 
HK-4 -6.09 33.09 μM n.d. n.d. -5.43 101.23 μM 
HK-6 -7.55 2.79 μM -5.56 81.22 μM -4.77 309.63 μM 
HK-8 -5.80 53.99 μM n.d. n.d. -4.52 472.89 μM 
 
Table 4.2.  Maestro docking scores of all compounds (Figure 4.1) to the dimer interface 
on PHE 55 of wildtypes, 2WJ7 and 2KLR, and the R120G mutant, 2Y1Z.  ATP was docked 
to the ATP binding pocket of each protein as the internal control.  A binding score of “n.d.” 




Maestro results exhibited an opposite effect where the methoxy derivatives JHX-8 (-6.49 
kcal/mol), HK-4 (-6.09 kcal/mol), and HK-8 (-5.80 kcal/mol) bound weaker than the non-
methoxy derivatives JHX-4 (-7.36 kcal/mol), HK-2 (-7.39 kcal/mol), and HK-6 (-7.55 
kcal/mol).  Not only do the non-methoxy derivatives bind tighter than the methoxy 
derivatives, they also bind with similar affinity to the dimer interface.  These scores suggest 
that the added bulkiness from the methoxy groups decrease the strength of binding, and 
that the general size of the MFAOs is ideal for fitting into the dimer interface of 2WJ7.  
Interestingly, docking to the interface of 2KLR only identified successful binding of the 
non-methoxy compounds JHX-4 (-4.27 kcal/mol), HK-2 (-5.78 kcal/mol), and HK-6 (-5.56 
kcal/mol).  None of the methoxy derivatives were able to bind to the 2KLR dimer interface, 
further suggesting that the bulkiness of the methoxy groups decreases MFAO binding 
affinity.  Additionally, HK-2 and HK-6 were calculated to bind ~1.4 kcal/mol stronger than 
JHX-4, suggesting the smaller size of the HK compounds is favorable for binding to the 
2KLR dimer interface.  This may be explained by the fact that the wildtype 2KLR model 
does not have an “open” dimer interface like the wildtype 2WJ7 model.  Instead, the 
protein is curved, and the dimer interface is smaller and less-accessible by larger 
molecules.  Finally, it was observed that neither JHX-4 nor JHX-8 could bind to the dimer 
interface of mutant 2Y1Z, but HK-2 (-5.84 kcal/mol), HK-4 (-5.43 kcal/mol), HK-6 (-4.77 
kcal/mol), and HK-8 (-4.52 kcal/mol) were all able to bind, also suggesting that the smaller 
size of the HK compounds may be favorable for mutant dimer interface binding. 
 
Could the oxysterol and MFAO binding perhaps occur at the ATP binding site?  To 
investigate this question, these compounds were also docked to the ATP interactive 
binding region, which is known as the β4-β8 groove, and these results are shown in Table 
4.3.  As already reported in the binding studies on the dimer interface (Table 4.2), 
adequate binding values for ATP binding to the ATP binding pocket of the 
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wildtype 2WJ7 and 2Y1Z mutant models were obtained but not for the wildtype 2KLR. 
The oxysterols were unable to adequately bind at the dimer interface, and it was observed 
that they were also unable to adequately bind to the ATP binding pockets of these αB-
crystallins.  25-hydroxycholesterol exhibited poor binding (-3.20 kcal/mol) to the 2WJ7 
wildtype ATP-binding pocket.  On the other hand, the MFAOs demonstrated modest but 
better binding than the oxysterols.  HK-2 (-5.78 kcal/mol; -5.19 kcal/mol) and HK-6 (-5.56 
kcal/mol; -5.25 kcal/mol) both bind tighter to the 2KLR dimer interface than the ATP 
binding region, respectively, whereas JHX-4 (-4.27 kcal/mol; -4.98 kcal/mol) was predicted 
to have greater affinity at the 2KLR ATP binding region.  Surprisingly, JHX-4 (-4.78 
kcal/mol) and JHX-8 (-4.76 kcal/mol) both exhibited similar affinity to the ATP binding 
region of 2Y1Z, but neither of them were able to bind to the 2Y1Z dimer interface.  All HK 
MFAOs demonstrated greater binding affinity to the 2Y1Z dimer interface except for HK-
4 (-5.73 kcal/mol), which seems to have slight preference to the ATP binding region of 
2Y1Z.  Interestingly, all MFAOs bound within ~1 kcal/mol to each other to the 2WJ7 ATP 
binding pocket, ~0.5 kcal/mol to the 2KLR ATP binding pocket, and ~2 kcal/mol to the 
2Y1Z ATP binding pocket, suggesting that the binding affinity of these compounds may 
be due to their similar properties and sizes.  Furthermore, the deviation of the binding 
scores of each MFAO to each of the protein ATP-binding pockets are close, suggesting 
that the compounds are able to similarly bind to the ATP binding pockets of each model 
αB-crystallin.   
 
Overall, Tables 4.1, 4.2, and 4.3 summarize the binding studies conducted using 
MOE dock and Schrödinger Glide dock methods, and these results support the protein 
binding studies which indicated that lanosterol or 25-hydroxycholesterol do not appear to 





β4-β8 Groove, ATP interactive binding region 
2WJ7 Wildtype 2KLR Wildtype 2Y1Z Mutant 
Best Pred Kd Best Pred Kd Best Pred Kd 
ATP -8.23 881.90 nM -5.57 79.86 μM -9.65 79.57 nM 
25-Hydroxycholesterol -3.20 4.42 mM n.d. n.d. n.d. n.d. 
Lanosterol n.d. n.d. n.d. n.d. n.d. n.d. 
JHX-4 -5.33 119.91 μM -4.98 216.95 μM -4.78 304.43 μM 
JHX-8 -5.11 174.07 μM -5.10 177.04 μM -4.76 314.92 μM 
HK-2 -6.06 34.82 μM -5.19 152.01 μM -5.51 88.40 μM 
HK-4 -5.25 137.32 μM -4.87 261.38 μM -5.73 60.90 μM 
HK-6 -5.78 55.95 μM -5.25 137.32 μM -4.10 963.26 μM 
HK-8 -4.73 331.34 μM -4.96 224.42 μM -4.25 747.13 μM 
 
Table 4.3.  Maestro docking scores and predicted Kd values of ATP, oxysterols, and 
MFAOs to wildtypes 2WJ7 and 2KLR, and mutant 2Y1Z.  All compounds were 
docked to the ATP interactive binding region containing the Walker-B motif.  A 
value of “n.d.” indicates that no docking data could be acquired after 30 iterations.   
 
 
4.5  Discussion 
 
The mammalian lens contains millions of densely packed fiber cells that are 
continuously formed throughout life from differentiating lens epithelial cells.  These fiber 
cells contain three major crystallin proteins families: α-crystallin, which resembles small 
heat shock proteins, and β- and γ-crystallins, that have structural and functional roles in 
maintaining transparency and the high refractive index of the lens.  Increased light 
scattering leading to the appearance of lens opacities is directly linked to lens protein 
aggregation of the β- and γ-crystallins.  To counteract this aggregation, Horwitz has 
proposed that small heat-shock proteins, αA- and αB-crystallins, serve as chaperones that 
protect the lens against protein aggregation [17, 18, 51].  The protein unfolding hypothesis 
for age-related cataract postulates that the progressive modifications of β- and γ-
crystallins reduce their free energies of unfolding and promote their binding to α-crystallin.  
By binding to α-crystallins, lanosterol and 25-hydroxycholesterol have been proposed to 
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enhance the ability of α-crystallin to bind to the unfolded (aggregated) β- and γ-crystallins.  
Solubilizing these insoluble, light scattering aggregated lens proteins should result in an 
increase of soluble proteins and a decrease in insoluble proteins, i.e. “the cataract should 
be dissolved”. 
 
Cholesterol derivatives, in addition to interacting with crystallins, also play an 
integral role in the regulation of cholesterol-dependent processes in fiber cell plasma 
membranes and in the maintenance of fiber cell membrane homeostasis [52].  With the 
loss of its organelles during fiber cell differentiation, the plasma membrane forming the 
external boundary of the fiber cell cytoplasm becomes the only remaining membrane in 
mature fiber cells [53].  Its extremely high cholesterol content makes this membrane one 
of the most saturated and ordered (stiff) membranes in the human body.  While the need 
for this high lipid content is unclear, disturbances of cholesterol homeostasis can lead to 
cataract formation. 
 
The first synthetic cholesterol lowering drug associated with irreversible cataract 
formation was triparanol (MER-29) [54].  This compound inhibited cholesterol synthesis at 
the desmosterol step, several steps downstream of lanosterol and resulted in the cellular 
accumulation of lanosterol [34, 35].  Although lens lanosterol levels were never specifically 
measured after triparanol administration, it can be assumed that downstream inhibition of 
cholesterol synthesis would similarly increase lanosterol levels in the lens.  Therefore, 
altered cholesterol homeostasis may lead to cataract formation despite an increase in 
lanosterol.  Similarly, cataracts have been associated with the lenticular accumulation of 
cholesterol oxides such as 25-hydroxycholesterol [36].  Cataract formation has also 
developed with other cholesterol lowering agents such as statins and fibrates.  Several 
clinical studies report that patients undergo cataract surgery at higher rates with long-term 
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statin or fibrate administration [39, 55-57].  Statins inhibit cholesterol biosynthesis at the 
initial mevalonic acid level, while fibrates modify lipids, decrease triglycerides, and alter 
cholesterol levels of HDL/LDL by activating alpha peroxisome proliferator-activated 
receptors (PPAR-α).  Studies suggest that cataract formation is induced by statins 
because they lower the isoprenylation of small GTPases [58, 59].  At present, the 
relationship between the regulation of cholesterol-dependent processes in lens fiber cells 
and their plasma membranes and cataract formation is not well established and more 
studies in this area are required. 
 
In vitro organ culture of lenses has become a powerful experimental tool for not 
only investigating the relationship between lens metabolism and lens clarity, but also for 
elucidating the mechanism(s) of cataract formation by drugs and biochemical agents [49, 
60].  These culture studies require carefully excised lenses that are cultured in specially 
buffered and osmotically compensated culture media at 37 °C in order to maintain their 
viability and clarity [61, 62].  Moreover, because the use of freshly excised lenses is ideally 
required, the majority of culture studies employ readily available rat lenses.  Rat lens organ 
culture studies have been used to elucidate the effect of statins on cataract formation [39, 
59], the role of osmotic changes on sugar cataract formation [40, 63], and the role of 
oxidative stress on oxidation-induced cataracts [64, 65]. 
 
In the present organ culture studies, freshly excised clear rat lenses were 
incubated under established conditions.  During the initial 48-hour culture period, cataracts 
were induced in select groups of these clear lenses with either physical blunt trauma, 
inhibition of ATP, or experimentally induced osmotic stress.  Blunt traumatic injury results 
in localized lens membrane damage and increased oxidative stress [66, 67], while ouabain 
alters the intracellular Na+ and K+ levels and affects the anabolism and catabolism of 
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protein during cataract formation [68].  Experimentally induced osmotic changes initiate 
increased endoplasmic reticulum (ER) stress in lens epithelial cells that subsequently 
results in the generation of reactive oxygen species (ROS) and oxidative stress [69-71].  
These biochemical insults all lead to similar protein destabilization, the presence of 
partially unfolded aggregation-prone intermediates, and the formation of insoluble, light-
scattering protein aggregates that appear as lens opacities [14].  Subsequent 48-hour 
exposure of these lenses to 15 mM of lanosterol liposomes failed to decrease the 
insoluble, light-scattering protein aggregates that had developed into lens opacities.  More 
importantly, the presence of lanosterol during this 48-hour period also had no effect on 
influencing the further progression of protein aggregate development as evidenced by lens 
opacity progression to the advanced nuclear stage (Figure 4.2).  Similarly, Shen et al. 
observed that lanosterol failed to prevent opacities induced by U18666A, an agent that 
induces cataracts in part by inhibiting the formation of lanosterol [72].  This is in contrast 
to the report by Zhao et al. who report that the clarity of cataractous rabbit lenses was 
improved in culture [24].  Their culture condition was quite different from ours as we ensure 
the viability of the cultured lenses by incubating under 37 °C physiological temperature.  
We also paid extra attention to ensure that the lens photos (Figure 4.2) taken after 
incubation were standardized to the same contrast, exposure, and pixel density by 
adjusting the outer grid lines to a standard value. 
 
These lens organ culture results, which strongly suggest that there was no 
apparent interaction between lanosterol and the experimentally aggregated lens proteins, 
concur with the subsequent protein binding studies (Figures 4.3, 4.4, 4.5) where 
lanosterol or the presumably more potent 25-hydroxycholesterol both failed to interact with 
aggregated proteins in human lenses to increase the levels of soluble proteins by 
decreasing the levels of insoluble proteins.  These results confirm those of Shanmugam et 
175 
 
al. in which the authors also failed to show any change in soluble protein levels in 40 
nuclear cataracts cultured with lanosterol [31].  It is well-known that fully denatured 
proteins lack both tertiary and secondary structure and exist as so-called random coils 
where the only fixed relationship between the amino acids is the peptide bond between 
adjacent residues.  While Zhao et al. [24] and Makley et al. [25] both focused on the 
misfolded crystallins only existing as amyloid fibrils characterized by intermolecular cross-
β-sheet formations and relatively ordered morphologies [73, 74], crystallin aggregates can 
also adopt alternative amorphous forms other than amyloid fibrils [75-77].  This may 
explain, in part, the observed inability of aggregated lens proteins to be re-dissolved in the 
present studies.  A recent study reported that sonicated human lens homogenates were 
partially solubilized by lanosterol and 25-hydroxycholesterol when the samples were kept 
in a shaker for 14 days [78].  Since it is known that sonication disaggregates and 
solubilizes water-insoluble lens proteins [79], it is unclear whether the prior sonication of 
the sample and several days of shaking contributed to the ability of sterols to partially 
solubilize the lens proteins.  In another study, treatment of sonicated bovine lens extract 
with 50–500 µM of 25-hydroxycholesterol for two days did not result in significant reduction 
of turbidity [80].  Further, it is yet to be determined whether the results of lens protein 
solubilization observed after sonication and shaking with sterols can be interpreted as in 
vivo therapeutic potential of the sterols since both sonication and shaking are not 
treatment modalities. 
 
Failure of lanosterol in our studies to alter the appearance of formation of cataracts, 
along with the inability of oxysterols to reduce insoluble protein levels, prompted us to 
examine if oxysterols can bind to the crystallin chaperones at the molecular level to 
enhance chaperone function to re-dissolve aggregated proteins.  Using both MOETM dock 
and Schrödinger’s Glide dock programs, in silico docking studies confirmed that both 
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lanosterol and 25-hydroxycholesterol failed to reach the therapeutically significant low 
micromolar range binding (docking score ≤ -8.00 kcal/mol) with the wildtypes 2WJ7 
and 2KLR, and the mutant 2Y1Z αB-crystallins chaperones (Tables 4.1, 4.2, and 4.3).  To 
confirm our methodology, the present studies used ATP as a control since ATP has a 
known binding site on the αB-crystallin chaperones [46, 48].  While the overall docking 
scores from the MOE dock program (Table 4.1) appeared to overestimate binding 
compared to the Glide dock program (Table 4.2), feasible binding with ATP was observed 
by both programs.  Glide dock docking scores (Table 4.2) for 2KLR provided an ATP 
binding scores (−5.57 kcal/mol) that was in good agreement with Palmisano et al. [81] who 
reported the binding constant of ATP to α-crystallin to be Ka = 8.1 * 103 M−1, which 
corresponds to −5.33 kcal/mol when converted to ΔG.  Significantly better ATP binding 
scores were obtained for binding at the ATP binding pocket of both 2WJ7 and 
2Y1Z (−8.23 kcal/mol and −9.65 kcal/mol, respectively).  In contrast to ATP, the present 
MOETM and Glide docking scores suggest that lanosterol and 25-hydroxycholesterol 
binding to α-crystallin is unlikely at less than micromolar concentrations (Tables 4.1 and 
4.2).  For example, the Kd for lanosterol and 25-hydroxycholesterol, respectively, are 
predicted to be 653 µM and 11 µM (Table 4.1, MOETM) and 3.55 mM and 579 µM (Table 
4.2, Glide) against wildtype 2WJ7.  For 25-hydroxycholesterol, the predicted Kd  for 2Y1Z 
is at a concentration of 7.74 mM (Table 4.2).  It is unlikely that these high micromolar or 
even millimolar concentrations can be clinically achieved in the lens. 
 
Our docking results were not contradictory to previously reported data in Makley et 
al. and Zhao et al.  In Makley et al., 100 µM concentration of drugs were used and at this 
concentration, 56% recovery versus wildtype in Tm was observed [25].  In Zhao’s report, 
the observation of “reduction in cataract severity” was achieved in using 25 mM 
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concentration of lanosterol [24].  The free energy ΔG for Kd of 25 mM range would be ca. 
-2.48 kcal/mol.  A ligand with a Kd above 10 µM (docking score more positive than -6.8 
kcal/mol) is normally considered to be low affinity.  Both our docking results, and the fact 
that the Makley’s and Zhao’s experiments used high concentration (from 100 µM to 
15 mM), suggest that under 10 µM concentrations are unlikely for the oxysterols to have 
significant and specific binding to α-crystallin. 
 
Additional protein-ligand interactions in our studies further disclosed the underlying 
cause for the poor binding of oxysterols, such as lanosterol, to the current αB-crystallins 
models.  The human wild-type dimer 2WJ7 contains residues ASP 109 and ARG 120, 
(Figure 4.6) which were identified to be synonymous with those described in Makley et al. 
[25].  These residues are located at the dimer interface where the carboxylic group of ASP 
109 on one chain and the guanidine group of ARG 120 on the opposite chain form a salt 
bridge that contributes to the protein’s stability.  This open groove binding pocket is shown 
to be hydrophobic (white) and surrounded by positively charged residues (blue).  
Inspection of this dimer interface reveals that the central open groove binding pocket 
identified in 2WJ7 becomes narrower in 2KLR and is blocked in 2Y1Z.  2KLR has a 
second salt bridge between ASP 80 and ARG 107 which further stabilizes the dimer 
interface so that a closed-groove conformation can be maintained.  Such a scenario may 
result in a poor binding environment for both lanosterol and 25-hydroxycholesterol.  This 
structural difference helps to explain why the docking scores of ATP and oxysterols are 
smaller in 2KLR than in 2WJ7.  Similarly, the open-structure observed in wildtype 2WJ7 is 
disrupted in the ARG120GLY mutant 2Y1Z, thereby making it impossible to form a 
stabilizing salt bridge between ARG120 and ASP109.  Instead, salt bridges between ASP 
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80 and HIS 83 are formed where the side chains of these two residues block the central 




Figure 4.6.  Comparison of the surface and charge differences (sphere structure), along 
with the location of key amino acid residues (ribbon structure) between the αB-crystallin 
wildtypes 2WJ7 and 2KLR and the ARG120GLY mutant 2Y1Z.  Locations of the defined 
ATP pocket and PHE 55 binding regions for docking studies are marked with arrows on 
the ribbon structures.  The experimentally determined ATP-binding site is in the β4-β8 
pocket where the amino acid sequence 82KHFSPEELKVKVLGD96 resembles the Walker-
B ATP-binding motif.  PHE 55 is in the centroid of the dimer interface.  Note the presence 
of the open groove at the dimer interface in 2WJ7, which is nonexistent in 2KLR and 
shielded by the ASP 80/HIS 83 salt bridge in 2Y1Z.  These protein models agree with 
previously reported results [45]. 
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Since no crystal structures of the αB-crystallin/oxysterol complex are available, 
and the published papers, including that of Makley et al.[25], have not identified specific 
binding residues used for docking oxysterols to αB-crystallins, residue PHE 55 of the “A” 
chain was chosen as the centroid to define the binding pocket for the dimer interface 
in 2WJ7, 2KLR and 2Y1Z.  In addition, the Walker-B ATP-binding motifs containing the 
sequence 82KHFSPEELKVKVLGD96  were used for docking on both wildtypes, 2WJ7 and 
2KLR, and mutant, 2Y1Z, to determine whether the oxysterols can also bind to the ATP 
binding pocket.  This ATP binding pocket was previously reported by Ghosh et al. [46], 
and both binding regions are marked in Figure 4.6. 
 
Because an ATP binding site on the αB-crystallins has previously been identified, 
successful binding of ATP to this site was easily and successfully achieved.  As discussed 
above, the Glide docking scores were in better agreement with the experimental data than 
those from the MOE dock method [81].  Depending on the αB-crystallin model employed, 
the binding constant for ATP was estimated to be in the range of 0.1 to 80 µM (Table 4.2).  
However, achieving similar binding results for the oxysterols was more difficult.  No 
suitable binding pose for lanosterol was identified.  For 25-hydroxycholesterol, the 
predicted Kd values were ca. 4.4 mM and 27.6 mM for the 2WJ7 and the 2Y1Z models, 
respectively.  It is not surprising that the narrowed pocket on the dimer interface (Figure 
4.6) is unable to accommodate the larger oxysterol molecules.  For the larger dimer 
interface, a docked pose for 25-hydroxycholesterol was identified; however, the predicted 
Kd values for 2WJ7, 2KLR, and 2Y1Z, were 579 µM, 1.22 mM, and 7.74 mM, respectively.  
Binding results for lanosterol in the dimer interface were even worse, with Kd values 
for 2WJ7 and 2KLR of 3.55 mM and 73.63 mM; Kd values for 2Y1Z could not be 
determined.  In addition, no suitable docked pose for the 2Y1Z mutant was identified.  
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Inspection of the protein structures and docked ligands showed that the 3-hydroxyl group 
of 25-hydroxycholesterol can form a favorable hydrogen-bond with ARG 57, which is 
missing in the similar binding of lanosterol.  This hydrogen-bond was absent in 
the 2KLR and 2Y1Z models (Figure 4.7).  Therefore, 25-hydroxycholesterol showed even 
worse binding activity (mM range, Table 4.2).  Furthermore, blocking of the dimer interface 
in the 2Y1Z model due to the salt bridge between ASP 80 and HIS 83 made it unlikely for 
either oxysterol to bind (Figures 4.6 and 4.7).  The only interaction between the oxysterols 
and the dimer interface was perpendicular to the interface pocket (Figure 4.7). 
 
Previous in vivo studies in our laboratory have found that the MFAO parent analog, 
JHX-1, was observed to delay the formation of sugar cataracts in vivo [37].  Because JHX-
1 did not affect lens polyol levels, it was evident that it did not have aldose reductase or 
sorbitol dehydrogenase activity.  This study suggested that JHX-1 may have inherent 
chaperone activity which was observed as a delay in cataract formation.  Because the 
MFAO derivatives showed therapeutic efficacy in various ocular pathologies, their binding 
capabilities in silico were also investigated.  As with the oxysterols, their binding was 
examined at the dimer interface of multiple αB-crystallin models to investigate whether 
they may also interact with this lens protein, thereby supporting the chaperone hypothesis.  
 
Compared to both ATP and the oxysterols, the MFAOs are smaller molecules.  
Due to their size, it was thought the MFAOs would fit in the open dimer interface of the 
2WJ7 wildtype.  This was confirmed upon examining the best docking poses of each the 
MFAOs to the dimer interface.  Reported in Figure 4.8 are the best docked poses of the 






Figure 4.7.  MOE ribbon structures depicting the best docked complexes for lanosterol 
and 25-hydroxycholesterol with the wildtype and mutant αB-crystallins.  Note that neither 
oxysterol could enter the dimer interface on the 2Y1Z mutant, and the only interaction was 





Figure 4.8.  MOE ribbon structures depicting the best docked complexes for all MFAOs 
to the dimer interface of the wildtype αB-crystallin, 2WJ7.  Each of these compounds fit in 
the binding pocket and were observed to interact with at least two amino acids. 
 
 
Both JHX-4 (-11.62 kcal/mol) and JHX-8 (-13.08 kcal/mol) bound with higher 
affinity than the HK series, which suggested that their size and bulkiness may be favorable 
compared to the smaller HK series and the larger, lipophilic oxysterols.  Additionally, 
compared to the lipophilic oxysterols, all MFAOs have an aromatic ring system and more 
polar functional groups which may contribute to their favorable binding.  JHX-4 participates 
in hydrogen bonding with ASP 17 on the “A” chain and LYS 19, HIS 20, ARG 53, and GLU 
54 on the “B” chain; JHX-8 participates in an arene-cation interaction between the 
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pyrimidine bottom ring and ARG 53 on the “B” chain and a hydrogen bond with LYS 19 on 
the “B” chain.  The HK series, though weaker binders than the JHX series, are still 
predicted to bind with low nanomolar affinity (docking scores ca. -9 to -10 kcal/mol) and 
participate in a variety of hydrogen and arene interactions.  HK-2 (-9.11 kcal/mol) forms a 
hydrogen bond with ARG 53 on the “B” chain and has an arene-arene interaction with 
PHE 55 on the “A” chain; HK-4 (-9.80 kcal/mol) forms hydrogen bonds with ASP 17 on the 
“A” chain and ARG 53 on the “B” chain; HK-6 (-9.18 kcal/mol) forms hydrogen bonds with 
ARG 53 and ARG 57 on the “B” chain and an arene-arene interaction with PHE 55 on the 
“A” chain; HK-8 (-10.10 kcal/mol) forms hydrogen bonds with ASP 17 on the “A” chain and 
ARG 53 on the “B” chain, and forms an arene-cation interaction between the pyrimidine 
ring and LYS 19 on the “B” chain. 
 
Relative to the 2WJ7 wildtype, there are significantly less interactions observed 
between the MFAOs and the 2KLR wildtype presumably due to the narrowed dimer 
interface pocket.  Based on the docking poses as reported in Figure 4.9, it appears he 
greatest contribution to the strength of the binding scores may be spatial fit.  Again, JHX-
4 (-9.71 kcal/mol) and JHX-8 (-10.15 kcal/mol) bound with higher affinity to the 2KLR dimer 
interface than the HK series, but their tight docking scores are a result of interactions with 
solely one amino acid residue.  JHX-4 forms a hydrogen bond with HIS 83 on the “A” 
chain, while JHX-8 forms a hydrogen bond with LYS 82 on the “B” chain.  Comparatively, 
HK-2 (-7.92 kcal/mol) forms a hydrogen bond with LYS 82 on the “A” chain and an arene-
hydrogen bond with HIS 83 on the “B” chain, and HK-6 (-8.29 kcal/mol) forms a hydrogen 
bond with LYS 82 on the “B” chain and an arene-hydrogen bond with PHE 84 on the “B” 
chain.  Neither HK-4 (-8.71 kcal/mol) nor HK-8 (-8.36 kcal/mol) exhibit any significant 




Figure 4.9.  MOE ribbon structures depicting the best docked complexes for all MFAOs 
with the dimer interface of the wildtype αB-crystallin, 2KLR.  Compared to the 2WJ7 
wildtype, less interactions with amino acids were observed.  Compounds HK-4 and HK-8 
were found to have no significant amino acid interactions, while all other MFAOs were 




Because most of these interactions do not necessarily indicate significant or 
selective binding with such strong docking scores,  it suggests that size, bulkiness, and 
spatial arrangement of the MFAOs dictates their binding feasibility.  From the 2KLR 
binding results, it is evident that the oxysterols are too large and too hydrophobic to bind 
at the dimer interface, while the MFAOs are have favorable size and electrostatic 
properties.  The results for binding of the MFAOs to both wildtype αB-crystallins, 2WJ7 
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and 2KLR, suggest that they may stabilize the wildtype proteins at the dimer interface.  
However, it is still unknown whether these compounds enhance the chaperone activity of 
the αB-crystallins, in addition to reducing oxidative stress, as the mechanism through 
which the in vivo observations of cataract prevention was observed. 
 
 
The majority of the MFAOs were too large to fit into the blocked pocket of the 2Y1Z 
mutant protein (Figure 4.10) just like the oxysterols.  Only HK-4 (-7.91 kcal/mol) appeared 
to fit in this tight pocket and form a hydrogen bond with PHE 118 on the “A” chain.  Analysis 
of the ligand interaction diagram of HK-4 revealed that one of its methoxy groups on the 
bottom ring were unable to fit into the closed binding pocket of 2Y1Z.  Further examination 
of the ligand interaction diagrams of the other MFAOs revealed that the N,N-
dimethylsulfamoyl top rings of both JHX-4 (-9.79 kcal/mol) and JHX-8 (-10.26 kcal/mol), 
not their pyrimidine bottom rings, were preferentially placed into the blocked binding 
pocket, presumably due to more favorable electrostatics.  The same was observed for HK-
2 (-6.08 kcal/mol) and HK-6 (-5.92 kcal/mol).  In contrast, the bottom ring of HK-8 (-7.86 
kcal/mol) was preferentially placed in the binding pocket.  These results suggest that even 
the smaller MFAO compounds are unable to fit into the blocked pocket of the 2Y1Z mutant 
dimer interface, suggesting that these molecules may be unable to bind or disrupt 





Figure 4.10.  MOE ribbon structures depicting the best docked complexes for all MFAOs 
to the dimer interface of the R120G mutant αB-crystallin, 2Y1Z.  None of the MFAOs 
showed any amino acid interactions with 2Y1Z except for HK-4 with F118.  Overall, the 
best docked structural models indicate that the MFAOs are unable to fit in the 








Figure 4.11.  Appearance of 25-hydroxycholesterol dissolved in PBS solution with or 
without the presence of αB-crystallin.  (1) 25-hydroxycholesterol (0.25 mM) in PBS.  (2) 





Despite the poor binding results of 25-hydroxycholesterol with the three αB-
crystallin models and the inability of 25-hydroxycholesterol to solubilize lens proteins 
(Figures 4.4 and 4.5), some interaction of αB-crystallin with this oxysterol can occur.  As 
illustrated in Figure 4.11, when 25-hydroxycholesterol is placed in a solution of PBS, it 
remains as a precipitate and fails to dissolve into the solution.  However, αB-crystallin 
does dissolve in PBS.  Combining both PBS solutions together results in the formation of 
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a white turbid solution.  While the oxysterol indeed appears to solubilize in the αB-crystallin 
solution, subsequent multi-angle light scattering (MALS) analysis indicates that the 25-
hydroxycholesterol becomes trapped within the oligomers of αB-crystallin.  The complex 
peak showed no significant change in the molar mass (MW) or hydrodynamic radii (Rh) of 
αB-crystallin incubated with 25-hydroxycholesterol.  Consistent with the present docking 
and binding studies, this suggests that 25-hydroxycholesterol is held within αB-oligomers 
without any apparent binding interaction with the protein.  This interaction may be similar 
to the partitioning of dexamethasone with α-crystallin as reported by Augusteyn and co-
workers and interpreted as a non-functional interaction [82]. 
 
 
Lens protein aggregation occurs within the millions of mature lens fiber cells where 
αB-crystallin chaperones are located.  Therefore, the oxysterols must penetrate within the 
millions of fiber cells to bind to the αB-crystallin chaperones.  While investigators have 
focused on lens protein aggregation and the role of oxysterol induction of chaperones in 
reversing lens protein aggregation in solutions, missing is the consideration of the unique 
properties of the lens fiber membranes and the required demonstration that oxysterols can 
actually penetrate through the highly saturated, stiff cholesterol containing membranes of 
these fiber cells which are tightly interconnected through ball and socket junctions.  In fact, 
in the rat lenses cultured with lanosterol liposomes (Figure 4.2), the amber appearance 
of the cortex and surrounding nucleus in the cataractous lenses does not rule out the 
possibility that the appearance is due only to the presence of liposomes in the extracellular 
space between the lens fibers.  However, the failure of both oxysterols to solubilize lens 
protein homogenates suggests that studies establishing oxysterol penetration into lens 










Using in vitro rat lens culture studies, in vitro human lens protein solubilization 
studies, and in silico molecular modeling studies, it was determined that the oxysterols 
lanosterol and 25-hydroxycholesterol failed to prevent the progression of, or clear, lens 
opacities.  These oxysterols also failed to reach acceptable thresholds for good predictive 
binding at either the protein dimer interface or the ATP binding pocket of three model αB-
crystallins.  ATP and the MFAOs were found to bind with high affinity to all model αB-
crystallins, whereas the oxysterols demonstrated low affinity binding.  The results for in 
silico ATP and oxysterol binding closely matched reported experimental data, indicating 
the computational methods were conducted appropriately.  It is presumed that the high 
affinity binding of the MFAOs to the wildtype αB-crystallin models, 2WJ7 and 2KLR, is 
due to their smaller size and the presence of more polar functionalities compared to the 
larger, neutral, lipophilic oxysterols.  However, neither the oxysterols nor the MFAOs were 
found to successfully fit into the dimer interface pocket of the R120G mutant, 2Y1Z, 
suggesting that these compounds most likely do not restoring vision through the proposed 
mechanism of binding to the R120G-mutated αB-crystallin chaperone protein.  Though 
our oxysterol results do not support the conclusions presented by Zhao et al. or Makley et 
al., the in silico MFAO molecular modeling results support our laboratory’s previously 
reported findings which demonstrated that the JHX series was able to delay the formation 
of cataracts without affecting aldose reductase or sorbitol dehydrogenase, suggesting 
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Approaches to the Synthesis of Mitochondrial-Targeted JHX-4 and their 
Preliminary In Vitro Evaluation in the HEI-OC1 Cell Line 
 




JHX-4 is an orally-active multifunctional antioxidant (MFAO) that has been shown 
to protect against a wide range of experimentally-induced oxidative stress.  Though it is 
well-established that reducing cytoplasmic ROS is important, studies have suggested that 
targeting antioxidants directly to the mitochondria may be more beneficial than to the 
cytoplasm in preventing mitochondrial linked ROS-induced cellular damage.  To test this 
hypothesis, a synthetic procedure was approached to develop a novel series of 
mitochondrially-targeted antioxidants based on the JHX series.  To increase the targeting 
capability of these compounds to the mitochondria, the main source of ROS in the cell, 
the N,N-dimethylsulfamoyl head group was replaced with the lipophilic 
triphenylphosphonium (TPP) cationic group, a well-known mitochondria-targeting linker.  
The present chapter describes the synthetic approach towards developing this JHX-TPP 
series.  Initial studies of JHX-2 (4-(5-hydroxypyrimidin-2-yl)-N,N-dimethylpiperazine-1-
sulfonamide), JHX-3 (N,N-dimethyl-3,5-dioxo-4-(pyrimidin-2-yl)piperazine-1-
sulfonamide), JHX-4 (4-(5-hydroxy-pyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-
sulfonamide), the novel non-functional JHX-1-TPP (triphenyl(3-(4-(pyrimidin-2-
yl)piperazin-1-yl)propyl)triphenyl-phosphonium bromide), and a novel model 
monofunctional chelator HK-2-CHL-TPP ((3-(1-(5-(benzyloxy)pyrimidin-2-yl)-2,5-
dioxopyrrolidin-3-yl)propyl)triphenylphosphonium bromide) were tested using the 
rhodamine-123 fluorophore, which measures mitochondrial membrane potential.  Our 
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results indicated that 1 mM of JHX-2, JHX-3, and JHX-4, as well as up to 100 nM of both 
JHX-1-TPP and HK-2-CHL-TPP are not mitochondriotoxic, demonstrating that further 
development of this novel compound class is feasible. 
 
 




The MFAOs scavenge free radicals and independently sequester and re-distribute 
free transition metals that facilitate the Fenton generation of toxic hydroxyl radicals.  As 
discussed in the previous chapters, MFAOs have been shown to be beneficial for 
neuroprotection [1-5].   Very recently, it has been suggested that mitochondrial dysfunction 
occurs in neurodegeneration as one of the main propagating factors [6].  Since mounting 
experimental studies pinpoint the importance of mitochondrial function in neural tissues, 
the premise that specifically targeting the mitochondria and preventing mitochondrial 
dysfunction should have therapeutic merit [7, 8].   
 
The mitochondria are complex intracellular organelles which are extremely critical 
for cellular function.  With the exception of glycolysis, they are the main organelles in 
cellular respiration through which each step occurs.  During the electron transport chain, 
NADH and FADH2 are oxidized and through a cascade of multi-enzyme complexes ADP 
is phosphorylated to form ATP [9].  Throughout this process, ROS are released as 
byproducts which include superoxide, hydrogen peroxide, and the hydroxyl radicals.  
Various organelles within the cell can generate ROS as ROS is used for cellular signaling, 
but the majority of intracellular ROS is created by the mitochondria [10].  Additionally, the 
mitochondria are a source of iron-sulfur clusters and heme-prosthetic groups utilized by 
proteins throughout the cell.  The post-transcriptional system that mammalian cells use to 
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regulate intracellular iron homeostasis depends on iron-sulfur cluster synthesis in the 
mitochondria.  Hence, proper mitochondrial function is crucial to cellular iron homeostasis.   
 
The excess production of ROS by mitochondria is one of the primary factors in the 
pathology of oxidative damage.  Specifically, mitochondrial ROS production causes 
oxidative damage to mitochondrial proteins, membranes, and DNA, impairing the ability 
of mitochondria to synthesize ATP and carry out their wide range of metabolic functions 
[11].  Mitochondrial oxidative damage can also activate the cell’s apoptotic machinery [12].  
Furthermore, it renders the impermeable inner membrane permeable to small molecules 
in situations such as ischemia/reperfusion injuries [13, 14].  Mitochondria-generated ROS 
are a major mediator of age-associated cellular damage because the antioxidant enzyme 
activity within the mitochondria defects with age.  Mitochondrial dysfunction, in addition to 
being linked to a number of neurodegenerations, may also initiate and/or contribute to iron 
dysregulation that is seen as an increase of iron levels during neurodegeneration. 
 
Mitochondrial dysfunction is linked to apoptotic cell death in not only 
neurodegeneration, but also many other diseased states [15].  There are currently no 
therapeutic treatments for preventing or reversing mitochondria dysfunction.  Therefore, 
maintaining functional mitochondria with pharmacological agents able to protect them 
against increased oxidative stress and promote mtDNA repair offers new strategies for the 
treatment of neurodegenerations.  For neuroprotective approaches to be effective, they 
must preserve or regenerate normal cell function and counter the toxicity resulting from 
ROS overproduction [16].  Targeting MFAOs to the mitochondria using established 
transport carriers, such as the triphenylphosphonium (TPP) group, should increase their 
therapeutic efficacy to prevent mitochondrial dysfunction.   
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The aim of this study was to synthesize a novel series of mitochondria-targeting 
analogs of the MFAOs and compare their activity to the non-targeting analogs to see if 
they provide superior protection.  In addition, an increase of free iron in the mitochondria 
has been detected during mitochondrial dysfunction, suggesting that targeting chelators 
may be beneficial to quenching ROS-associated damage in the mitochondria, but this 
topic is controversial since it has also been reported that mitochondrially-targeted 
chelators have adverse effects in the mitochondria [17].  To evaluate this premise, the 
synthesis of the JHX-TPPs derivatives including the nonfunctional parent (JHX-1-TPP, 1), 
the monofunctional free radical scavenger (JHX-2-TPP, 2) and bio-active transition metal 
chelator (JHX-3-TPP, 3), and the multifunctional antioxidant containing both free radical 
scavenging and transition metal chelating activity (JHX-4-TPP, 4), and evaluated their 
efficacy against the initial JHX-series in HEI-OC1 inner ear cells was approached.  The 
structures of the JHX-TPP class of compounds are shown in Figure 5.1.  No adverse 
effects were anticipated with the free radical scavenger 2, and no effects were anticipated 


















Figure 5.1.  Proposed structures of the novel JHX-TPP class of compounds.  Compound 
1 shows the structure of the JHX-1-TPP (triphenyl(3-(4-(pyrimidin-2-yl)piperazin-1-yl)-
propyl)triphenyl-phosphonium bromide), compound 2 shows the structure of the JHX-2-
TPP ((3-(4-(5-hydroxypyrimidin-2-yl)piperazin-1-yl)propyl)triphenylphosphonium bromide, 
compound 3 shows the structure of the JHX-3-TPP ((3-(3,5-dioxo-4-(pyrimidin-2-
yl)piperazin-1-yl)propyl)triphenylphosphonium bromide), and compound 4 shows the 

















The initial approach towards synthesizing parent-TPP (1), triphenyl(3-(4-
(pyrimidin-2-yl)piperazin-1-yl)-propyl)triphenyl-phosphonium bromide, is shown in 
Scheme 5.1.   The commercially available 3-bromopropanol 5 was benzyl protected with 
benzyl bromide to give the bromo-benzyl 6, which underwent nucleophilic substitution with 
piperazine 7 to yield product 8 according to Capuano [18].  The nucleophilic aromatic 
substitution of piperazine product 8 with 2-chloropyrimidine 9 yielded the benzyl-protected 
parent precursor 10.  However, subsequent removal of the benzyl protecting group from 
10 under standard hydrogenolysis conditions was unsuccessful.  Hydrogenolysis using 
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Pd/C catalyst at various loading ratios (5-15 wt%) in 95% ethanol under hydrogen balloon 
for 72 hours were unsuccessful.  It was thought that increasing the catalytic loading to 25 
wt% would drive the reaction forward, but this was unsuccessful.  The solvent systems 
were also changed because their properties, such as different dielectric constant and 
polarities, could affect the hydrogenolysis.  However, hydrogenolysis reactions using 
different solvents such as methanol, acetone, ethyl acetate, and dichloromethane with 20 
wt% Pd/C under hydrogen balloon for up to 48 hours failed to cleave the benzyl group.  
Finally, Pd/C was replaced with Pearlman’s catalyst (Pd(OH)2/C) because it is reported 
that some hydrogenolysis reactions may be catalyst-selective [19].  Using 20 wt% 
Pd(OH)2/C with various solvents under hydrogen balloon for up to 48 hours also failed to 
cleave the benzyl protecting group. These reactions were also unsuccessful.  As a final 
attempt, the hydrogen pressure was increased to 50 psi by placing 10 was under high 
temperature (120 oC) in a Parr Reactor with 20 wt% Pd/C for 48 hours.  This also failed to 
remove the benzyl protecting group.  The reason for this failure to debenzylate are not 
clear; however, conflicting reports suggest that the presence of amines can adversely 




Scheme 5.1.  Progress towards the C3-linked JHX-1-TPP (1).  Reagents and conditions:  
(a)  5, BnBr, NaH, DMF, -90 oC to rt, 18 hours; (b) 6, 7, toluene, reflux, 4 hours; (c) 8, 9, 




Because the benzyl group on compound 10 failed to cleave, an alternate approach 
towards compound 1 was investigated as shown in Scheme 5.2.  This alternate synthetic 
approach directly conjugates 1,4-dibromobutane with the parent ring scaffold 13 to give 
15 which should then react with TPP to give the desired product 17.  A 4-carbon linker 
rather than the 3-carbon linker was used in this approach because the starting material 
was readily available in the laboratory.  The parent scaffold 13 was prepared according to 
Mills [24] by nucleophilic aromatic substitution between piperazine 7 with 2-
chloropyrimidine 9.  Reaction between equimolar ratios of the parent scaffold 13 and 1,3-
dibromobutane 14 under reflux in acetonitrile according to Mou [25] gave the desired 
product 15.  The low boiling point of 14 required the use of PEG-1000 as a phase-transfer 
catalyst to facilitate the transition of 14 back into liquid phase.  The final addition of TPP 
installation to yield the 4-carbon-linked parent-TPP 17 was unsuccessful.  Initially, an 
overnight reflux of bromo 17 with TPP yielded only recovery of starting material.  
Hypothesizing that the reaction may require a higher activation energy, reflux was then 
extended to 5 days with the reaction and monitored by thin-layer chromatography (TLC).  
During this 5-day period, no change in product formation was observed.  In accordance 
with the activation energy hypothesis, the reaction energy was then increased by replacing 
the acetonitrile solvent with higher boiling toluene.  This also failed to produce product 17.  
This suggests that perhaps an even higher than anticipated temperature is required, or 
perhaps that steric hindrance of the bromo-parent precursor 15 with the bulky TPP 





Scheme 5.2.  Progress towards the C4-linked JHX-1-TPP (17).  Reagents and conditions:  





Since the parent scaffold 13 easily reacted with the 1,4-dibromobutane 14, the 
possibility of reacting 13 with 4-bromobutyl-TPP salt 18 was investigated to circumvent 
the failure of TPP to react with 15.  As shown in Scheme 5.3, the 4-bromobutyl-TPP salt 
18 was formed in 26% yield by refluxing an equimolar ratio of 1,4-dibromobutane 14 and 
triphenylphosphine 16 under reflux.  The 4-bromobutyl-TPP salt 18 then underwent 
nucleophilic substitution with the parent scaffold 13 in acetonitrile reflux in the presence of 
K2CO3 to form the 4-carbon-linked parent-TPP 17.  This approach was then repeated with 
the commercially available C3-bromo-TPP 19 and the parent scaffold 13 with the organic 
base (N,N-diisopropylethylamine) at room temperature to yield the initially proposed 





Scheme 5.3.  Synthesis of the first C4-linked JHX-1-TPP (17).  Reagents and conditions:  







Scheme 5.4.  Synthesis of the first C3-linked JHX-1-TPP (1).  Reagents and conditions:  








The initial desired synthetic approach for making the JHX-3-TPP (3), ((3-(3,5-
dioxo-4-(pyrimidin-2-yl)piperazin-1-yl)propyl)triphenylphosphonium bromide), is shown in 
Scheme 5.5.  This uses a similar final conjugation procedure of the C3-bromo-TPP as 
shown in Scheme 5.4.  The di-acid 20 was first Boc-protected to give the Boc-di-acid 21, 
which was heated to reflux with 2-aminopyrimidine 22 in toluene to form an amide 
intermediate in situ, followed by ring closure in acetic anhydride (Ac2O) to form the Boc-
protected chelating scaffold 23.  Boc-deprotection of 23 using trifluoroacetic acid in 
dichloromethane (DCM) gave the chelating precursor 24.  However, the nucleophilic 
substitution reaction between 24 and 3-bromopropyl-TPP 19 failed to produce JHX-3-TPP 
(3).  This was unexpected since the same approach had yielded the JHX-1-TPP (Scheme 
5.4).  It is assumed that in this nucleophilic substitution, the hydrogen from the secondary 
amine on 24 is first deprotonated by a base (DIPEA), which turns the secondary amine 
into a strong nucleophile.  This amine then attacks the electron-poor carbon adjacent to 
the bromine on 19.  Because the bromine is the better leaving group during the transition 
state of this reaction, it eliminates to give product 3.  This formation of product 3 was not 
208 
 
observed because this reaction may also have a high activation energy.  No product was 
formed as indicated by TLC.  The base was then removed, thinking that the base may 
somehow preferentially interact with the 3-bromopropyl-TPP.  No product formation was 
again observed, indicating that the base was not the factor.  The reaction was repeated 
using a higher boiling solvent and sodium hydride, an even stronger base than DIPEA.  
Again, no product was formed (reflux, up to 72 hours).  Since this reaction worked with 
the amine 13 but failed with the amine 24, the presence of the 2,6-carbonyl groups may 
possibly affect the reactivity of the 4-amino group in the piperazine ring [26].  Therefore, 






Scheme 5.5.  Progress towards the C3-linked JHX-3-TPP (3).  Reagents and conditions:  
(a)  20, Boc2O, NaOH, Dioxane, H2O;  (b)  21, 22, toluene, Ac2O, reflux;  (c)  23, TFA, 














The initial synthetic approach for the JHX-2-TPP, (3-(4-(5-hydroxypyrimidin-2-
yl)piperazin-1-yl)propyl)triphenylphosphonium bromide, is shown in Scheme 5.6.  This 
approach is similar to the initial route of the JHX-1-TPP (Scheme 5.3) where the scaffold 
is first formed, followed by the nucleophilic substitution of the C3-bromo-TPP and 
subsequent aryl O-benzyl deprotection to give the final product 2.  Following the benzyl 
protection of commercially available chloro-alcohol 25 to give the chloro-benzyl 26, its 
nucleophilic aromatic substitution with piperazine 7 yielded the scavenging scaffold 27.  
The nucleophilic substitution of 27 to the 3-bromopropyl-TPP 19 yielded the scavenging-
benzyl 28.  The debenzylation was assumed to proceed similar to that of the parent 
precursor.  However, similar to that of the parent precursor 10, various attempts at 
debenzylation were unsuccessful.  Since it has been reported that the presence of 
phosphorus in 28 can poison the Pd catalyst [27-29], an alternate approach for the 
synthesis of 2 was investigated.  The literature suggests that, in the presence of both an 
N-H and an O-H group on a compound, the reaction can be modified to selectively N-
alkylate or O-alkylate based on the polarity of the solvent.  Reactions conducted in more 
polar solvents are more likely to yield the N-alkylated product [30].  Thus, the O-benzyl 
group was deprotected from the scavenging scaffold 27 according to Ito [31] to give the 
conjugated amino-alcohol 30, which was subsequently subject to nucleophilic substitution 
under conditions reported to selectively yield the N-alkylated product (aqueous methanol).  
TLC monitoring and mass spectrum analysis indicated product formation (m/z = 562.4), 
and 1H NMR  suggested that the reaction yielded a mixture which contained the desired 
product 2.  5% MeOH/DCM was identified as the best mobile phase for purification by 
silica gel chromatography, but no final product could be isolated from column 
chromatography.  Instead, a mixed fraction was obtained containing both the desired 
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product 2 and a di-substituted byproduct (triphenyl(3-(4-(5-(3-(triphenyl-
phosphonio)propoxy)pyrimidin-2-yl)piperazin-1-yl)propyl)phosphonium bromide).  
Purification was then attempted first using 20% EtOH/DCM column elution, followed by a 
100% EtOH elution, but the product was not successfully isolated.  The stationary phase 
was then changed from silica to alumina, and again the purification attempts were 
unsuccessful at isolating the desired compound 2.  Due to this unsuccessful approach, 
attention was re-directed towards the JHX-4-TPP while the synthetic approach towards 




Scheme 5.6.  Progress towards the C3-linked JHX-2-TPP (2).  Reagents and conditions:  
(a) 25, BnBr, K2CO3, MeCN; (b) 26, 7, Et3N, toluene, reflux; (c) 27, 19, MeOH, H2O;  (d)  









The initial desired synthetic approach towards the JHX-4-TPP, (3-(4-(5-
hydroxypyrimidin-1-yl)-3,5-dioxopiperazin-1-yl)-propyl)triphenylphosphonium bromide, is 
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shown in Scheme 5.7.  This follows a similar approach for the synthesis of JHX-3-TPP in 
Scheme 5.5.  The Boc-di-acid 21 was heated to reflux with 2-amino-5-
benzyloxypyrimidine 31 in toluene to form an amide intermediate in situ, followed by ring 
closure in acetic anhydride (Ac2O) to give the Boc-protected MFAO-benzyl 32.  Boc-
deprotection of 32 using trifluoroacetic acid in DCM gave the MFAO-benzyl-precursor 33.  
The nucleophilic substitution between the CHL-precursor 24 and C3-bromo-TPP 19 did 
not give the JHX-3-TPP (3) (Scheme 5.5).  Since the presence of the carbonyls on the 
top piperazine ring appeared to alter the amine reactivity, perhaps the presence of the O-
benzyl group could also alter the reactivity of the molecule.  The nucleophilic substitution 
between the 3-bromopropyl-TPP and the MFAO-benzyl-precursor 33 was conducted and 
also found to be unsuccessful as indicated by TLC monitoring.  In a similar fashion to the 
approaches described for the synthesis of JHX-3-TPP, higher boiling solvents such as 
toluene were also used to overcome the activation energy of the reaction.  The reactions 
were run under reflux conditions and monitored by TLC for 5 days without success.  Since 
microwave-assisted synthesis is an alternate, convenient method of conducting high 
temperature and pressure refluxes, it was performed using both DMF and toluene.  Again, 
no product was observed and only starting material was obtained.  These results provided 
further evidence that suggests that the reactivity of this secondary amine is significantly 
reduced by the presence of the carbonyl groups, which prevents the nucleophilic 







Scheme 5.7.  Progress towards the C3-linked JHX-4-TPP (4).  Reagents and conditions: 
(a)  21, 31, toluene, Ac2O, reflux;  (b)  32, TFA, DCM;  (c)  19, 33, NaH, THF, reflux;  (d)  




Both Scheme 5.5 and Scheme 5.7 provide evidence that the secondary amine 
precursors (24 and 33) are unreactive with the 3-bromopropyl-TPP 19.  Therefore, an 
alternate approach was required.  Instead of starting with the di-acid 20 or the Boc-di-acid 
21, the new approach started with the amine already linked to an alcohol (Scheme 5.8).  
Unlike with the JHX-1-TPP where it was demonstrated that the O-benzyl deprotection did 
not proceed (Scheme 5.1), the more labile tert-butyldimethylsilyl (TBDMS) O-protecting 
group was employed [32].  The amino-alcohol 35 was protected with TBDMS 36 to give 
TBDMS-amine 37, followed by the di-nucleophilic substitution with ethyl bromoacetate 38 
to obtain the di-ester 39.  Saponification of di-ester 39 under either standard base-
catalyzed conditions with NaOH (6 eq.), or milder conditions using trimethyltin hydroxide 
(2.5 eq.) [33], did not yield the di-acid 40; only the cleaved TBDMS group was recovered.  
Direct formation of the amide 41 was next attempted by refluxing the di-ester 39 with 2-
amino-5-benzyloxypyrimidine (31) in the presence or absence of K2CO3, but this was also 
unsuccessful.  Finally, the saponification was conducted using acid-catalyzed conditions 
which yielded the O-deprotected di-ester alcohol 42.  This approach suggested that this 







Scheme 5.8.  Alternate MFAO-TPP synthesis using the TBDMS protecting group.  
Reagents and conditions:  (a)  35, 36, DIPEA, DCM;  (b)  37, 38, K2CO3, KI, MeCN;  (c)  
39, NaOH, H2O, THF;  (d)  39, Me3SnOH, DCE, 70 oC;  (e)  39, 31, K2CO3, MeCN, reflux;  




At this point in the JHX-4-TPP synthesis, the empirical evidence indicates that 
neither the benzyl nor the TBDMS protecting groups are optimal.  Because the silyl 
protecting groups are generally easier to work with and are more labile, one of the most 
stable silyl protecting groups, the tert-butyldiphenylsilyl group (TBDPS), was used to 
protect the hydroxyls in both the top ring and bottom ring.  The TBDPS group is reported 
to have a higher stability in both acidic and basic conditions compared to the TBDMS 
group, which suggests it may survive saponification of the di-ester and the acetic 
anhydride reflux ring closure  [32].  The synthesis of the TBDPS-protected amino bottom 
ring is shown in Scheme 5.9  The chloro-alcohol 25 was benzyl protected to give the 
chloro-benzyl 26.  The initial synthesis of chloro-benzyl 26 to amino-benzyl 31 according 
to Jin [1] is a low-yielding multi-step process.  This synthesis was improved to a one-pot 
reaction by using a high-temperature, high-pressure reaction vessel containing compound 
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26 dissolved in EtOH with 30% NH4OH and EtOH.  High temperature is necessary for the 
activation of the nucleophilic aromatic substitution, but these conditions also result in the 
phase-transition of ammonia to the gaseous phase from liquid ammonium hydroxide.  
Gaseous ammonia cannot participate in the nucleophilic aromatic substitution, which is 
why the simultaneous high temperature and pressure of the Parr reactor is advantageous 
because it forces gaseous ammonia back in the liquid phase to drive the reaction forward 
according to Le Chatelier’s Principle [34].  The amino-benzyl 31 was deprotected by 
hydrogenolysis with Pearlman’s catalyst (Pd(OH)2/C) to form the aryl amino-alcohol 43, 
which was subsequently protected with TBDPS 44 to form the aryl amino-TBDPS 45.  The 
TBDPS group did not survive the nucleophilic aromatic substitution reaction in the Parr 





Scheme 5.9.  Synthesis of the bottom ring intermediates for the MFAO synthesis.  
Reagents and conditions:  (a)  25, BnBr, K2CO3, MeCN;  (b)  26, NH4OH, EtOH, Parr 
reactor;  (c)  31, H2, 20% Pd(OH)2/C, EtOAc, EtOH;  (d)  43, 44, DIPEA, DCM;  (e)  25, 




The protection of the bottom ring with O-TBDPS initiated the new approach 
towards the synthesis of JHX-4-TPP (4), shown in Scheme 5.10.  Unlike the TBDMS 
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group, which was used in Scheme 5.8, the more stable TBDPS group was also employed 
to protect the top ring alkyl alcohol.  The amino-alcohol 35 was protected with TBDPS 44 
to give the TBDPS-amine 47, which subsequently underwent di-nucleophilic substitution 
with ethyl bromoacetate 38 to give the TBDPS-protected di-ester 48.  The base-catalyzed 
saponification of di-ester 48 could not be isolated.  TLC and mass spectrum analysis (m/z 
= 429.3) indicated in the reaction mixture formation of product 49, but the compound was 
unable to be properly characterized by 1H NMR.  Since the TLC and mass spectrum 
analysis indicated that 49 was present in the reaction mixture, ring closure with the 
intermediate 49 was conducted.  No product was identified and only the TBDPS and the 
aryl amino-alcohol 43 were recovered, suggesting that acetic anhydride may have de-





Scheme 5.10.  Progress towards the MFAO-TPP with the TBDPS protecting group.  
Reagents and conditions:  (a)  35, 44, DIPEA, DCM;  (b) 47, 38, K2CO3, KI, MeCN;  (c)  











Due to the problems encountered in the unsuccessful synthesis of compounds 2-
4, in which direct conjugation of the alkyl linkage to the secondary amine were employed, 
the use of an alternate linker was investigated [35, 36].  This not only simplified the 
chemical approach towards the synthesis of the JHX-TPP series, but the ester linkage 
could potentially be more advantageous by increasing the ease of metabolism.  The 




Figure 5.2.  Proposed structures of the novel JHX-TPP-Ester class of compounds.  
Compound 51 shows the structure of the JHX-1-TPP-Ester ((triphenyl(3-(2-(4-(pyrimidin-
2-yl)piperazin-1-yl)acetoxy)propyl)phosphonium bromide), compound 52 shows the 
structure of the JHX-2-TPP ((3-(2-(4-(5-hydroxypyrimidin-2-yl)piperazin-1-yl)acetoxy)-
propyl)triphenylphosphonium bromide), compound 53 shows the structure of the JHX-3-
TPP ((3-(2-(3,5-dioxo-4-(pyrimidin-2-yl)piperazin-1-yl)acetoxy)propyl)triphenylphospho-










Synthesis of the parent scaffold ester linked to the TPP is shown in Scheme 5.11.  
The nucleophilic substitution of parent scaffold 13 and ethyl bromoacetate 38 gave the 
parent ethyl ester 55.  The acid-catalyzed saponification of 55 yielded the product parent 
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acid 56.  Nucleophilic substitution of parent acid 56 with the 3-bromopropyl-TPP 19 yielded 





Scheme 5.11.  Synthesis of the JHX-1-TPP-Ester (51).  Reagents and conditions:  (a)  13, 








The synthesis of the JHX-2-TPP-Ester, as shown in Scheme 5.12, is similar to that 
of the JHX-1-TPP Ester (Scheme 5.11).  The nucleophilic aromatic substitution between 
commercially available piperazine ethyl ester 57 and chloro-benzyl 26 gave the ester-
benzyl 58.  Modifications to this compound were approached two different ways.  First, the 
benzyl protecting group was removed to give the ester-alcohol 59, but the subsequent 
base-catalyzed or acid-catalyzed saponification failed to yield the acid-phenol 61.  The 
second approach, conducted by Mr. Theodor Woolman in the Kador Laboratory, utilized 
a base-catalyzed saponification of 58 to obtain the benzyloxy acid 60, but its subsequent 
O-debenzylation failed to yield the phenolic acid 61.  Both TLC and mass spectrum 
analysis (m/z = 238.3) indicated product formation, however characterization by 1H NMR 
was inconclusive.  The purification of this mixture using both silica and alumina gel 
chromatography with highly polar solvent systems such as 20% EtOH/DCM and 100% 
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EtOH were both unsuccessful.  Purification by reverse-phase HPLC on a C18 column 
using 75% aqueous methanol was also unsuccessful.  Identifying the contaminants with 





Scheme 5.12.  Progress towards the JHX-2-TPP-Ester (52).  Reagents and conditions:  
(a)  26, 57, Et3N, toluene, reflux; (b)  58, H2, 20% Pd(OH)2/C, MeOH; (c)  59, 6M HCl, H2O, 








The approach to synthesizing JHX-3-TPP-Ester (53) is outlined in Scheme 5.7.  
To circumvent the problem of the poor reactivity of the 4-amino group in the piperazine-
2,6-dione 33 and the potential ring opening of ethyl 2-(3,5-dioxo-4-phenylpiperazin-1-
yl)acetate under both acid and base removal of the ethyl ester, a scheme employing 
commercially available nitrilotriacetic acid 62 was used.  As shown in Scheme 5.13, 
refluxing nitrilotriacetic acid 62 in pyridine with acetic anhydride formed an in situ 
anhydride according to Burns [37] that reacted with the 2-aminopyrimidine 22 to give acid 
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Scheme 5.13.  Synthesis of the JHX-3-TPP-Ester (53).  Reagents and conditions:  (a)  62, 








After the successful synthesis of the JHX-1-TPP-Ester and the JHX-3-TPP-Ester, 
attention was turned to the synthesis of the multifunctional analog JHX-4-TPP-Ester 54.  
The anhydride of nitrilotriacetic acid 62 was formed in situ under reflux with acetic 
anhydride in pyridine according to Burns [37], followed by reaction with 2-amino-5-
benzyloxypyrimidine 31 to yield the benzyloxy-protected pyrimidine 64.  The O-
debenzylation of 64 with hydrogen and Pearlman’s catalyst (Pd(OH)2/C) gave the phenolic 
acid 65.  To prevent any undesired side products during the nucleophilic substitution to 3-
bromopropyl-TPP 19, protection of the phenol with a labile OH protecting group was 
investigated [38].  Since the final conjugation of 65 to 19 is not conducted under harsh 
conditions, and since the silyl groups do not protect carboxylic acids, this approach was 
used to maximize the ability to obtain the final JHX-4-TPP-Ester (54).  However, both the 
reaction of the phenolic acid 65 with TBDMS using Et3N or DIPEA in DCM to give 66, and 
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the reaction of the phenolic acid 65 with TBDPS using Et3N or DIPEA in DCM to give 67, 
failed.  Because these protection attempts failed, attempts were made to utilize the 
significant differences in the pKa values between the carboxylic acid and phenolic 
functional groups.  Since the pKa of the carboxylic acid is ca. 5 and the pKa of the phenol 
is ca. 9-10, it was postulated that using weak bases would help drive the reaction towards 
the ester formation and yield the desired product 54.  To do this, K2CO3 (pKa ~ 10.3) was 
added to a stirring mixture of phenolic acid 65 in DMF and was stirred for ca. 1 hour to 
ensure the full deprotonation of the carboxylic acid.  In theory, the carbonate from K2CO3 
should preferentially strip the proton off of the carboxylic acid, yielding the carboxylate 
anion and bicarbonate in solution which would not affect the phenolic hydrogen.  The 
resonance on the carboxylate stabilizes the negative charge, which should allow for the 
nucleophilic attack to the 3-bromopropyl-TPP 19 and yield the JHX-4-TPP 54.  Evidence 
collected by TLC, mass spectrum analysis (m/z = 569.2), and the presence of anticipated 
1H NMR peaks all indicated product formation.  However, purification attempts using silica 
gel chromatography with 20% EtOH/DCM as eluent yielded only a mixed fraction 
containing a mixture of di-substituted side product ((3-((2-(2,6-dioxo-4-(2-oxo-2-(3-
(triphenylphosphonio)propoxy)ethyl)piperazin-1-yl)pyrimidin-5-yl)oxy)propyl)triphenylph-
osphonium bromide) and desired product 54 which co-eluted.  Chromatography was 
repeated using a longer column to increase the theoretical plates and better resolve the 
mixed fraction, but again only the co-eluting mixture was obtained.  The reaction was then 
repeated using a weaker base, KHCO3 (pKa ~ 6), but the TLC, mass spectrum analysis 
(m/z = 436.3), and 1H NMR indicated only formation of the undesired di-substituted side 
product.  Using pyridine, an even weaker base, yielded no reaction and only starting 
material was recovered.  As an alternative method, a Fischer esterification using a 
catalytic amount of acid to catalyze the ester formation between the phenolic acid 65 and 
3-bromopropyl-TPP 19 was conducted [39, 40].  Reflux for 96 hours in a dean-stark trap 
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yielded no product.  Just as observed with the JHX-2-TPP-Ester (Scheme 5.12), these 
results were unexpected.  Since the pKa’s of various pyrimidinols have not been well 
documented, so it is possible that the pKa of the pyrimidinol ring is not as similar to the 
phenol as anticipated.  For example, Nam and colleagues report the pKa’s of compounds 
similar to the bottom ring of the MFAO series, where the pKa of N-(4-
hydroxyphenyl)acetamide is ca. 9.8, the pKa of 2-(dimethylamino)pyrimidin-5-ol is ca. 8.2, 
and the pKa of N-(5-hydroxypyrimidin-2-yl)acetamide is ca. 5.9, suggesting that the 
pyrimidinol of the acid-phenol 65 is ca. 1000x more acidic than of a phenol [41].  The 
properties of phenolic acid 65 should be further investigated to develop a better synthetic 
approach towards the JHX-4-TPP-Ester (54). 
 
In summary, three novel JHX-1-TPP compounds were synthesized as shown in 
Schemes 5.3, 5.4, and 5.11, and one novel JHX-3-TPP was synthesized as shown in 
Scheme 5.13.  These developed schemes are shorter, higher-yielding, and greener 
compared to the initially proposed schemes towards the development of the JHX-TPP 
series.  Additionally, many novel intermediates have also been successfully synthesized 







Scheme 5.14.  Progress towards JHX-4-TPP-Ester (54).  Reagents and conditions:  (a)  
62, 31, Ac2O, pyridine, reflux;  (b)  64, H2, Pd(OH)2/C, acetone;  (c)  65, 36, DIPEA, DCM;  
(d)  65, 44, DIPEA, DCM; (e)  65, 19, K2CO3, DMF;  (f)  65, 19, KHCO3, DMF;  (g)  65, 19, 









Since the MFAO HK-2 has recently been shown to prevent hearing loss by 
protecting the cochlear hair cells [42], the synthesized compounds non-functional JHX-1-
TPP (1, (3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl)triphenylphosphonium bromide)) and 
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the metal chelating HK-2-Benzyl-TPP ((3-(1-(5-(benzyloxy)pyrimidin-2-yl)-2,5-
dioxopyrrolidin-3-yl)-propyl)triphenylphosphonium bromide), synthesis not shown), as well 
as the non-conjugated JHX-series [1], were evaluated in the HEI-OC1 cochlear hair cell 
line present in our laboratory.  To confirm that the non-conjugated compounds JHX-2, 
JHX-3, and JHX-4 were not cytotoxic to the cells, cell viability was measured using the 
MTS viability assay.  Results of this assay indicated that after 24 hours of exposure to 1 
mM of JHX-2, JHX-3, or JHX-4 in FBS-free media, there was no significant difference in 




Figure 5.3.  HEI-OC1 cytotoxicity with the non-conjugated JHX compounds.  HEI-OC1 
cell viability, measured by MTS assay, is not significantly affected by exposure to 1 mM of 




To assess whether these compounds adversely affected mitochondrial activity, 
fluorescence measurements were done using the rhodamine-123 dye.  Rhodamine-123 
is an indicator of mitochondrial membrane potential which indirectly measures 
mitochondrial activity [43, 44].  After 2 hours of incubation with 1 mM JHX-2, JHX-3, and 
JHX-4, cells were stained with rhodamine-123 (20 μg/mL).  One set of cells was imaged 
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under a fluorescence microscope, and another set of cells was measured by fluorescence 
microplate reader.  Compared to controls, none of the non-conjugated JHX compounds 
adversely affected mitochondria activity as indicated by rhodamine-123 staining (Figure 




Figure 5.4.  HEI-OC1 mitochondriotoxicity study with the non-conjugated JHX 
compounds.  The JHX compounds do not adversely affect mitochondria fluorescence after 
2 hours of incubation as measured by rhodamine-123 (20 μg/mL) staining.  (Top) 
Mitochondria fluorescence of HEI-OC1 cells with rhodamine-123 after exposure to 1 mM 
of JHX-2, JHX-3, or JHX-4 for 2 hours.  (Bottom)  Fluorescence microplate results of HEI-
OC1 cells with rhodamine-123 after exposure to 1 mM of JHX-2, JHX-3, or JHX-4 for 2 
hours.    No statistically significant differences between treatment groups as determined 
by ANOVA (n = 3 ± SEM). 
 
 
Preliminary cell culture studies with the nonfunctional JHX-1-TPP ((3-(4-(pyrimidin-




phosphonium bromide) have been conducted using currently available HEI-OC1 cochlear 
neural cells in our laboratory.  The two TPP compounds at concentrations greater than 1 
μM rapidly entered the cells, altering the mitochondrial membrane potential so that the 
uptake of rhodamine-123 stain and cell viability was reduced.  Figure 5.5 shows a dose 
response study indicating at doses below 1 μM, the 24-hour culture resulted in maintained 
cell viability in a dose-dependent manner.  Similarly, Figure 5.6 shows that mitochondrial 
function, measured by rhodamine-123 fluorescence staining, was also maintained in a 
dose dependent manner.  Importantly, there was no difference in cell viability between the 
JHX-1-TPP and the HK-2-CHL-TPP, indicating that the presence of a chelator within the 
mitochondria did not lead to mitochondrial dysfunction.  This concurs with reports that two 
new TPP-hydroxybenzoic acid derivatives with antioxidant and iron chelating properties 
demonstrate low toxicity and that the presence of the chelating moiety does not adversely 








Figure 5.5.  Cell viability of HEI-OC1 cells after 24 hours of culture with or without the 
JHX-1-TPP or HK-2-Benzyl-TPP.  Cells were seeded into 96-well plates and incubated at 
33 oC and 10% CO2.  Viability was determined using Calcein-AM staining, measured by 
fluorescence plate reader with results normalized to untreated control cells.  The results 
show that the presence of the chelating group on the HK-2-Benzyl-TPP does not 
significantly alter cell viability compared to the nonfunctional JHX-1-TPP parent.  Statistical 
significance was identified using ANOVA followed by Post-Hoc t-test with Bonferroni 
Correction (* indicates statistical significance compared to untreated control; # indicates 









Figure 5.6.  Mitochondria membrane potential of HEI-OC1 cells after 8 hours of culture 
with or without the JHX-1-TPP or HK-2-Benzyl-TPP.  Cells were seeded into 96-well plates 
and incubated at 33 oC and 10% CO2.  Mitochondria membrane potential was determined 
using rhodamine-123 staining.  (Top) Imaged were taken with a fluorescence microscope, 
and (Bottom) fluorescence was quantified by fluorescence plate reader with results 
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normalized to untreated control cells.  The results indicate that the compounds do not 
adversely affect the mitochondria membrane potential at sub-micromolar concentrations.  
Statistical significance was identified using ANOVA followed by Post-Hoc t-test with 
Bonferroni Correction (* indicates statistical significance compared to untreated control; # 





A significant loss of the mitochondrial membrane potential impairs oxidative 
phosphorylation, depleting cells of energy, and inducing cell death.  Translocation of 
protons from the matrix to the intermembrane space to establish the mitochondrial 
membrane potential is coupled to the electron transport chain [46].  Inhibition of complex 
I and/or complex II leads to an increase of ROS and a decrease in ATP production which 
results in mitochondrial dysfunction [47].  The loss of mitochondrial membrane potential, 
which can be visualized by fluorescent dyes such as Rhodamine-123, is an early marker 
of cellular apoptosis [48].  The mitochondria membrane potential was evaluated in order 
to investigate whether the JHX-series compounds or the TPP compounds could perturb 
mitochondrial function in the HEI-OC1 cells.  In Figure 5.4, it was shown that incubation 
of the HEI-OC1 cells with 1 mM of JHX-2, JHX-3, and JHX-4 do not affect fluorescence 
staining of the mitochondria, suggesting that these compounds are not mitochondriotoxic 
and do not affect the mitochondria membrane potential.  The TPP compounds at 
concentrations over 1 μM alter membrane potentials and indicate mitochondrial 
dysfunction [49].  This has also been seen with MitoQ, a compound currently undergoing 
clinical studies [50, 51]. 
 
The TPP moiety has been identified as an effective cellular and mitochondrial 
carrier for many small molecules, but little is known about the pharmacological effects and 
properties of the TPP.  The principles of TPP-assisted drug transport across plasma and 
mitochondria membranes are well-documented, and the mitochondrial targeting of 
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antioxidants have been of great interest to researchers since they have proven to be a 
promising therapeutic strategy towards developing more potent antioxidants [52, 53].  
Despite the established importance of TPPs, little is known about their effects on cellular 
bioenergetics [54].  To date, limited studies have assessed the impact of coupling 
functional molecules to alkyl-TPP moieties.  One group examining the effects of 1 μM 
concentrations of MitoQ, MitoTempol, and MitoE and found that the alkyl-TPP chains 
elicited cellular bioenergetic responses consistent with inhibition of oxidative 
phosphorylation independent of the functional antioxidant group [55].  Others have shown 
that conjugation of different length carbon chain linkers between TPP to ubiquinol (MitoQ 
derivatives) affect retention and accumulation of the TPP in the mitochondria.  Longer 
carbon chain linkers achieving a rapid steady state and contribute to rapid decreases in 
mitochondrial membrane potential [56-58], suggesting that shorter carbon chain linkers 
may yield less toxic TPP therapeutics. 
 
The extensive accumulation of lipophilic cations within isolated mitochondria at 
micromolar concentrations, especially approaching millimolar levels, are known to disrupt 
membrane integrity and impair respiration and ATP synthesis.  Ng and colleagues 
observed that maintaining mitochondrial membrane potential required sub-micromolar 
concentrations of MitoQ as low micromolar concentrations were observed to decrease 
respiration of isolated mitochondria [49].  This similar study was reported by Reily and 
colleagues who showed that 1 μM of MitoQ caused a 25% decline in the cellular 
respiration due to an inhibition of oxidative phosphorylation in as little as 2 hours [55].  
Likewise, Rogov and colleagues observed that SkQ1 rapidly destroyed the mitochondrial 
membrane at concentrations between 1-10 μM [59].  In the present study, low nanomolar 
concentrations are not shown to negatively affect HEI-OC1 cell viability or the 
mitochondrial membrane potential (Figure 5.5 and 5.6).  The explanation for the protective 
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effects of the examined novel TPP compounds have yet to be elucidated because the 
mechanisms by which the TPP compounds affect mitochondria are still unknown.  Though, 
a study has suggested that the TPP-based antioxidants directly affect mitochondrial Ca2+ 
homeostasis by interacting with the Na+/Ca2+ or H+/Ca2+ calcium exchangers, which are 
implicated in the regulation of mitochondrial dynamics and sensitivity to apoptotic 
challenges [60], further investigations are required to understand the intricacies of TPP-
based antioxidants on mitochondria health. 
 
5.4  Conclusion 
 
Three novel JHX-1-TPP compounds were synthesized as shown in Schemes 5.3, 
5.4, and 5.11, and one novel JHX-3-TPP was synthesized as shown in Scheme 5.13.  
With these two compounds, these developed schemes are shorter and higher-yielding 
than the originally proposed synthetic routes towards the TPP compounds.  Although the 
desires compounds were not obtained, several novel intermediates were successfully 
synthesized which may be used for future JHX-based compound development. The 
results from the in vitro studies on HEI-OC1 cells with the non-conjugated JHX-2, JHX-3, 
and JHX-4 compounds, as well as the novel synthesized JHX-1-TPP and the HK-2-
Benzyl-TPP compounds, show that compounds with Fe, Cu, or Zn chelating potential 
entering the mitochondria may not adversely affect mitochondrial function at sub-
micromolar concentrations and provide evidence that development of the TPP-based 















General.  All solvents and reagents were obtained from commercial sources.  NMR 
spectra were obtained with a Bruker 500 MHz or 600 MHz spectrometer.  Melting points 
were obtained with the Melting Poing Apparatus MPA-120 EZ-Melt (Stanford Research 
Systems, Sunnyvale, CA).  Column chromatography utilized Sigma Aldrich silica gel (70-
230 mesh, 60 Å pore size).  UV-visible spectra were measured on a Molecular Devices 
SpectraMax Plus384 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA).  
Final compound purities were assessed as ≥ 99% and intermediate compound purities 
were assessed as ≥ 96% by NMR and ESI-MS on a Thermo Finnigan LCQ (Thermo Fisher 
Scientific, Waltham, MA), and LRMS data was obtained on a Thermo Finnigan LCQ in 
positive scanning mode. 
 
 
((3-bromopropoxy)methyl)benzene (6).  To a stirred solution of 3-bromopropan-1-ol 
(25.0 grams, 179.9 mmol) and benzyl bromide (35.0 grams, 204.6 mmol) in 200 mL DMF 
at -90 oC was added 60% NaH in mineral oil (8.7 grams, 215.9 mmol) portionwise.  Stirring 
was continued for another 30 minutes at -90 oC before the mixture was warmed to room 
temperature over a period of 18 hours.  The mixture was quenched with aqueous NH4Cl 
(400 mL) and extracted with ether (3 x 300 mL).  Combined organics were washed with 
brine (3 x 200 mL), dried over MgSO4, filtered, and concentrated under reduced pressure.  
The crude material was purified by silica gel chromatography with 15% ether:pentanes, 
yielding the product as a pale yellow oil in 45% yield. 1H NMR (500 MHz, CDCl3) δ 7.35-
7.29 (m, 5H), 4.52 (s, 2H), 3.62-3.60 (t, J = 5.4 Hz, 2H), 3.55-3.52 (t, J = 7.2 Hz) 2H), 2.16-
2.12 (m, 2H). 
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1-(3-(benzyloxy)propyl)piperazine (8).  To a flame-dried 100 mL round-bottom flask was 
added piperazine (1.00 grams, 11.6 mmol) and toluene (25 mL).  While stirring, ((3-
bromopropoxy)methyl)benzene (1.33 grams, 5.8 mmol) was added dropwise and washed 
with toluene (25 mL).  Solution was refluxed for 2 hours.  After cooling to rt and filtering 
the mixture, the organic mixture was partitioned between 50 mL 1M HCl : 50 mL CHCl3 
and extracted with CHCl3 (3 x 50 mL).  The aqueous phase was adjusted to pH 14 with 
2M NaOH, and the resulting organic oil was extracted and combined to the combined 
organic layers.  The basic aqueous layer was extracted with CHCl3 (3 x 50 mL) and all 
organics were combined, washed with brine (3 x 50 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude material was purified by silica gel 
chromatography using CHCl3 : MeOH : NH4OH (94.5 : 5.0 : 0.5), resulting in the product 
as a pale yellow oil in 68% yield.  1H NMR (500 MHz, CDCl3) δ 7.38-7.29 (m , 5H), 4.51 




2-(4-(3-(benzyloxy)propyl)piperazin-1-yl)pyrimidine (10).  To a solution of K3PO4 (680 
mg, 3.2 mmol) in H2O (10 mL) was added 1-(3-(benzyloxy)propyl)piperazine (351 mg, 1.5 
mmol) and 2-chloropyrimidine (172 mg, 1.5 mmol).  The mixture was refluxed for 18 hours, 
cooled to rt, quenched with 0.1M aqueous K2CO3 (20 mL), extracted with EtOAc (4 x 30 
mL), washed with brine (3 x 25 mL), dried under MgSO4, and concentrated under reduced 
pressure.  Resulting deep orange oil was purified on silica gel column using 30% 
EtOAc:Hexanes, yielding the product as a pale orange oil in 32% yield. 1H NMR (500 MHz, 
CDCl3), δ 8.30-8.29 (d, J = 6.6, 2H), 7.35-7.27 (m, 5H), 6.49-6.47 (t, J = 7.4, 1H), 4.51 (S, 





2-(piperazin-1-yl)pyrimidine (13).  To a stirring solution of piperazine (3.88 grams, 45 
mmol) and K2CO3 (3.5 grams, 25.3 mmol) in H2O (20 mL) at 60 oC was slowly added 2-
chloropyrimidine (2.06 grams, 18 mmol).  The mixture was stirred for 2 hours and filtered 
upon cooling to rt.  The aqueous layer was extracted with CHCl3 (3 x 25 mL), dried over 
Na2SO4, and concentrated under reduced pressure, resulting in the product as a pale 
yellow oil in 81% yield. 1H NMR (500 MHz, CDCl3) δ 8.30-8.29 (d, J = 6.7, 2H), 6.48-6.46 
(t, J = 7.2 Hz, 1H), 3.80-3.78 (t, J = 6.5 Hz, 4H), 2.94-2.92 (t, J = 6.8 Hz, 4H), 1.97 (s, 1H). 
 
 
2-(4-(4-bromobutyl)piperazin-1-yl)pyrimidine (15).  To a flame-dried round-bottom flask 
was added 2-(piperazin-1-yl)pyrimidine (750 mg, 4.6 mmol), K2CO3 (691 mg, 5.0 mmol), 
MeCN (20 mL), 1,4-dibromobutane (1.48 grams, 6.9 mmol), and PEG-1000 (100 mg) as 
a phase-transfer catalyst.  The mixture was heated under reflux for 7 hours and upon 
cooling was filtered, washed with MeCN, and cooled overnight at  0 oC.  The crystallized 
white solid was collected as the product in 18% yield. 1H NMR (500 MHz, CDCl3) δ 8.47-
8.46 (d, J = 5.9 Hz, 2H), 6.79-6.78 (t, J = 3.2, 1H), 4.05 (s, 4H), 3.65-3.63 (m, 4H), 3.53-
3.51 (m, 4H), 2.11 (s, 4H). 
 
 
(4-bromobutyl)triphenylphosphonium bromide (18).  To a flame-dried round-bottom 
flask was added 1,4-dibromobutane (2.16 grams, 10 mmol) and triphenylphosphine (2.63 
grams, 10 mmol) in toluene (25 mL).  The solution was refluxed for 12 hours and upon 
cooling to rt was filtered.  The white solid was washed multiple times with ether (5 x 25 
mL), and air drying of this solid yielded product in 26% yield.  1H NMR (600 MHz, D2O) δ 
7.88-7.70 (m, 15H), 3.51-3.49 (t, J = 6.7, 2H), 3.35-3.31 (m, 2H), 2.07-2.03 (m, 2H), 1.90-





Triphenyl(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)phosphonium bromide (17).  A 
mixture of (4-bromobutyl)triphenylphosphonium bromide (840 mg, 1.75 mmol) dissolved 
in MeCN (20 mL) was added slowly to a mixture of 2-(piperazin-1-yl)pyrimidine (860 mg, 
5.25 mmol) and K2CO3 (490 mg, 3.55 mmol) in MeCN (50 mL).  The mixture was heated 
to reflux for 12 hours.  Upon cooling to rt, the mixture was diluted with EtOAc (50 mL), 
extracted with EtOAc (3 x 50 mL), and washed with brine (3 x 50 mL).  The resulting 
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure.  
The resulting sticky off-white/pale yellow solid was boiled in EtOH for 45 minutes and 
filtered of all insoluble stick solids.  The mother liquor was concentrated under reduced 
pressure, yielding the product in 5% yield. 1H NMR (600 MHz, DMSO-d6) δ 8.35-8.34 (d, 
J = 6.9, 2H), 7.91-7.76 (m, 15H), 6.62-6.61 (t, J = 3.9, 1H), 3.66 (br s, 4H), 3.61-3.56 (m, 
2H), 2.37 (br s, 6H), 1.66-1.58 (dm, J = 31 Hz, 4H). 
 
 
Triphenyl(3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl)phosphonium bromide (1).  2-
(piperazin-1-yl)pyrimidine (1.0 grams, 6.1 mmol), DIPEA (2.2 grams, 17 mmol), and MeOH 
(25 mL) were stirred at room temperature for 30 minutes before the addition of (3-
bromopropyl)triphenylphosphonium bromide (1.0 grams, 2.2 mmol) slowly portion-wise.  
The mixture was stirred vigorously at room temperature.  After 24 hours, the mixture was 
concentrated under reduced pressure and the residue was partitioned between DCM (30 
mL) and H2O (30 mL).  The aqueous layer was washed with DCM (3 x 30 mL) and the 
combined organics were dried under Na2SO4, filtered, and concentrated under reduced 
pressure.  The resulting sticky oil was dissolved in EtOH and a solid was triturated with 
EtOAc.  The resulting sticky solid was filtered by vacuum filtration, washed with EtOAc, 
and dried in vacuo, resulting in the product in 28% yield.  1H NMR (600 MHz, DMSO-d6) δ 
8.35-8.34 (d, J = 6.6 Hz, 2H), 7.93-7.77 (m, 15H), 6.63-6.61 (t, J = 6.2, 1H), 3.70 (br s, 
4H), 3.61-3.56 (m, 2H), 2.46-2.43 (t, J = 6.9 Hz, 2H), 2.34-2.33 (m, 4H), 1.76-1.72 (m, 2H); 
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13C NMR (125 MHz, DMSO-d6) δ 162.4, 158.6,  135.7, 133.1, 130.2, 110.5, 57.4, 52.8, 
43.8, 19.9, 18.7; LRMS m/z: 467.6 [M+]; mp 203-206 oC. 
 
 
2,2’-((tert-butoxycarbonyl)azanediyl)diacetic acid (21).  A stirring solution of 
iminodiacetic acid (2.0 grams, 15 mmol) in dioxane (30 mL) and H2O (10 mL) was cooled 
to 0 oC, after which Boc2O (3.93 grams, 18 mmol) and 2M NaOH (10 mL) were added.  
The mixture was stirred overnight at rt, concentrated under reduced pressure, and the 
aqueous layer was acidified with 1M HCl (50 mL) to pH 3.5.  The mixture was extracted 
with EtOAc (3 x 50 mL) and combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure, yielding an off-white solid as the product in 86% 
yield.  1H NMR (600 MHz, DMSO-d6) δ 12.62 (br s, 2H), 3.91-3.88 (d, J = 14.4 Hz, 4H), 
1.36 (s, 9H). 
 
 
Tert-butyl 3,5-dioxo-4-(pyrimidin-2-yl)piperazine-1-carboxylate  (23).  2,2’-((tert-
butoxycarbonyl)azanediyl)diacetic acid (4.6 grams, 21.4 mmol) was refluxed in Ac2O (30 
mL) for 45 minutes, after which the mixture was concentrated under reduced pressure to 
dryness.  To the residue was added 2-aminopyrimidine (2.04 grams, 21.4 mmol) in toluene 
(30 mL) which was set to reflux for 48 hours.  Upon cooling to rt, the mixture was 
concentrated under reduced pressure to near-dryness, and the residue was set to reflux 
in Ac2O (30 mL) for another 24 hours.  Upon cooling to rt, the mixture was concentrated 
under reduced pressure and purified using silica gel chromatography with 1% 
MeOH/CHCl3, resulting in the product as an orange oil in 32% yield.  1H NMR (500 MHz, 






1-(pyrimidin-2-yl)piperazine-2,6-dione (24).  To a stirring solution of tert-butyl 3,5-dioxo-
4-(pyrimidin-2-yl)piperazine-1-carboxylate (500 mg, 1.7 mmol) in DCM (5 mL) was added 
trifluoroacetic acid (1 mL) dropwise.  The mixture was vigorously stirred for 6 hours and 
concentrated under reduced pressure.  The residue was partitioned between DCM (10 
mL) and saturated NaHCO3 (10 mL), extracted with DCM (3 x 10 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure, yielding the product as a pale yellow 
oily solid in 81% yield.  1H NMR (500 MHz, CDCl3) δ 8.90-8.89 (d, J = 5.4 Hz, 2H), 7.43-
7.42 (t, J = 4.8 Hz, 1H), 3.86 (s, 4H). 
 
 
5-benzyloxy-2-chloropyrimidine (26).  To a stirring solution of 2-chloro-5-hydroxy-
pyrimidine (25 grams, 191.5 mmol) in MeCN (1000 mL) was added K2CO3 (29.1 gra,s 
210.7 mmol), followed by dropwise addition of benzyl bromide (36 grams, 210.7 mmol).  
The reaction was run at room temperature overnight, quenched with H2O (100 mL), and 
concentrated under reduced pressure.  The residue was dissolved in a 50/50 mixture of 
CHCl3 (150 mL) and H2O (150 mL), extracted with CHCl3 (3 x 150 mL), washed with brine 
(3 x 150 mL), dried under Na2SO4, filtered, and concentrated under reduced pressure.  
The resulting crude solid was purified using silica gel chromatography with 2.5% 
MeOH/CHCl3, and the product was obtained as a pale yellow solid in 75% yield.  1H NMR 
(CDCl3) δ 8.34 (s, 2H), 7.42-7.39 (m, 5H), 5.15 (s, 2H). 
 
 
5-(benzyloxy)-2-(piperazin-1-yl)pyrimidine (27).  To a stirring solution of piperazine (1.0 
grams, 11.6 mmol) in toluene (20 mL) was added Et3N (1.20 grams, 11.8 mmol)) dropwise, 
and a solution of 5-benzyloxy-2-chloropyrimidine (2.82 grams, 12.8 mmol) in toluene (20 
mL) was cannulated into the reaction vessel.  Th mixture was refluxed overnight, cooled 
to rt, and concentrated under reduced pressure.  The oily residue was partitioned between 
DCM and H2O, extracted with DCM (3 x 50 mL), washed with brine (3 x 25 mL), dried over 
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Na2SO4, and concentrated under reduced pressure.  The crude product was purified via 
acid/base extraction, where it was first partitioned between DCM and 1M HCl.  The acidic 
aqueous layer was extracted with DCM (3 x 25 mL, organic I).  The acidic aqueous layer 
was then brought to pH 9 with 1M NaOH, and the aqueous layer was re-extracted with 
DCM (3 x 25 mL, organic II).  Organic II layer was concentrated under reduced pressure, 
resulting in product as a yellow solid in 23% yield.  1H NMR (500 MHz, CDCl3) δ 8.12 (s, 





bromide (28).  To a stirring solution of (3-bromopropyl)triphenylphosphonium bromide (86 
mg, 184 mmol) in MeOH (3 mL) was added 5-(benzyloxy)-2-(piperazin-1-yl)pyrimidine 
(100 mg, 369 mmol) in H2O (3 mL).  The mixture was stirred for 1 hour at room 
temperature, followed by overnight reflux.  After cooling to rt, the solution was 
concentrated under reduced pressure.  The residue was partitioned between DCM and 
H2O, extracted with DCM (3 x 15 mL), washed with brine (3 x 10 mL), dried over Na2SO, 
filtered, and concentrated under reduced pressure.  The crude material was boiled in 
EtOAc, filtered, concentrated under reduced pressure.  The sticky solid was dissolved 
DCM (1 mL) and triturated with hexanes (10 mL) to give the product as a tan solid in 41% 
yield.  1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 2H), 7.92-7.76 (m, 15H), 7.43-7.33 (m, 
5H), 5.09 (s, 2H), 3.60 (br s, 6H), 2.44-2.42 (t, J = 6.2, 2H), 2.33-2.31 (t, J = 5.8, 4H), 1.76-
1.68 (m, 2H). 
 
 
2-(piperazin-1-yl)pyrimidin-5-ol (30).  The N2 atmosphere of a stirring solution containing 
5-(benzyloxy)-2-(piperazin-1-yl)pyrimidine (200 mg, 0.73 mmol) in EtOAc/EtOH (27 mL:13 
mL) containing 20 wt% Pd(OH)2/C was purged with H2 gas.  After 24 hours, the H2 
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atmosphere was purged, the mixture was filtered through celite, and the filtrate was 
concentrated under reduced pressure to give the product as an off-white solid in 88% 
yield. 1H NMR (500 MHz, DMSO-d6) δ 8.00 (s, 2H), 3.48-3.46 (t, J = 3.6 Hz, 4H), 2.71-
2.70 (t, J = 3.4 Hz, 4H). 
 
 
2-amino-5-(benzyloxy)-pyrimidine (31).  5-(benzyloxy)-2-chloropyrimidine (20 grams, 
90.6 mmol), NH4OH (200 mL), and EtOH (200 mL) were added to a 600 mL Parr Reactor, 
sealed, and stirred at 120 oC for 60 hours.  Upon cooling, the product was collected and 
evaporated of organic solvent under reduced pressure.  The resulting aqueous layer was 
basified with 1M NaOH (250 mL) and extracted with EtOAc (4 x 200 mL).  The collected 
organics were extracted vigorously with 1M HCl (4 x 200 mL).  The combined acidic layers 
were adjusted to pH 12 with 1M NaOH and extracted with EtOAc (4 x 250 mL).  The 
combined final organics were dried over Na2SO4, filtered, and concentrated under reduced 
pressure yielding a yellow-tan solid in 65% yield.  1H NMR (500 MHz, CDCl3) δ 8.08 (s, 
2H), 7.43-7.33 (m, 5H), 6.21 (s, 2H), 5.05 (s, 2H). 
 
 
2-amino-5-hydroxypyrimidine (43).  The N2 atmosphere of a stirring solution containing 
2-amino-5-(benzyloxy)-pyrimidine (6.0 grams, 29.8 mmol) in EtOAc/EtOH (140 mL:70 mL) 
with 20 wt% Pd(OH)2/C was purged with H2 gas.  After 24 hours, the H2 atmosphere was 
purged, the mixture was filtered through celite, and the filtrate was concentrated under 
reduced pressure.  The product was obtained as a straw-yellow solid in 96% yield.  1H 
NMR (600 MHz, DMSO-d6) δ 9.04 (br s, 1H), 7.85 (s, 2H), 5.90 (s, 2H). 
 
 
5-((tert-butyldiphenylsilyl)oxy)pyrimidin-2-amine (45). To a stirring solution of 2-
amino-5-hydroxypyrimidine (3.1 grams, 27.9 mmol) and DIPEA (7.1 grams, 54.9 mmol) in 
DCM (225 mL) was added tert-butyl(chloro)diphenylsilane (6.9 grams, 25.1 mmol) 
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dropwise and the reaction was stirred overnight.  Reaction mixture was concentrated 
under reduced pressure and diluted in EtOAc/H2O, extracted with EtOAc (4 x 200 mL), 
washed with brine, dried over Na2SO4, and concentrated under reduced pressure.  The 
crude oil was purified using silica gel chromatography with 0-3% MeOH/CHCl3 gradient, 
yielding the product as a pale yellow oil in 55% yield.  1H NMR (600 MHz, CDCl3) δ 7.78 
(s, 2H), 7.67-7.65 (d, 7.4 Hz, 4H), 7.46-7.37 (m, 6H), 5.40 (br s, 2H), 1.12 (s, 9H). 
 
 
5-((tert-butyldiphenylsilyl)oxy)-2-chloropyrimidine (46).  To a stirring solution of 2-
chloro-5-hydroxypyrimidine (5.0 grams, 38.3 mmol) in DCM (250 mL) was added DIPEA 
(9.90 grams, 76.6 mmol), followed by slow dropwise addition tert-
butyl(chloro)diphenylsilane (9.48 grams, 34.5 mmol).  The mixture was stirred overnight, 
after which it was partitioned between DCM (250 mL) and H2O (250 mL), extracted with 
DCM (3 x 250 mL), washed with brine (2 x 250 mL), dried under Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude orange oil was purified using silica gel 
chromatography with CHCl3, yielding the product as a deep orange oil in 38% yield.  1H 
NMR (500 MHz, CDCl3) δ 8.05 (s, 2H), 7.66-7.64 (m, 4H), 7.49-4.39 (m, 6H), 1.14 (s, 9H). 
 
 
Tert-butyl 4-(5-(benzyloxy)pyrimidin-2-yl)-3,5-dioxopiperazine-1-carboxylate (32).  
2,2’-((tert-butoxycarbonyl)azanediyl)diacetic acid (1.08 grams, 5.0 mmol) was refluxed in 
Ac2O (50 mL) for 45 minutes, after which the mixture was concentrated under reduced 
pressure to dryness.  To the residue was added 2-amino-5-(benzyloxy)-pyrimidine (500 
mg, 2.5 mmol) in toluene (100 mL) which was set to reflux for 48 hours.  Upon cooling to 
rt, the mixture was concentrated under reduced pressure to near-dryness and the residue 
was set to reflux in Ac2O (100 mL) for an additional 24 hours.  Upon cooling to rt, the 
mixture was concentrated under reduced pressure and purified using silica gel 
chromatography with 1% MeOH/CHCl3, yielding the product as an orange oil in 46% yield.  
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1H NMR (500 MHz, CDCl3) δ 8.55 (s, 2H), 7.47-7.38 (m, 5H), 5.21 (s, 2H), 4.50 (s, 4H), 
1.51 (s, 9H). 
 
 
1-(5-(benzyloxy)pyrimidin-2-yl)piperazine-2,6-dione (33).  To a vigorous stirring 
solution of tert-butyl 4-(5-(benzyloxy)pyrimidin-2-yl)-3,5-dioxopiperazine-1-carboxylate 
(100 mg, 0.25 mmol) in DCM (5 mL) was added trifluoroacetic acid (1 mL) dropwise.  
Solution was stirred at room temperature for 3 hours, concentrated under reduced 
pressure, dissolved in saturated NaHCO3 (20 mL), and extracted with DCM (4 x 15 mL).  
Organics were combined, dried under Na2SO4, filtered, and concentrated in vacuo, 
yielding the product as a clear oil  in 55% yield.  1H NMR (500 MHz, CDCl3) δ 8.55 (s, 2H), 
7.44-7.39 (m, 5H), 5.19 (s, 2H), 3.85 (s, 4H). 
 
 
3-((tert-butyldimethylsilyl)oxy)propan-1-amine (37).  To a stirring solution of 3-
aminopropan-1-ol (8.25 grams, 109.8 mmol) and tert-butyldimethylsilyl chloride (19.04 
grams, 126.3 mmol) in DCM (200 mL) was added DIPEA (21.35 grams, 165 mmol).  The 
mixture was vigorously stirred at rt overnight, diluted with H2O (200 mL), extracted with 
DCM (3 x 200 mL), dried over MgSO4, filtered, and concentrated under reduced pressure.  
The crude oil was set on hi-vac to remove residual DIPEA before carrying forward to the 
next step (yield > 90% by NMR). 
 
 
Diethyl 2,2’-((3((tert-butyldimethylsilyl)oxy)propyl)azanediyl)diacetate (39).  To a 
suspension of K2CO3 (7.33 grams, 53 mmol) and KI (7.04 grams, 42.4 mmol) in MeCN 
(50 mL) was cannulated 3-((tert-butyldimethylsilyl)oxy)propan-1-amine (2.00 grams, 10.6 
mmol) dissolved in MeCN (150 mL).  The mixture was heated to 70 oC, followed by 
cannulation of ethyl bromoacetate (3.54 grams, 21.2 mmol) portionwise every 30 minutes.  
After stirring for an additional 2 hours, mixture was cooled to rt, quenched with H2O (100 
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mL), and extracted with EtOAc (3 x 150 mL).  The combined organics were washed with 
saturated NH4Cl (2 x 150 mL) and brine (2 x 150 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude oil was purified using silica gel 
chromatography with 15% EtOAc/Hexanes, yielding the product as a dark yellow oil in 
74% yield.  1H NMR (500 MHz, CDCl3) δ 4.15-4.11 (q, J = 7.4 Hz, 4H), 3.63-3.61 (t, 5.8 
Hz, 2H), 3.51 (s, 4H), 2.78-2.75 (t, J = 7.6 Hz, 2H), 1.68-1.63 (m, J = 7.2 Hz, 2H), 1.25-
1.22 (t, J = 6.8 Hz, 6H), 0.85 (s, 9H), 0.00 (s, 6H). 
 
 
Diethyl 2,2’-((3-hydroxypropyl)azanediyl)diacetate (42).  To a stirring mixture of 3-
((tert-butyldimethylsilyl)oxy)propan-1-amine (2.0 grams, 5.5 mmol) in EtOH (30 mL) was 
added conc. HCl (1 mL) dropwise.  After 4 hours, the solution was concentrated under 
reduced pressure, the residue was partitioned between CHCl3 (30 mL) and H2O (30 mL), 
extracted with CHCl3 (3 x 30 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure, yielding the product as a pale yellow oil in 27% yield.  1H NMR (500 
MHz, CDCl3) δ 4.70 (br s, 1H), 4.16-4.12 (q, J = 7.8 Hz, 4H), 3.75-3.73 (t, J = 5.6 Hz, 2H), 
3.48 (s, 4H), 2.84-2.82 (t, J = 6.4 Hz, 2H), 1.66-1.62 (m, 2H), 1.25-1.22 (t, J = 7.4 Hz, 6H). 
 
 
3-((tert-butyldiphenylsilyl)oxy)propan-1-amine (47).  To a stirring mixture of 3-
aminopropan-1-ol (3.0 grams, 39.9 mmol) in DCM (400 mL) was added DIPEA (10.31 
grams, 79.8 mmol) and tert-butyl(chloro)diphenylsilane (9.89 grams, 36.0 mmol).  The 
reaction was stirred at rt overnight, quenched with 0.5 M HCl (300 mL), and extracted with 
DCM (3 x 300 mL).  The organics were washed with brine (2 x 250 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The crude oil was set on hi-vac to 





Diethyl 2,2’-((3-((tert-butyldiphenylsilyl)oxy)propyl)azanediyl)diacetate (48).  To a 
suspension of K2CO3 (24.47 grams, 177 mmol) and KI (23.5 grams, 141.6 mmol) in MeCN 
(200 mL) was cannulated 3-((tert-butyldiphenylsilyl)oxy)propan-1-amine (11.1 grams, 35.4 
mmol) dissolved in MeCN (600 mL).  The mixture was heated to 70 oC, followed by 
cannulation of ethyl bromoacetate (11.83 grams, 70.8 mmol) portionwise every 30 minutes 
over a period of 6 hours.  After stirring overnight, mixture was cooled to rt, quenched with 
H2O (100 mL), and concentrated under reduced pressure.  The residue was dissolved in 
EtOAc (200 mL) and H2O (200 mL) and extracted with EtOAc (3 x 200 mL).  The combined 
organics were washed with brine (2 x 150 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The crude yellow oil was purified using silica gel 
chromatography with 17% EtOAc/Hexanes, yielding the product as a dark yellow oil in 
62% yield.  1H NMR (500 MHz, CDCl3) δ 7.65-7.64 (d, J = 5.6 Hz, 4H), 7.43-7.35 (m, 6H), 
4.17-4.12 (q, J = 6.8 Hz, 4H), 3.71-3.69 (t, J = 5.4 Hz, 2H), 3.52 (s, 4H), 2.85-2.82 (t, 7.2 
Hz, 2H), 1.75-1.70 (m, 2H), 1.27-1.24 (t, J = 7.2 Hz, 6H), 1.03 (s, 9H). 
 
 
Ethyl 2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetate (55).  Ethyl bromoacetate (1.02 grams, 
6.1 mmol) was added dropwise to a stirred mixture of 2-(piperazin-1-yl)pyrimidine (1.0 
grams, 6.1 mmol), K2CO3 (2.11 grams, 15.3 mmol), and KI (2.03 grams, 12.2 mmol) in 
MeCN (100 mL).  The mixture was heated to 70 oC and ran overnight.  After cooling to rt, 
the mixture was quenched with 50 mL H2O and MeCN was removed under reduced 
pressure.  The remaining aqueous layer was extracted with EtOAc (3 x 50 mL), washed 
with brine (3 x 30 mL), dried under Na2SO4, filtered, and concentrated under reduced 
pressure.  The crude oil was purified with silica gel chromatography using 75% 
EtOAc:Hexanes, and the product was obtained as a deep orange oil in 84% yield. 1H NMR 
(500 MHz, CDCl3) δ 8.30-8.29 (d, J = 3.8 Hz, 2H), 6.48-6.47 (t, J = 1.6 Hz, 1H), 4.22-4.18 
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(q, J = 8.3, 2H), 3.89-3.87 (t, J = 6.4, 4H), 3.25 (s, 2H), 2.65-2.63 (t, J = 8.2 Hz, 4H), 1.29-
1.26 (t, J = 7.3 Hz, 3H). 
 
 
2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetic acid (56).  A solution of ethyl 2-(4-(pyrimidin-
2-yl)piperazin-1-yl)acetate (210 mg, 0.84 mmol) was heated in 6M HCl (8 mL) at 75 oC 
overnight.  Upon cooling to rt, the water was removed under reduced pressure and the 
resulting residue was adjusted to pH ~5.5 with 1M NaOH, resulting in a solid crash out 
from the oil.  This mixture was concentrated to dryness, resulting in a heterogeneous 
mixture of white and tan solids.  The solids were dissolved in EtOH and 50% aqueous 
MeOH was slowly added dropwise until a granular white solid crashed out of solution.  The 
mixture was filtered through celite, the mother liquor concentrated under reduced 
pressure, and the product was obtained as a brown solid in 85% yield. 1H NMR (500 MHz, 
DMSO-d6) δ 8.35-8.34 (d, J = 3.9, 2H), 6.63-6.61 (t, J = 6.1 Hz, 1H), 3.75-3.73 (br t, 4H), 




bromide (51).  To a stirring solution of 2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetic acid (50 
mg, 0.23 mmol) in DMF (5 mL) was added K2CO3 (77 mg, 0.56 mmol 2.5 eq.) and KI (75 
mg, 0.45 mmol).  After 5 minutes of stirring, (3-bromopropyl)triphenylphosphonium 
bromide (105 mg, 0.23 mmol) was added and the mixture was set to stir overnight at room 
temperature.  DMF was removed under reduced pressure, and the remaining residue was 
partitioned between DCM and ice-cold H2O, extracted with DCM (3 x 15 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The crude product was 
purified using silica gel chromatography with 6% MeOH/DCM.  The resulting oil was 
resuspended in DCM (1 mL) and hexanes (15 mL) were used to triturate the product as a 
yellow solid in 44% yield.  1H NMR (500 MHz, DMSO-d6) δ 8.30-8.29 (2, J = 3.6 Hz, 2H), 
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7.88-7.69 (m, 15H), 6.49-6.47 (t, J = 3.1 Hz, 1H), 4.48-4.46 (t, J = 3.8 Hz, 2H), 4.00-3.94 
(m, 2H), 3.85-3.83 (t, J = 3.3 Hz, 4H), 3.29 (s, 2H), 2.61-2.59 (t, J = 3.5 Hz, 4H), 2.08-2.01 
(m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 176.4, 162.4, 158.6, 134.0, 133.9, 130.8, 130.7, 
110.8, 62.7, 56.8, 43.7, 20.2, 18.8; LRMS m/z: 525.2 [M+]; mp = 209-212 oC. 
 
 
Ethyl 2-(4-(5-(benzyloxy)pyrimidin-2-yl)piperazin-1-yl)acetate (58).  A mixture of 5-
(benzyloxy)-2-chloropyrimidine (750 mg, 3.4 mmol), ethyl 2-(piperazin-1-yl)acetate (702 
mg, 4.1 mmol), Et3N (1.03 grams, 10.1 mmol), and toluene (40 mL) was refluxed for 16 
hours.  Upon cooling to rt, toluene was removed under reduced pressure, and the residue 
was partitioned between CHCl3 (40 mL) and H2O (40 mL), extracted with CHCl3 (3 x 40 
mL), dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude 
oil was purified using silica gel chromatography with 100% EtOAc, yielding the product as 
a deep orange oil in 18% yield. 1H NMR (500 MHz, CDCl3) δ 8.11 (s, 2H), 7.40-7.33 (m, 
5H), 5.01 (s, 2H), 4.22-4.19 (q, J = 5.4 Hz, 2H), 3.82-3.80 (t, J = 4.4 Hz, 4H), 3.30 (s, 2H), 
2.70-2.68 (t, J = 4.8 Hz, 4H), 1.29-1.27 (t, 5.4 Hz, 3H). 
 
 
Ethyl 2-(4-(5-hydroxypyrimidin-2-yl)piperazin-1-yl)acetate (59).  The N2 atmosphere 
of a stirring solution containing ethyl 2-(4-(5-(benzyloxy)pyrimidin-2-yl)piperazin-1-
yl)acetate (180 mg, 0.5 mmol) in MeOH (10 mL) containing 20 wt% Pd(OH)2/C was purged 
with H2 gas.  After 24 hours, the H2 atmosphere was purged, the mixture was filtered 
through celite, and the filtrate was concentrated under reduced pressure.  The product 
was obtained as a deep yellow oil in 90% yield. 1H NMR (500 MHz, CDCl3) δ 7.94 (s, 2H), 






2-(4-(5-(benzyloxy)pyrimidin-2-yl)piperazin-1-yl)acetic acid (60).  To a stirring solution 
of ethyl 2-(4-(5-(benzyloxy)pyrimidin-2-yl)piperazin-1-yl)acetate (500 mg, 1.4 mmol) in 
THF (17 mL) was added NaOH (168 mg, 4.2 mmol) in H2O (17 mL), and the reaction was 
stirred overnight.  The reaction was quenched, brought to pH 5 with 1M HCl (10 mL), and 
extracted with 5% MeOH in EtOAc (5 x 15 mL) to keep product soluble.  Organics were 
dried over Na2SO4, filtered, and concentrated under reduced pressure, yielding the 
product as a white solid in 65% yield.  1H NMR (500 MHz, DMSO-d6) δ 8.24 (s, 2H), 7.44-




2-(3,5-dioxo-4-(pyrimidin-2-yl)piperazin-1-yl)acetic acid (63).  To a reaction vessel 
was added 1 gram of activated powdered molecular sieves, followed by nitrilotriacetic acid 
(5.0 grams, 26.16 mmol) and pyridine (80 mL).  After 45 minutes of heating at 50 oC, Ac2O 
(3.2 grams, 31.39 mmol) was added and the mixture was set to reflux for 2 hours.  The 
mixture was cooled to 50 oC and 2-aminopyrimidine (2.49 grams, 26.16 mmol) dissolved 
in pyridine (25 mL) was cannulated into the reaction vessel.  The reaction was heated to 
reflux for an additional 2 hours, cooled to rt, filtered through celite, and concentrated under 
reduced pressure.  The crude solid was suspended in DCM (50 mL) and the DCM-
insoluble solid was filtered and washed with MeOH (20 mL), yielding the product as an 
off-white solid in 37% yield.  1H NMR (600 MHz, DMSO-d6) δ 12.72 (br s, 1H), 8.99-8.98 




nium bromide (53).  To a stirring solution of 2-(3,5-dioxo-4-(pyrimidin-2-yl)piperazin-1-
yl)acetic acid (510 mg, 2.04 mmol) in DMF (30 mL) was added K2CO3 (704 mg, 5.1 mmol) 
and KI (677 mg, 5.0 mmol).  After stirring for 5 minutes, (3-
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bromopropyl)triphenylphosphonium bromide (950 mg, 2.04 mmol) was added and the 
mixture was stirred overnight at rt.  The mixture was concentrated under reduced pressure 
and partitioned between DCM (15 mL) and H2O (15 mL), extracted with DCM (4 x 15 mL), 
dried over Na2SO4, filtered, and concentrated under reduced pressure.  The crude oil was 
purified using silica gel chromatography with 5.5% MeOH/DCM.  The resulting oil was 
dissolved in DCM (1 mL) and triturated with heptanes (25 mL) to give the product as a 
yellow solid in 35% yield.  1H NMR (600 MHz, DMSO-d6) δ 8.99-8.98 (d, J = 4.6 Hz, 2H), 
7.93-7.77 (m, 15H), 7.68-7.66 (t, J = 4.8 Hz, 1H), 4.23-4.21 (t, J = 6.2 Hz, 2H), 3.84 (s, 
4H), 3.69-3.63 (m, 4H), 1.94-1.88 (m, 2H);  13C NMR (150 MHz, DMSO-d6) δ 169.7, 169.4, 
159.9, 154.8, 135.1, 135.0, 133.7, 133.6, 130.4, 130.3, 121.8, 118.5, 117.9, 63.5, 54.6, 
21.4, 17.4;  LRMS m/z: 553.3 [M+]; mp 216-218 oC. 
 
 
2-(4-(5-(benzyloxy)pyrimidin-2-yl)-3,5-dioxopiperazin-1-yl)acetic acid (64).  To a 
reaction vessel was added 1 gram of activated powdered molecular sieves, followed by 
nitrilotriacetic acid (2.50 grams, 13.08 mmol) and pyridine (80 mL).  After 45 minutes of 
heating at 50 oC, Ac2O (1.47 grams, 14.4 mmol) was added and the mixture was set to 
reflux for 2 hours.  The mixture was cooled to 50 oC and 2-amino-5-(benzyloxy)-pyrimidine 
(2.60 grams, 13.08 mmol) dissolved in pyridine (25 mL) was cannulated into the reaction 
vessel.  The reaction was heated to reflux for an additional 2 hours before being cooled to 
rt, filtered through celite, and concentrated under reduced pressure.  The mixture was re-
suspended in DCM (30 mL) and the off-white solid that crashed out was filtered, washed 
with DCM (5 x 30 mL), and dried to give the product in 32% yield.  1H NMR (600 MHz, 
DMSO-d6) δ 12.69 (br s, 1H), 8.75 (s, 2H), 7.51-7.39 (m, 5H), 5.34 (s, 2H), 3.80 (s, 4H), 





2-(4-(5-hydroxypyrimidin-2-yl)-3,5-dioxopiperazin-1-yl)acetic acid (65).  The N2 
atmosphere of a stirring solution containing 2-(4-(5-(benzyloxy)pyrimidin-2-yl)-3,5-
dioxopiperazin-1-yl)acetic acid (1.4 grams, 3.93 mmol) in acetone (100 mL) containing 25 
wt% Pd(OH)2/C was purged with H2 gas.  After 48 hours the H2 atmosphere was purged, 
the mixture was filtered through celite, and the filtrate was concentrated under reduced 
pressure, yielding the product as a pale yellow solid in 93% yield.  1H NMR (500 MHz, 
DMSO-d6) δ 11.87 (br s, 1H), 8.44 (s, 2H), 3.78 (s, 4H), 3.47 (s, 2H). 
 
 




General.  All reagents used were of reagent grade.  Compounds JHX-2 [4-(5-
hydroxypyrimidin-2-yl)-N,N-dimethylpiperazin-1-sulfonamide], JHX-3 [N,N-dimethyl-3,5-
dioxo-4-(pyrimidin-2-yl)piperazine-1-sulfonamide], and JHX-4 [4-(5-hydroxypyrimidin-2-
yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide] were synthesized according to Jin 
[1].  JHX-1-TPP [Triphenyl(3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl)phosphonium 
bromide] was synthesized as shown in Scheme 4, and HK-2-Benzyl-TPP [(3-(1-(5-
(benzyloxy)pyrimidin-2-yl)-2,5-dioxopyrrolidin-3-yl)propyl)triphenylphosphonium bromide] 
was synthesized by my colleague, Mr. Theodor Woolman (synthesis not published).  Cell 
Titer 96® AQueous One Solution Cell Proliferation Assay Kit was obtained from Promega 
(Madison, WI).  Rhodamine-123 was purchased from Sigma Aldrich (St. Louis, MO).  UV-
visible assays were measured on a Molecular Devices SpectraMax Plus384 microplate 
spectrophotometer (Molecular Devices, Sunnyvale, CA).  Fluorescence assays were 
measured on a FLx800 Microplate Fluorescence Reader (Bio-Tek Instruments, Winooski, 
VT).  All fluorescence images were captured with a Nikon Diaphot 200 inverted 
microscope equipped with a Hamamatsu ImagEM EMCCD camera using the Red 
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Excitation Filter Block Cy5 (Nikon Instruments Inc, Melville, NY) with 250 ms exposure 
and gain of 5. 
 
 
General Incubation Procedure.  House Ear Institute-Organ of Corti 1 (HEI-OC1) cells 
[61] were provided by Dr. Federico Kalinec, David Geffen School of Medicine, University 
of California, Los Angeles, CA.  These cells were grown under permissive conditions (33 
°C under a 10% CO2 atmosphere), which induces expression of an immortalizing gene 
that triggers de-differentiation and accelerated proliferation, in Dulbecco's Modified 
Eagle's Medium (DMEM, Mediatech Inc., Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS, ThermoFisher, Waltham, MA) in 250 mL plastic Cell Culture Flasks 
as previously described [62].  A uniform population of adhering, growing cells were 
obtained by performing multiple "slap-and-wash" cycles where the flask was smacked to 
detach all the non-adhesive, free-floating cells and rinsed with media.  For the planned 
experiments, the cells were seeded onto either 24-well or 96-well clear flat-bottom plastic 
plates (Nunclon Delta, Round, Thermo Fisher Scientific, Waltham, MA) at a density of ca. 
2.0 x 105 cells/mL using 500 μL or 200 μL per well, respectively.  One day of growth in 
standard media resulted in around 80% confluence.  All studies were conducted, at a 
minimum, in triplicate. 
 
 
Non-Conjugated JHX-4 Family Toxicology.  1 mM of JHX-2, JHX-3, or JHX-4 in FBS-
free media containing 1.0% DMSO was added to seeded cells in 96-well plates.  After 24 
hours, the media was removed by aspiration, the cells were washed three times with PBS+, 
and the media was replaced with Cell Titer 96® AQueous One Solution Cell Proliferation 
Assay (MTS, Promega, Madison, WI) solution (20 μL assay solution in 100 μL culture 
media) and incubated for 1 hour according to manufacturer’s protocol. Absorbance was 
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Effects of the Non-Conjugated JHX-4 Family on Mitochondria Fluorescence.  The 
fluorescence staining of mitochondria was conducted according to Chazotte [63].  1 mM 
of either JHX-2, JHX-3, or JHX-4 in FBS-free media containing 1.0% DMSO was added 
to the seeded cells in either 24-well or 96-well plates.  Cells were incubated for 2 hours, 
after which the media was aspirated.  The cells were washed 3x with PBS+ and stained 
with 20 μg/mL Rhodamine-123-labeling solution (in PBS+) and incubated for another 30 
minutes.  The stain was aspirated, and the cells were washed 3x with PBS+.  The cells in 
the 24-well plates were imaged in PBS+ with a fluorescence microscope.  The cells in the 
96-well plates were analyzed with a fluorescence plate reader, and results were 
normalized to untreated control cells (100%).  
 
 
JHX-1-TPP and HK-2-Benzyl-TPP Toxicology.  Either 1 nM, 10 nM, 100 nM, 1 μM, or 
10 μM of either JHX-1-TPP or HK-2-Benzyl-TPP in FBS-free media containing 1.0% 
DMSO was added to the seeded cells in 96-well plates.  After 24 hours, the media was 
removed by aspiration, the cells were washed three times with PBS+, and the media was 
replaced with Calcein-AM Staining (Thermo Fisher Scientific, Waltham, MA) solution (2 
μM final solution concentration with 100 μL per well) and incubated for 30 minutes 
according to manufacturer’s protocol.  Calcein-AM staining was measured with a 
fluorescence plate reader with results normalized to untreated control cells (100%). 
 
Effects of TPP Compounds on Mitochondria Fluorescence.  The fluorescence staining 
of mitochondria was conducted according to Chazotte [63].  Either 1 nM, 10 nM, 100 nM, 
1 μM, or 10 μM of either JHX-1-TPP or HK-2-Benzyl-TPP in FBS-free media containing 
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1.0% DMSO was added to the seeded cells in either 24-well or 96-well plates.  Cells were 
incubated for 8 hours, after which the media was aspirated.  The cells were washed 3x 
with PBS+ and stained with 20 μg/mL Rhodamine-123-labeling solution (in PBS+) and 
incubated for another 30 minutes.  The stain was aspirated, and the cells were washed 3x 
with PBS+.  The cells in the 24-well plates were imaged in PBS+ with a fluorescence 
microscope.  The cells in the 96-well plates were analyzed with a fluorescence plate 
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Conclusions and Future Directions 
 
6.1.  Biodistribution Study 
 
To confirm the preliminary distribution studies of the MFAOs conducted in mice, 
the bioavailability studies presented in Chapter 2 were expanded on Sprague Dawley rats.  
All compounds were orally-administered to the rats for 7 days with each rat fed chow 
containing 0.05% of compound.  The measured average daily dose based on food weight 
measurements was 46.2 ± 2.2 mg drug/kg body weight.  The levels of unmetabolized 
compounds were analyzed in ocular, neural, and visceral tissue which included the 
cornea, iris with ciliary body, lens, neural retina, retinal pigmented epithelium with the 
choroid, brain, sciatic nerve, kidney, and liver.  The distribution values of the compounds 
ranged from 0 ng drug/mg protein to 3.7 mg drug/mg protein.  The parent HK-15 was 
undetectable in the ocular tissue and the brain, and parents JHX-1 and JHX-5 were 
undetectable in the sciatic nerve.  No clear trends were identified in the distribution profiles 
of the compounds, suggesting that further investigation is necessary to understand the 
factors of drug permeation across the various physiological barriers to reach target 
tissues. 
 
Future work to support the biodistribution study may include in vitro and in vivo 
assessments of ADME and PK properties including drug binding to plasma proteins, 
biological half-life, and toxicity.  The bioavailability study has shown that, with the 
exception of HK-15 in ocular tissues and the brain, and JHX-1, and JHX-5 in the SN, the 
remainder of the compounds are found in all tissues.  It is possible that the metabolites of 
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the MFAOs and their analogs may also have biological effects.  A previous short-term 
maximum tolerated dose experiment was conducted in mice where the JHX-4 and HK-2 
MFAOs were administered up to 1800 mg drug/kg body weight/day without any observed 
adverse effects.  A long-term maximum tolerated dose experiment and/or dose-escalation 
study will be conducted to confirm these initial results.   
 
6.2.  Predictive Modeling Study 
 
The data from the biodistribution study were analyzed with two different data 
mining algorithms, hierarchical cluster analysis (HCA) and quantitative structure activity 
relationship analysis (QSAR), to investigate relationships between the calculated 
physicochemical descriptors of the compounds with their measured tissue levels.  The 
analyses indicated that these two methods were able to identify a myriad of relationships 
between the compounds, resulting in several physiologically-relevant predictive models of 
compound distribution to various ocular, neural, and visceral tissues.  Many of the models 
derived from both algorithms were similar, if not identical, and the identified trends agreed 
with other reported experimental trends of drug passage through various physiological 
barriers such as the blood-aqueous (BAB), blood-retinal (BRB), blood-brain (BBB), and 
blood-nerve barriers (BNB). 
 
Future work in this area may include expanding the QSAR models using other 
physicochemical descriptors as well as multi-variable analysis.  The single variable results 
reported in Chapter 3 identified several physiologically-relevant predictive models.  
Preliminary investigations using multi-variable correlations have been conducted and 
suggest that many more models can be developed by expanding these initial approaches.  
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Analysis with multiple variables may further elucidate the critical relationships between 
physicochemical descriptors necessary for specific tissue uptake. 
 
6.3.  Oxysterol Study 
 
The novel paradigm that oxysterols could restore vision from cataracts was 
investigated using in vitro lens culture studies, solubilization studies, and computational 
docking studies in Chapter 4.  The oxysterols failed to prevent the progression of, or clear, 
lens opacities.  In silico, the oxysterols also failed to reach acceptable thresholds for good 
predictive binding at either the protein dimer interface or the ATP-binding pocket of three 
model αB-crystallins.  Comparatively, the MFAOs were found to bind with higher affinity 
than the oxysterols to both the dimer interfaces and the ATP-binding pockets of all three 
model αB-crystallins.  These results suggest that the oxysterols most likely do not restore 
vision through the reported mechanism of action as an αB-crystallin molecular chaperone.  
The in silico docking results support the experimental results of our research group which 
previously demonstrated that the NF JHX-1 was able to significantly delay the advanced 
progression of sugar cataract formation in vivo without sorbitol dehydrogenase or aldose 
reductase inhibition, suggesting it may have inherent chaperone activity. 
 
It may be possible that small molecules help prevent the aggregation of the α-
crystallins.  Computational simulations can help verify these docking results and provide 
a method to study what happens at the molecular level during the aggregation process.  
This in silico tool may help us understand how the small molecule MFAOs interact with 





6.4.  Mitochondria-Targeted TPP Synthesis and In Vitro Studies 
 
New synthetic approaches were developed towards a new series of 
triphenylphosphonium-based (TPP) MFAOs.  Three non-functional parent compounds 
and one monofunctional metal chelating compound were successfully synthesized: the 
C3-linked JHX-1-TPP, the C4-linked JHX-1-TPP, the JHX-1-TPP-Ester, and the JHX-3-
TPP-Ester.  The results from the in vitro studies on HEI-OC1 cells with the non-conjugated 
JHX-2, JHX-3, and JHX-4 compounds, as well as the novel synthesized JHX-1-TPP and 
the HK-2-Benzyl-TPP compounds, show that compounds with Fe, Cu, or Zn chelating 
potential entering the mitochondria may not adversely affect mitochondrial function at sub-
micromolar concentrations and provide evidence that development of the TPP-based 
MFAOs should be further explored.  The effects of the TPP compounds confirm our 
hypothesis that the activity of the MFAOs can be enhanced by directly targeting 
mitochondrial dysfunction.  These findings are summarized in Chapter 5. 
 
Additionally, the progress towards the development of the TPPs have yielded new 
synthetic strategies for a new series of MFAOs.  The initial JHX-series of MFAOs include 
the N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide or the N,N-dimethylpiperazine-1-
sulfonamide top ring systems.  Using the newly developed synthetic strategies, several 
novel MFAO series with the piperazine top ring scaffold can be further developed.  Figure 








Figure 6.1.  The new proposed JHX-based compound series.  This series is based on the 
intermediates developed during the JHX-TPP synthetic approaches which uses an acetic 
acid or ester group instead of the N,N-dimethylsulfamoyl group. 
